stn seminar bio- und gentechnologie bei stn (1998)

STN-Seminar

Bio- und Gentechnologiebei STN International

STN-Vertrieb und -Schulung Schweiz, c/o InfoLit Infobroker GmbH

E-Mail: [email protected] Web: http://www.infolit.ch/

Stand 1998-08

BG01 Bio- und Gentech (c) STN-Vertrieb und -Schulung Schweiz c/o InfoLit / 1998-08 / Seite 2

Der Weg vom Fachartikel zum Datenbankdokument:Die intellektuelle Indexierung

1. Lesen 2. Auswerten 3. Erfassen

4.a) Verarbeitung

4.b) Indexierung

5. Kontroll-ausdruck

6. IntellektuelleKorrektur

7. EDV-Korrektur 8. Speichern,anbieten


Generierung der relationalen Datenbanktabellenund des Basic Index:


Aufbau einer Datenbank

Datenbank

DOKUMENT FILE INDEX FILE(invertierte Listen)

enthält die voll- sortierte Listenständigen Angaben mit Schlagworten,zu jedem Dokument Autoren, Titelworten

Daten für die Daten für dieErgebnis-Anzeige Suche

(DISPLAY) (SEARCH)


Beispieldokument aus derbibliographischen Datenbank CHEMICAL ABSTRACTS

Dokumententyp: Journal

AN 1997:57222 CAPLUSDN 126:101551TI Chaperone functions common to nonhomologous Epstein-Barr

virus gL and Varicella-Zoster virus gL proteinsAU Li, Qingxue; Buranathai, Chantanee; Grose, Charles; Hutt-Fletcher,

Lindsey M.CS School of Biological Sciences, University of Missouri-Kansas City,

Kansas City, MO, 64110, USASO J. Virol. (1997), 71(2), 1667-1670

CODEN: JOVIAM; ISSN: 0022-538XDT JournalLA EnglishCC 10-1 (Microbial, Algal, and Fungal Biochemistry)AB Herpesviruses encode the complex-forming, essential glycoproteins gH

and gL. Maturation and transport of gH are dependent oncoexpression of its chaperone, gL. The gL proteins ofalpha herpesviruses and gamma herpesviruses do not have asignificant percentage of amino acid sequence homol. Yet, as wereport herein, the diverse gL glycoproteins of Epstein-Barr virus(EBV) and varicella-zoster virus (VZV) were functionallyinterchangeable, although membrane expression and maturation of gHwere sep. functions for these viruses. In VZV both functions wereperformed by a single protein. EBV required two sep. glycoproteins,one of which can be replaced by its homologous protein from VZV, adistant relative of EBV. Collectively, these results suggested thatVZV gL is a simpler form of the gL chaperone protein thanEBV gL.

ST Epstein Barr virus gL protein; Varicella Zoster virus gLglycoprotein

IT Human herpesvirus 3Human herpesvirus 4

(chaperone functions common to nonhomologousEpstein-Barr virus gL and Varicella-Zoster virus gL proteins)

IT ChaperoninsRL: BSU (Biological study, unclassified); BIOL (Biological study)

(chaperone functions common to nonhomologousEpstein-Barr virus gL and Varicella-Zoster virus gL proteins)

IT Proteins, specific or classRL: BSU (Biological study, unclassified); BIOL (Biological study)

(gene UL1; chaperone functions common to nonhomologousEpstein-Barr virus gL and Varicella-Zoster virus gL proteins)


Beispieldokument aus derbibliographischen Datenbank CHEMICAL ABSTRACTS

Dokumententyp: Konferenz

AN 1996:587746 CAPLUSDN 125:266705TI Pulsed field gel electrophoresis for detection of gene

rearrangements in Duchenne muscular dystrophyAU Cockburn, David J.; Seller, AnnekeCS Oxford Medical Genetics Laboratories, Churchill Hospital, Oxford, UKSO Mol. Diagn. Genet. Dis. (1996), 283-298. Editor(s): Elles, Rob.

Publisher: Humana, Totowa, N. J.CODEN: 63JUAW

DT ConferenceLA EnglishCC 3-1 (Biochemical Genetics)

Section cross-reference(s): 9, 14AB Pulsed-field gel electrophoresis (PFGE) is one of several techniques

available for mutation detection and carrier identification indystrophinopathies. The power of the technique is shown by itscapacity for unambiguous carrier diagnosis and detection ofduplications or more complex rearrangements. The authors believethat the technique deserves to be more widely used, and so theydiscuss the methodol. in detail.

ST Duchenne muscular dystrophy gene rearrangement detection; gelelectrophoresis gene rearrangement muscular dystrophy; PFGEDNA analysis Duchenne muscular dystrophy

IT Mutation(pulsed-field gel electrophoresis for gene rearrangementsdetection in Duchenne muscular dystrophy)

IT Deoxyribonucleic acidsRL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study);BIOL (Biological study); USES (Uses)

(pulsed-field gel electrophoresis for gene rearrangementsdetection in Duchenne muscular dystrophy)

IT Gene, animalRL: BPR (Biological process); BIOL (Biological study); PROC(Process)

(rearrangement; pulsed-field gel electrophoresis for generearrangements detection in Duchenne muscular dystrophy)

IT Muscular dystrophy(Duchenne, pulsed-field gel electrophoresis for generearrangements detection in Duchenne muscular dystrophy)

IT Proteins, specific or classRL: ADV (Adverse effect, including toxicity); BIOL (Biologicalstudy)

(dystrophins, metabolic disorders; pulsed-field gelelectrophoresis for gene rearrangements detection in Duchennemuscular dystrophy)

IT Electrophoresis and Ionophoresis(gel, pulsed-field (PFGE), pulsed-field gel electrophoresis forgene rearrangements detection in Duchenne muscular dystrophy)


Beispieldokument aus derbibliographischen Datenbank BIOTECHABS

Dokumententyp: Journal

AN 97-04199 BIOTECHABSTI Propachlor and alachlor degradation by immobilized and suspended

Pseudomonas cells;Pseudomonas sp. immobilization on Sepiolite ceramic support forpesticide degradation; application in soil decontamination andgroundwater decontamination (conference paper)

AU Ferrer E; Blanco J; Alonso R; Martin MCS Univ.Madrid-Complutense-Vet.; CSIC-Madrid; Univ.Madrid-Polytech.LO Dpt. Bioquimica y Biologia Molecular IV, F. Veterinaria,

Universidad Complutense de Madrid, Spain.SO Prog.Biotechnol.; (1996) 11, 762-69

CODEN: PBITE3 ISSN: 0921-0423Immobilized Cells: Basics and Applications, Noordvrijkerhout, TheNetherlands, 26-29 November, 1996.

DT JournalLA EnglishAB Propachlor (PCH) and alachlor (ACH) pesticide degradation by

immobilized and suspended Pseudomonas sp. PEM1 was investigated forsoil decontamination and groundwater decontamination. Cells wereimmobilized on a ceramic (Sepiolite) support and grown aerobicallyat 30 deg in minimal medium PJC. C-sources were added at 100-500ppm PCH and 100-500 ppm ACH, respectively. The OD of the mediumwas measured at 600 nm and the biomass concentration was determinedusing a previously established calibration curve. PCH and ACHconcentrations were determined by HPLC. Kinetic parameters wereestimated using nonlinear parameter estimation methods and comparedbetween immobilized and suspended cells. The effect ofinoculum/support ratio on kinetic parameters was investigated.Implications of these results for developing an industrial processwith immobilized cells are discussed. (16 ref)

CC M WASTE DISPOSAL AND THE ENVIRONMENT; M2 EnvironmentalBiotechnology; K BIOCATALYSIS; K2 Application; E AGRICULTURE; E3Pesticides

CT PROPACHLOR, ALACHLOR PESTICIDE DEGRADATION, PSEUDOMONAS SP.IMMOBILIZATION, SEPIOLITE CERAMIC SUPPORT, APPL. SOILDECONTAMINATION, GROUNDWATER DECONTAMINATION HERBICIDE C-AMIDECHLORINE AMINE ARENE ETHER BACTERIUM BIOREMEDIATION (VOL.16, NO.7)


Beispieldokument aus derbibliographischen Datenbank BIOTECHABS

Dokumententyp: Patent

AN 95-14744 BIOTECHABSTI Polypeptide with a sequence comprising repeats of a unit amino acid

sequence; used to form spider silk fiberAU Lewis R V; Colgin MPA Univ.WyomingPI WO 9525165 21 Sep 1995AI WO 95-US3139 14 Mar 1995PRAI US 94-209747 14 Mar 1994DT PatentLA EnglishOS WPI: 95-336970 [43]AB A minor ampullate ***spider*** ***silk*** protein of a

specified sequence is claimed. Also claimed are: i. an isolatedDNA encoding the protein; ii. a fiber comprising an aggregate ofthe polypeptide; iii. a host cell transformed with the DNA of (i.);iv. a polypeptide comprising repeats of an amino acid sequence offormula: ((GR)(GA)a(A)b)(GGX)c(GA)a(A)b, where X = Tyr, Gln, Ala, a= 1-6, b = 0-4 and c = 1-4, and the sequence first sequence (inparentheses) may be absent; v. DNA encoding (iv); vi. a host celltransformed with the DNA of (v.); and vii. DNA comprising apolynucleotide which will hybridize to the DNA of (i.). The proteinsequence preferably comprises at least 1 repeating unit of 14 givenunit amino acid repeat sequences. The polypeptide furthercomprises 1 or 2 N-terminal and 1 of 4 C-terminal amino acidsequences. The preferred DNA of (i.) has a 2795 base sequence.Comparison of the amino acid sequences derived from the translationwith the sequences of short peptides obtained from solubilizedminor ampullate ***spider*** ***silk*** suggests that thenonrepetitive portions of the protein are cleaved from the proteinduring secretion from the cells synthesizing the spidroins. (86pp)

CC H OTHER CHEMICALS; H3 Miscellaneous Chemicals; A GENETICENGINEERING AND FERMENTATION; A1 Nucleic Acid Technology

CT MINOR AMPULLATE ***SPIDER*** ***SILK*** PROTEIN DNASEQUENCE, PROTEIN SEQUENCE REPEAT UNIT CHARACTERIZATION, APPL. SILKFIBER PREP. ANIMAL (VOL.14, NO.24)


Beispieldokument aus derForschungsdatenbank FORKAT

FILE 'FORKAT' ENTERED AT 11:00:29 ON 14 DEC 96COPYRIGHT (C) 1996 Bundesminister fuer Forschung und Technologie (BMFT)FILE LAST RELOADED: 15 SEP 96 <960915/UP>FILE COVERS 1986 TO DATE.

L2 ANSWER 5 OF 394 FORKAT COPYRIGHT 1996 BMFTAN 96(1):31123 FORKATTI Verbundprojekt: Identifizierung von Rapssorten mit

Mikrosatelliten-Markern.Mikrosatelliten-Marker beim Raps.

CSCO Norddeutsche Pflanzenzucht Hans-Georg Lembke KGHohenlieth24363 Holtsee

CSP Norddeutsche Pflanzenzucht Hans-Georg Lembke KGHohenlieth24363 Holtsee

NC 0311261; 00002436CSSC BMFT-Referat: 514CSMC PT-KFA BEO22DB 01 Jul 1996DE 30 Jun 1999FU DM 316.410,00CC K04011 Biotechnische Methoden zur PflanzenzuechtungGC Empfaenger: 01058080 Durchf. Inst.: 01058080

Display Code Definition------------ ----------

AN Accession NumberTI Title of ProjectCSCO ContractorCSP Performing OrganizationNC Number of ContractCSSC Supporting Organization CodeCSMC Monitoring Organization CodeDB Duration Date, BeginDE Duration Date, EndFU FundingRE ReferenceCC Classification CodeGC Geographical Code


Beispieldokument aus derFaktendatenbank RTECS(Registry of Toxic Effexts of Chemical Substances)

L9 ANSWER 2 of 336 RTECS COPYRIGHT 1996 DOCCAS Registry Number (RN): 145594-43-0 RTECSRTECS Number (RTN): TW3580500Molecular Formula (MF): C32 H51 N7 O9 . Cl HFormula Weight (FW): 714.36Chemical Name (CN): L-Prolinamide, 5-oxo-L-prolyl-L-histidyl-N-(6-

oxo-6-(1,4,7-tetraoxa-13-azacyclopentadec-13-yl)hexyl)-, monohydrochlorideN-(Pyroglytamylhistidylprolyl-6-aminohexanoyl)aza-15-crown-5 hydrochloride;

Class Identifier (CI): DrugEntry/Update Date (DATE): Sep 1995Character Count: 524

Absolute stereochemistry.

TOXICITY DATA (TOX):

Route |Organism| Dose | SourceRTE | ORGN | DOSE | SO

===============+========+=========+=========intraperitoneal|mouse |LD50 >500|PCJOAU

| |mg/kg |26,446,92

TOXICITY DATA REFERENCES:PCJOAU Pharmaceutical Chemistry Journal (English Translation)Translation of KHFZAN. (Plenum Pub. Corp., 233 Spring St., New York, NY10013) No.1- 1967-


Beispieldokument aus derFaktendatenbank REGISTRY

RN 79517-01-4 REGISTRYCN L-Cysteinamide, D-phenylalanyl-L-cysteinyl-L-phenylalanyl-D-

tryptophyl-L-lysyl-L-threonyl-N-[2-hydroxy-1-(hydroxymethyl)propyl]-, cyclic (2.fwdarw.7)-disulfide, [R-(R*,R*)]-, acetate (salt) (9CI)(CA INDEX NAME)

OTHER CA INDEX NAMES:CN 1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane, cyclic peptide deriv.OTHER NAMES:CN Octreotide acetateCN SandostatinCN SMS 201-995acFS PROTEIN SEQUENCEMF C49 H66 N10 O10 S2 . x C2 H4 O2LC STN Files: AGRICOLA, BIOBUSINESS, BIOSIS, CA, CAPLUS, CIN,

DRUGPAT, DRUGUPDATES, IPA, PNI, PROMT, RTECS*, TOXLINE, TOXLIT,USAN, USPATFULL

(*File contains numerically searchable property data)

CM 1

CRN 83150-76-9CMF C49 H66 N10 O10 S2CDES *

CM 2

CRN 64-19-7CMF C2 H4 O2

90 REFERENCES IN FILE CA (1967 TO DATE)3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

90 REFERENCES IN FILE CAPLUS (1967 TO DATE)


Sequenz-Informationen aus derFaktendatenbank REGISTRY

=> d sqd

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1997 ACSRN 79517-01-4 REGISTRYFS PROTEIN SEQUENCESQL 8NTE modified----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------bridge Cys-2 - Cys-7 disulfide bridgemodification - - undetermined modificationmodification Thr-8 - undetermined modification----------------------------------------------------------------------

SEQ 1 FCFWKTCT

=> d seq3

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1997 ACS

SEQ3 1 Phe-Cys-Phe-Trp-Lys-Thr-Cys-Thr


Beispieldokument aus der „gemischten“ DatenbankDGENE (Bibliographie + Fakten)

AN 88P-P80855 protein DGENETI Creating new breed(s) of animals - by introducing a gene sample of

hormone homolgous with the ovum into the male nucleus of afertilised ovum

IN Seamark R F; Wells J R EPA (LUMI-N) Luminis Pty LtdPI WO 8808026 A 881020 35 ppAI WO 88-AU109 880414PRAI AU 87-5326 871110PSL Example; Fig 6DED 15 JAN 1991 (first entry)DT PatentLA EnglishOS 88-307564 [43]CR N-PSDB: 88N-N80882; 88N-N80885; 88N-N80886; 88N-N80887; 88N-N80888DESC Sequence of N-terminal methionyl-porcine growth hormone encoded on

plasmid pGHX.1KW Transgenic animal; somatotrophinORGN Sus scrofaAB A method for creating new breeds of animals comprises (a) obtaining

a recently fertilised ovum, (b) isolating a gene sample of acharacterising hormone homologous with the ovum, (c) introducingthe gene sample into the male nucleus of the ovum prior to fusionwith the female nucleus to form a single cell embryo and (d)subsequently implanting the ovum into a suitably prepd. femaleanimal. Also claimed is a plasmid expression vector comprising aplasmid cloning vector including a first cloned sequence of DNAencoding a non-porcine promoter region and a second cloned sequenceencoding porcine growth hormone activity

AA 1 A; 0 R; 0 N; 2 D; 0 B; 0 C; 0 Q; 1 E; 0 Z; 0 G; 0 H; 0I; 0 L; 0 K; 3 M; 1 F; 2 P; 0 S; 0 T; 0 W; 0 Y; 0 V; 1Others;

SQL 11SEQ

1 meddxmfpam p


Zugang zu STN International

Über folgende Datennetze ist ein Zugang zu STN aus der Schweiz möglich:

1. TELEPAC 2. BT Tymnet 3. Internet

1. TELEPAC:

Das TELEPAC ist das paketvermittelnde Datennetz der SWISSCOM und ermöglichteinen geschwindigkeitsanpassenden Zugang zu STN. STN ist z. Z. mit einerGeschwindigkeit von 2 Mbit/s am internationalen paketvermittelnden Datennetzangeschlossen. Die Nutzer von STN können mit jeder in TELEPAC erlaubtenGeschwindigkeit zu STN kommen. Die Geschwindigkeiten werden durch einenPuffer angepasst.

Das TELEPAC-Netz können die Nutzer unterschiedlich erreichen:

a) Zugang über das Fernsprechnetz (TELEPAC X.28):

Dabei wird der nächstliegende TELEPAC X.28 Knoten über das Telefonnetzangewählt. In der ganzen Schweiz sind Einwählzugänge mit der einheitlichenRufnummer 0848828800 (28800 bit/s oder weniger) und Möglichkeiten derFehlerkorrektur (MNP 1 bis 5) und Datenkompression (V42bis) eingerichtet.

Für die Datenübertragung können BAKOM-zugelassene Modems benutzt werden.Multifunktionsmodems nach V32bis für 14.400 bit/s sind ab Fr. 200.-- erhältlich.

Die Anpassung dieser asynchronen Datenübertragung an das synchrone TELEPAC-Netz wird in den Knoten durch sogenannte PAD’s (Packet Assembly/Disassemblyfacility) vorgenommen. Beim Zugang über das Fernsprechnetz muss zusätzlich zuden monatlichen Abonnements- und den daten- und zeitabhängigen Gebühren(Rechnung Swisscom) die Telefongebühr zum nächsten TELEPAC-Knoten bezahltwerden, die entfernungsunabhängig berechnet wird (Stand August 1997:Fr. 15.-- pro Monat).


Zugang zu STN International

b) Hauptanschluss (synchron) an den „Basisdienst“ (TELEPAC X.25):

Hier wird eine feste Verbindung zum TELEPAC-Knoten geschaltet. Es handelt sichum eine synchrone Verbindung nach CCITT-Empfehlung X.25 direkt an daspaketvermittelnde Datennetz. Die Datenpakete werden direkt vom Endgerätbereitgestellt. Wenn man also einen PC (oder LAN-Server) an TELEPAC X.25anschliesst, muss das Datenendgerät über einen Software- oder einen Hardware-PAD nach den Konventionen X.3/X.28/X.29 verfügen (Kosten: ab Fr. 1500.-). DerVorteil bei einem TELEPAC X.25 Anschluss liegt darin, dass man bis zu 256Datenkanäle gleichzeitig über einen Hauptanschluss betreiben kann, wobeizusätzliche Datenkanäle abgestuft zusätzlich berechnet werden. Die monatlichenGrundgebühren richten sich nach der Datenübertragungsgeschwindigkeit und liegenbei Fr. 240.-- bis 800.-- pro Monat.

Auskünfte und Anmeldung TELEPAC bei Ihrer Swisscom, Tel. 113.

2. BT Tymnet:

Eine Alternativ-Verbindung zu STN bietet BT mit Einwählknoten für 9600 bit/s.Sie können sofort ohne Anmeldung damit arbeiten. Die Netzwerkkosten werdendirekt über STN verrechnet.

Basel: 0613321777 Genf: 0227886800 Helpdesk Tymnet:Neuenburg: 0327530333 Zürich: 018370077 0800553534

3. Internet:

STN ist auch über das weltweite Datennetz Internet erreichbar (TCP/IP-Protokoll).Neben den Zugriffen auf die Datenbanken ist auch eine elektronische Auslieferungder Prints über das Internet möglich. Via STNmail lassen sich auch Internet-Mailboxen ansprechen und Internet-Benutzer können STNmail-Adressen erreichen.

Netzwerkadressen:

Internationale NUA: 26245724720001(Telepac) 26245724790114

Internet: stn.fiz-karlsruhe.de

WWW-Server für Informationenzu STN International und InfoLit: http://www.fiz-karlsruhe.de/

http://www.infolit.ch/


Datenbanken auf den Gebieten der BIOTECHNOLOGIE

Von den rund 200 Datenbanken bei STN International befassen sich im Prinzip ca.40 mehr oder weniger mit den Themen der BIOTECHNOLOGIE. Diese Files befassensich mit verschiedenen Disziplinen, so z.B. Landwirtschaft, Umwelttechnologie, Pharma.Gemäss Wichtigkeit für den Informationssuchenden können sie in vier Kategorieneingeteilt werden:

Datenbank mit Schwerpunkt BIOTECHNOLOGIE:

BIOTECHABS Hersteller: Derwent Information Ltd., UK(BIOTECHDS) Zeitraum: 1982 bis heute

Update: Zweiwöchentlich

Datenbanken mit Schwerpunkt GENTECHNOLOGIE:

DGENE Hersteller: Derwent Information Ltd., UKZeitraum: 1981 bis heuteUpdate: Zweiwöchentlich

GENBANK Hersteller: National Center for BiotechnologyInformation, U.S.A.

Zeitraum: 1982 bis heuteUpdate: Wöchentlich

Datenbanken beinhaltend die Themen der BIOTECHNOLOGIEunter anderen Themen:

Beispielsweise ADISALERTS, ADISINSIGHT, AGRICOLA, AIDSLINE,BIOBUSINESS, BIOSIS, CABA, CANCERLIT, CAPLUS,CBNB, CEN, CIN, CONFSCI, DISSABS, DDFU, DRUGU(nur Derwent Subscriber), EMBASE, FSTA, FORIS,MEDLINE, REGISTRY, SCISEARCH, TOXLINE, TOXLIT

Patentdatenbanken:

Beispielsweise DRUGPAT, WPI, PATDPA, PATOS, USPATFULL, JAPIO


Pharmazeutische Datenbanken bei STN,und wozu Sie benutzt werden können (Auswahl)

Chemische Strukturen REGISTRY

Biosequenzen REGISTRY (GENBANK), DGENE

Patentanmeldungenund -familien

USPATFULL, WPINDEX / WPIDS

Details klinischer Studien,

Stand derEntwicklung/Anmeldung

PHAR, DRUGUPDATES, ADISALERT, ADISINSIGHT

Biologie, Medizin,Toxikologie

BIOSIS, LIFESCI, BIOTECHABS, IPA,MEDLINE, EMBASE, TOXLINE, TOXLIT

Business (inkl. rechtl. bzw.patentrechtliche Angaben)

CIN, BIOBUSINESS, PROMT, DRUGNL,INVESTEXT, PNI, PHIC / PHIN


Die Abfragesprache Messenger

Informationen werden bei STN mit der Retrievalsprache Messenger abgefragt.

Die Suchsprache Messenger kennt eine Anfänger- und eine Fortgeschrittenen-Version.

Anfänger-Version: Hilfestellung bei Verwendung eines Kommandos. Der Rechnerfordert alle erforderlichen Optionen für ein Kommando an.

Experten-Version: das System setzt voraus, dass alle möglichen Optionen für dasKommando bekannt sind.

Grundbefehle in der Anfänger-Version:

file caplus Auswahl der Datenbank

search pcr Suche nach Begriffen

expand westblom t/au Auflisten von Feldinhalten

display L5 1-10 all Online-Ausgabe der Suchergebnisse

print Offline-Ausgabe bei STN in Karlsruhe bzw. in eine E-Mailbox

logoff Beenden der Online-Sitzung

Grundbefehle in der Experten-Version:

fil biobusiness Datenbank „BIOBUSINESS“

s health care system Suche nach Dokumenten

e mydans s/au Alphabetische Auflistung der Autoren um „S. Mydans“

d L5 1-10 all Online-Ausgabe der Dokumente Nr 1 bis 10 desAntwortsatzes L5, Ausgabeformat „All“,d. h. alle Datenbank-Felder

pri Offline-Ausgabe bei STN in Karlruhe bzw. in eine E-Mailbox

log Beenden der Online-Sitzung


Die Grundbefehle der Retrievalsprache Messenger

1. NEWS Anzeige der News

2. HELP Online-Hilfesystem

3. FILE DGENE Auswahl einerDatenbank

4. EXPAND MILER/IN Auflisten vonFeldinhalten

5. SEARCH LASER Suche nachBegriffen

LOGISCHEVERKNÜPFUNG OR AND NOT

6. DISPLAY L5 1-3 PA Online-Ausgabe der Suchergebnisse

7. LOGOFF Beenden derOnline-Sitzung


Typisches Beispiel einer Recherchemit Freitextoperatoren:

Gesucht sind Peptidsequenzen als Appetitzügler.

=> fil dgene

FILE 'DGENE' ENTERED AT 07:14:28 ON 18 MAR 1997COPYRIGHT (C) 1997 DERWENT INFORMATION LTDFILE LAST UPDATED: 09 MAR 97 <970309/UP>

=> sea (appetite?(3a)suppress?)/ti or (weight and (loss or regulat?))/ti174 APPETITE?/TI

2220 SUPPRESS?/TI143 (APPETITE?(3A)SUPPRESS?)/TI98 WEIGHT/TI

234 LOSS/TI5014 REGULAT?/TI

L1 143 (APPETITE?(3A)SUPPRESS?)/TI OR (WEIGHT AND (LOSS OR REGULAT?))/TI

=> d ti sqide

L1 ANSWER 1 OF 143 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDTI New glyco:protein isolated from Pleurotus ostreatus - useful as

***appetite*** ***suppressing*** agentAN 95P-R84095 peptide DGENEAA 2 A; 1 R; 0 N; 0 D; 0 B; 0 C; 1 Q; 0 E; 0 Z; 1 G; 0 H; 1

I; 0 L; 1 K; 0 M; 1 F; 1 P; 0 S; 3 T; 0 W; 0 Y; 1 V;SQL 13SEQ

1 atvkitatpr qfg

=> d ti sqide 120

L1 ANSWER 120 OF 143 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDTI Peptide agonists of litorin, gastrin releasing peptide - neuromedin

B or C or bombesin, for treating cancer, preventing smooth muscleproliferation and ***suppressing*** ***appetite*** andalcohol craving

AN 91P-R14878 Protein DGENEAA 2 A; 0 R; 0 N; 0 D; 0 B; 0 C; 0 Q; 0 E; 0 Z; 0 G; 2 H; 0

I; 2 L; 0 K; 0 M; 0 F; 0 P; 0 S; 0 T; 1 W; 0 Y; 1 V;SQL 8SEQ

1 hwavahll

FEATURE TABLE:Key |Location|Qualifier|===============+========+=========+=======================Modified_site |5 |label |D-Ala


Datenbankübergreifende Suche (Crossfile searching)

Fortsetzen der Suche in einer anderenDatenbank mit bereits erzeugtenL-Nummern

Feldkennungen müssen identisch sein

Suchprofil muss suchbar sein

=> fil medline

FILE 'MEDLINE' ENTERED AT 16:18:17 ON 30 JUN 1998FILE LAST UPDATED: 25 JUN 1998 (19980625/UP). FILE COVERS 1966 TO DATE.

=> s multiple sclerosis and gene### and therap?247496 MULTIPLE37712 SCLEROSIS17794 MULTIPLE SCLEROSIS

(MULTIPLE(W)SCLEROSIS)784982 GENE###

1671413 THERAP?L1 237 MULTIPLE SCLEROSIS AND GENE### AND THERAP?

=> fil biosis

FILE 'BIOSIS' ENTERED AT 16:19:33 ON 30 JUN 1998COPYRIGHT (C) 1998 BIOSIS(R)FILE COVERS 1969 TO DATE.RECORDS LAST ADDED: 24 June 1998 (980624/ED)

=> s L1194296 MULTIPLE44859 SCLEROSIS15538 MULTIPLE SCLEROSIS

(MULTIPLE(W)SCLEROSIS)927445 GENE###604786 THERAP?

L2 105 MULTIPLE SCLEROSIS AND GENE### AND THERAP?


Datenbankübergreifende Suche (Crossfile searching)

Spezialfall: Nach Substanzsuche im CAS Registry File wird mit Crossfile searchingim CAPLUS die RN (und DR!) übernommen. Die RN wird in alle Files übertragen,die zu den entsprechenden Substanzen im REGISTRY-Feld LC (Locator) aufgelistetsind.

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:21:57 ON 13 MAR 1997COPYRIGHT (C) 1997 American Chemical Society (ACS)

=> e sorbitol/cnE1 1 SORBITHOME TE/CNE2 1 SORBITHOME TO/CNE3 1 --> SORBITOL/CNE4 1 SORBITOL .5 HYDRATE/CNE5 1 SORBITOL 1,2,5,6-TETRADECANOATE/CNE6 1 SORBITOL 1,5,6-TRIDECANOATE/CNE7 1 SORBITOL 1,5-DISTEARATE/CNE8 1 SORBITOL 1,6-DIDECANOATE/CNE9 1 SORBITOL 1,6-DIDOCOSANOATE/CNE10 1 SORBITOL 1,6-DIEICOSANOATE/CNE11 1 SORBITOL 1,6-DIPALMITATE/CNE12 1 SORBITOL 1,6-DISTEARATE/CN

=> s e3L1 1 SORBITOL/CN

=> d str



=> fil caplusFILE 'CAPLUS' ENTERED AT 16:22:23 ON 13 MAR 1997COPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1 and side effect#9633 L1

197205 SIDE3378614 EFFECT#

19379 SIDE EFFECT#(SIDE(W)EFFECT#)

L2 30 L1 AND SIDE EFFECT#


Fortgeschrittene Messenger-Kommandos: TypischesBeispiel einer Recherche mit SELECT und ANALYZE:

Gesucht sind Beispiele (deutscher) Firmen auf dem Gebiet der Kosmetika imZusammenhang mit „Alterung der Haut“.

Suchkommando mit Freitext und Patentklasse kombiniert:

=> s (aging or ageing) and A61K007/icm and skin?

80871 AGING3805 AGEING13075 A61K007/ICM

104314 SKIN?L1 246 (AGING OR AGEING) AND A61K007/ICM AND SKIN?

SELECT aller Patentanmelder aus L1:(mit SELECT werden E-Nummern erzeugt)

=> sel L1 pa 1-

E1 THROUGH E129 ASSIGNED

Anzeige der selektierten Angaben nach Häufigkeit:

=> d sel e1-e10

E1 27 KANEBO LTD, JAPAN/PAE2 22 KANEBO, LTD., JAPAN/PAE3 20 SHISEIDO CO LTD, JAPAN/PAE4 11 OREAL S. A., FR./PAE5 8 KOSEI KK, JAPAN/PAE6 8 NOEVIR KK, JAPAN/PAE7 7 BEIERSDORF A.-G., GERMANY/PAE8 6 POLA KASEI KOGYO KK, JAPAN/PAE9 6 PROCTER AND GAMBLE CO., USA/PAE10 5 SHISEIDO CO., LTD., JAPAN/PA

ANALYZE aller Patentanmelder aus L1:(mit ANALYZE werden L-Nummern erzeugt)

=> ana L1 pa 1-

*** SmartSELECT INITIATED ***

L2 SEL L1 1- PA : 129 TERMS


Fortgeschrittene Messenger-Kommandos: TypischesBeispiel einer Recherche mit SELECT und ANALYZE:

Anzeige der selektierten Angaben in alphabetischer Reihenfolge:

=> d alp


TERM # # OCC # DOC % DOC PA------ ------- ------ ------ ---------------

1 1 1 0.41 ADOBANSUTO SUKIN RISAACHI KENK, JAPAN2 1 1 0.41 AJINOMOTO KK, JAPAN3 1 1 0.41 ARVAL S.P.A., ITALY4 1 1 0.41 BASF A.-G., GERMANY5 1 1 0.41 BAYER A.-G., GERMANY6 1 1 0.41 BEECHAM GROUP PLC, UK7 7 7 2.85 BEIERSDORF A.-G., GERMANY8 1 1 0.41 BEIJING PETROCHEMICAL COLLEGE, PEOP. REP. CHI9 1 1 0.41 BIOTECH HAIR K. K., JAPAN

10 1 1 0.41 BISOO KK, JAPAN

Anzeige der selektierten Angaben nach Häufigkeit:(Weitere Einengung: nur diejenigen Ergebnisse mit der Zeichenkette „germany“)

=> d doc with "germany"


TERM # # OCC # DOC % DOC PA------ ------- ------ ------ ---------------

7 7 7 2.85 BEIERSDORF A.-G., GERMANY18 2 2 0.81 GERMANY35 1 1 0.41 BASF A.-G., GERMANY36 1 1 0.41 BAYER A.-G., GERMANY58 1 1 0.41 GOLDWELL GMBH, GERMANY78 1 1 0.41 LTS LOHMANN THERAPIE-SYSTEME GMBH UND CO. KG,80 1 1 0.41 MARBERT GMBH, GERMANY85 1 1 0.41 NEW STANDARD GMBH, GERMANY

123 1 1 0.41 WOGEPHRAM GMBH, GERMANY

Anderes Beispiel, Anzeige im Delimited-Format:

=> d delim 1-3

L8 SEL L7 1- PA IN : 699 TERMS

1;25;25;5.04;AMADA CO LTD2;17;17;3.43;NIPPON STEEL CORP3;11;11;2.22;TOYOTA JIDOSHA KK


SDI

Selective Disseminationof Information

= Profildienst

In einem nach jeder Aktualisierung einerbestimmten Datenbank aktivierten Suchlaufwerden alle neu hinzugekommenen Zitatedurchsucht. Die gefundenen Antwortsätzekönnen online verschickt oder gespeichertwerden.

=> sdi

ENTER QUERY L# FOR SDI REQUEST OR (END):l2ENTER SDI REQUEST NAME, (AA001/S), OR END:leqwfa/sENTER COST CENTER (NONE) OR NONE:.ENTER TITLE (NONE):Protein with Subsequence leqwfaENTER METHOD OF DELIVERY (OFFLINE),ONLINE,EMAIL, OR FAX:emailENTER EMAIL ID (2441K):[email protected]@THENET.CH.INTERNET

RECEIVE DELIVERY NOTIFICATION? (Y)/N:nELIMINATE PREVIOUSLY SEEN ANSWERS WITH EACH SDI RUN? Y/(N):.ENTER PRINT FORMAT (BIB) OR ?:allHIGHLIGHT HIT TERMS? (Y)/N:nENTER MAXIMUM NUMBER OF HITS TO BE PRINTED PER RUN (100):.SORT SDI ANSWER SET (N)/Y?:.SEND SDI WITH NO ANSWERS? (Y)/N:nENTER SDI EXPIRATION DATE 'YYYYMMDD' OR (NONE):.QUERY 'L2' HAS BEEN SAVED AS SDI REQUEST 'LEQWFA/S'


ORDER / ORD

= Bestellen von Originalliteraturdirekt nach einer Recherche:

=> fil wpindex

FILE 'WPINDEX' ENTERED AT 15:01:59 ON 14 MAR 1997'TRIAL' IS DEFAULT FORMAT FOR 'WPINDEX' FILE

=> s spider silk and lewis?/inL1 2 SPIDER SILK AND LEWIS?/IN

=> fil dgene


=> s L1L2 41 SPIDER SILK AND LEWIS?/IN

=> d ti pa pi

L2 ANSWER 1 OF 41 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDTI Polypeptide(s) comprising repeated unit amino acid sequences, also

cDNAs - derived from minor ampullate spider silk proteins and usedto form spider silk fibres

PA (UYWY-N) UNIV WYOMINGPI WO 9525165 A1 950921 86 pp

=> order wilaPLEASE ENTER YOUR NAME AND PHONE, TELEX, OR TELEFAX NUMBER:Andreas Litscher +41 31 998 44 77 +41 31 998 44 73ENTER CUSTOMER NO. ASSIGNED BY SUPPLIER OR (NONE):.MAILING ADDRESS = HERRN ANDREAS LITSCHER

INFOLIT INFORMATION BROKERMORGENSTR. 129CH-3018 BERN

MODIFY MAILING ADDRESS? Y/(N):.ENTER METHOD OF PAYMENT (BILL) OR OTHER:.URGENT DELIVERY? Y/(N):.ENTER METHOD OF SHIPPING (STANDARD) OR OTHER:.ENTER (L2 ), L#, ACC, OR BIB:.ENTER ANSWER NUMBERS, RANGE, OR (END):1ENTER REMARKS OR (NONE):.DOCUMENT ORDER NUMBER D073078F ASSIGNED TO ANSWER '1' OF 'L2 'ENTER ANSWER NUMBERS, RANGE, OR (END):.


Offline-Vorbereitung / Automatische Abläufe:Die STN Express Command Files

Das Command File (oder sog. "Script" oder "Makro") OFFLINE

\* STN Express Command File nspray.sc\*\* Recherchenaufgabe: Zum Thema "Nasenspray bei Schnupfen"\* soll wissenschafliche und Patentliteratur der letzten\* 10 Jahre gefunden werden\* ----------------------------------------------------------------------

=> DEL HIS Y

=> FILE CAPLUS=> S NASAL DRUG DELIVERY SYSTEMS/CT,TI \> _L1=> S _L1 AND SPRAY### \> _L2=> S _L2 OR (NASAL OR NOSE)(1A)SPRAY### \> _L4=> S DECONGEST####/CT,TI \> _L5=> S _L4 AND _L5 \> _L6=> S _L6 AND PY>1987 \> _L7

=> FILE MEDLINE=> S NASAL DECONGESTANT?/CT,TI \> _L8=> S _L8 AND SPRAY?/CT,TI \> _L9=> S _L9 AND PY>1987 \> _L10

=> FILE EMBASE=> S DECONGEST?/CT,TI \> _L11=> S _L11 AND (NOSE? OR NASAL)/CT,TI AND SPRAY?/CT,TI \> _L12=> S _L12 AND PY>1987 \> _L13

=> FILE BIOSIS=> S DECONGEST#### AND (NASAL OR NOSE)(1A)SPRAY### \> _BL1=> S _BL1 AND PY>1987 \> _BL2

=> FILE CAPLUS MEDLINE EMBASE BIOSIS=> S _L7 OR _L10 OR _L13 OR _BL2 \> _L14=> SET DUPORDER FILE=> DUP REM _L14 \> _L15=> D TI CT TOT NOH

=> FILE ADISALERT=> S DECONGEST#### AND (NASAL OR NOSE)(1A)SPRAY### AND PY>1987 \> _ADISL1\* sind alles klinische Studien. Originaldokumente im Volltext!=> D TRIAL TOT NOH

=> FILE WPINDEX=> S (NASAL OR NOSE)(1A)SPRAY### \> _PL1=> S DECONGEST#### \> _PL2=> S _PL1 AND _PL2 OR (NASAL DECONGEST#### AND SPRAY?) \> _PL2=> S _PL2 AND PY>1987 \> _PL3=> D TI TRIAL TOT NOH

=> D HIS

\* ----------------------------------------------------------------------\* InfoLit Information Broker - Andreas Litscher - 15.8.1998


Offline-Vorbereitung / Automatische Abläufe:Die STN Express Command Files

Die Ausführung des Command File ONLINE

=> D HIS

(FILE 'HOME' ENTERED AT 16:39:20 ON 15 AUG 1998)DEL HIS Y

FILE 'CAPLUS' ENTERED AT 16:39:42 ON 15 AUG 1998L1 279 S NASAL DRUG DELIVERY SYSTEMS/CT,TIL2 76 S L1 AND SPRAY###L3 501 S L2 OR (NASAL OR NOSE)(1A)SPRAY###L4 242 S DECONGEST####/CT,TIL5 11 S L3 AND L4L6 8 S L5 AND PY>1987

FILE 'MEDLINE' ENTERED AT 16:39:59 ON 15 AUG 1998L7 705 S NASAL DECONGESTANT?/CT,TIL8 44 S L7 AND SPRAY?/CT,TIL9 17 S L8 AND PY>1987

FILE 'EMBASE' ENTERED AT 16:41:13 ON 15 AUG 1998L10 952 S DECONGEST?/CT,TIL11 17 S L10 AND (NOSE? OR NASAL)/CT,TI AND SPRAY?/CT,TIL12 14 S L11 AND PY>1987

FILE 'BIOSIS' ENTERED AT 16:42:18 ON 15 AUG 1998L13 39 S DECONGEST#### AND (NASAL OR NOSE)(1A)SPRAY###L14 29 S L13 AND PY>1987

FILE 'CAPLUS, MEDLINE, EMBASE, BIOSIS' ENTERED AT 16:44:05 ON 15AUG 1998

L15 152 S L6 OR L9 OR L12 OR L14SET DUPORDER FILE

L16 89 DUP REM L15 (63 DUPLICATES REMOVED)

FILE 'ADISALERTS' ENTERED AT 16:57:25 ON 15 AUG 1998L17 16 S DECONGEST#### AND (NASAL OR NOSE)(1A)SPRAY### AND PY>19

FILE 'WPINDEX' ENTERED AT 16:57:38 ON 15 AUG 1998L18 271 S (NASAL OR NOSE)(1A)SPRAY###L19 445 S DECONGEST####L20 15 S L18 AND L19 OR (NASAL DECONGEST#### AND SPRAY?)L21 11 S L20 AND PY>1987

=> LOG YCOST IN DEUTSCHMARKS SINCE FILE TOTAL

ENTRY SESSIONFULL ESTIMATED COST 31,65 137,43

STN INTERNATIONAL LOGOFF AT 17:01:42 ON 15 AUG 1998


Bibliographische Recherchen:Ausgesuchte STN-Files (Multifile Search)

Gesucht ist Literatur über die Behandlung der Parkinson-Krankheit mitGentherapie oder Gentechnologie

=> index biosis caplus embase medline ddfu lifesci

INDEX 'BIOSIS, CAPLUS, EMBASE, MEDLINE, DDFU, LIFESCI'ENTERED AT 07:30:04 ON 17 AUG 1998

6 FILES IN THE FILE LIST IN STNINDEX

=> s parkinson

16581 FILE BIOSIS5124 FILE CAPLUS

18360 FILE EMBASE24312 FILE MEDLINE2182 FILE DDFU1827 FILE LIFESCI

6 FILES HAVE ONE OR MORE ANSWERS, 6 FILES SEARCHED IN STNINDEX

L1 QUE PARKINSON

=> s L1 and gene### and therap?

268 FILE BIOSIS200 FILE CAPLUS577 FILE EMBASE459 FILE MEDLINE16 FILE DDFU54 FILE LIFESCI

6 FILES HAVE ONE OR MORE ANSWERS, 6 FILES SEARCHED IN STNINDEX

L2 QUE L1 AND GENE### AND THERAP?

=> d rank

F1 577 EMBASEF2 459 MEDLINEF3 268 BIOSISF4 200 CAPLUSF5 54 LIFESCIF6 16 DDFU

Variante:

=> file F2,F3-F5


Bibliographische Recherchen:Der biochemische Aspekt

Wenn viele Suchbegriffe benutzt werden,lohnt sich kostenmässig HCAPLUS statt CAPLUS:

=> file hcaplus

=> e parkinson/ct

E1 1 PARKIA STREPTOCARPA/CTE2 1 PARKIA TIMORIANA/CTE3 0 --> PARKINSON/CTE4 928 PARKINSON'S DISEASE/CTE5 4 PARKINSONIA/CTE6 30 PARKINSONIA ACULEATA/CTE7 4334 PARKINSONISM/CTE8 1 PARKUIA FILICOIDEA/CTE9 1 PARKVILLE VIRUS/CTE10 5 PARLATORIA/CTE11 2 PARLATORIA BLANCHARDI/CTE12 7 PARLATORIA PERGANDII/CT

=> s e4,e7

928 "PARKINSON'S DISEASE"/CT4334 PARKINSONISM/CT

L3 5262 ("PARKINSON'S DISEASE"/CT OR PARKINSONISM/CT)

=> e therapy 5

E1 1 THERAPUTICS/BIE2 1 THERAPWEUTIC/BIE3 91699 --> THERAPY/BIE4 1 THERAPYIN/BIE5 2 THERAPYL/BI

=> e chemotherapy 5

E1 1 CHEMOTHERAPIST/BIE2 2 CHEMOTHERAPUTIC/BIE3 16717 --> CHEMOTHERAPY/BIE4 1 CHEMOTHERAPY2/BIE5 24 CHEMOTHERMAL/BI

=> e left therapy 8

E1 1 THERAPUTICS/BIE2 1 THERAPWEUTIC/BIE3 91699 --> THERAPY/BIE4 2 ACTINOTHERAPY/BIE5 1 ACTIONOTHERAPY/BIE6 1 ADIOIMMUNOTHERAPY/BIE7 1 ADJUNCTTHERAPY/BIE8 4 AEROIONOTHERAPY/BI



=> e 8

E13 20 ANTIBIOTHERAPY/BIE14 1 ANTIGENOTHERAPY/BIE15 2 APITHERAPY/BIE16 21 AROMATHERAPY/BIE17 1 AUREOTHERAPY/BIE18 9 AUTOHEMOTHERAPY/BIE19 1 BACHYTHERAPY/BIE20 4 BACTERIOTHERAPY/BI

=> e left treatment 7

E1 4 TREATMENS/BIE2 1 HYDROTREATMENS/BIE3 1139477 --> TREATMENT/BIE4 1 0TREATMENT/BIE5 1 0RETREATMENT/BIE6 1 106TREATMENT/BIE7 1 1PRETREATMENT/BI

=> s L3 and (control? or ?treat? or ?therap?)

1148737 CONTROL?1918972 ?TREAT?181076 ?THERAP?

L4 3584 L3 AND (CONTROL? OR ?TREAT? OR ?THERAP?)

=> query

ENTER LOGIC EXPRESSION OR (END):gene### therap? or genetic? engineer? orrecombin? or gene### regulat? or transgen? or mol? clon?

GENE### THERAP?(GENE###(W)THERAP?)

GENETIC? ENGINEER?(GENETIC?(W)ENGINEER?)

GENE### REGULAT?(GENE###(W)REGULAT?)

MOL? CLON?(MOL?(W)CLON?)

L5 QUE GENE### THERAP? OR GENETIC? ENGINEER? OR RECOMBIN? OR GENE### REGULAT? OR TRANSGEN? OR MOL? CLON?



=> s L4 and L5

879501 GENE###154488 THERAP?

7938 GENE### THERAP?(GENE###(W)THERAP?)

380876 GENETIC?65452 ENGINEER?10030 GENETIC? ENGINEER?

(GENETIC?(W)ENGINEER?)172187 RECOMBIN?879501 GENE###493038 REGULAT?15540 GENE### REGULAT?

(GENE###(W)REGULAT?)23465 TRANSGEN?

2435789 MOL?194865 CLON?49692 MOL? CLON?

(MOL?(W)CLON?)L6 146 L4 AND L5

=> d scan

L6 146 ANSWERS HCAPLUS COPYRIGHT 1998 ACSCC 2-0 (Mammalian Hormones)

Section cross-reference(s): 1, 14TI Dopamine synthesis, uptake, metabolism, and receptors: relevance to

gene therapy of Parkinson's diseaseST review dopamine receptor parkinsonism gene therapyIT Gene therapy

Parkinson's disease(dopamine synthesis, uptake, metab., and receptors relevance to

gene therapy of Parkinson's disease)IT Dopamine receptors

RL: ADV (Adverse effect, including toxicity); BPR (Biologicalprocess); BIOL (Biological study); PROC (Process)

(dopamine synthesis, uptake, metab., and receptors relevance togene therapy of Parkinson's disease)

IT 51-61-6, Dopamine, biological studiesRL: ADV (Adverse effect, including toxicity); BAC (Biologicalactivity or effector, except adverse); BPR (Biological process); MFM(Metabolic formation); BIOL (Biological study); FORM (Formation,nonpreparative); PROC (Process)

(dopamine synthesis, uptake, metab., and receptors relevance togene therapy of Parkinson's disease)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1



L6 146 ANSWERS HCAPLUS COPYRIGHT 1998 ACSIC ICM C12N015-86

ICS A61K048-00; C12N015-12; C07K014-475; C12N007-01; C12N005-10;A61K039-235

CC 3-5 (Biochemical Genetics)Section cross-reference(s): 1

TI Recombinant adenoviruses coding for brain-derivedneurotrophic factor and their use in pharmaceuticals or implants totreat neurodegenerative diseases

ST adenovirus recombinant brain derived neurotrophic factor;neurodegenerative disease treatment recombinantadenovirus

IT FibroblastMyoblastNeuroglia

(adenovirus-infected; recombinant adenoviruses codingfor brain-derived neurotrophic factor and their use inpharmaceuticals or implants to treat neurodegenerativediseases)

IT Animal cell(mammalian, adenovirus-infected; recombinantadenoviruses coding for brain-derived neurotrophic factor andtheir use in pharmaceuticals or implants to treatneurodegenerative diseases)

IT Plasmid and Episome(pSH-AD-BDNF; recombinant adenoviruses coding forbrain-derived neurotrophic factor and their use inpharmaceuticals or implants to treat neurodegenerativediseases)

IT Parkinsonism(recombinant adenoviruses coding for brain-derivedneurotrophic factor and their use in pharmaceuticals or implantsto treat neurodegenerative diseases)

IT Mental disorder(Alzheimer's disease, recombinant adenoviruses codingfor brain-derived neurotrophic factor and their use inpharmaceuticals or implants to treat neurodegenerativediseases)

IT Gene, microbialRL: BUU (Biological use, unclassified); BIOL (Biological study);USES (Uses)

(E1A, promoter of; recombinant adenoviruses coding forbrain-derived neurotrophic factor and their use inpharmaceuticals or implants to treat neurodegenerativediseases)

IT Virus, animal(adeno-, defective, recombinant; recombinantadenoviruses coding for brain-derived neurotrophic factor andtheir use in pharmaceuticals or implants to treatneurodegenerative diseases)



Bibliographische Recherchen:Der biologische Aspekt

=> file biosis

=> s L2

16581 PARKINSON939100 GENE###613792 THERAP?

L7 268 L1 AND GENE### AND THERAP?

=> d scan

L7 268 ANSWERS

TI Dopaminergic neurons protected from degeneration by GDNF genetherapy.

ST RESEARCH ARTICLE; RAT; HUMAN; GLIAL CELL LINE-DERIVED NEUROTROPHICFACTOR; GDNF; GENE THERAPY; DOPAMINERGIC NEURONS;6-HYDROXYDOPAMINE; NEUROTOXINS; PARKINSON'S DISEASE;NERVOUS SYSTEM; MOLECULAR GENETICS; NERVOUS SYSTEM; NERVOUS SYSTEMDISEASE


L7 268 ANSWERS

TI Long-term gene expression and phenotypic correction usingadeno-associated virus vectors in the mammalian brain.

ST RESEARCH ARTICLE; RAT; HUMAN TYROSINE HYDROXYLASE;BETA-GALACTOSIDASE; LACZ GENE; NON-PATHOGENIC DNA VECTOR;NEURON; GLIA; DENERVATED STRIATUM; PARKINSON'S DISEASE;

GENETIC ENGINEERING; POTENTIAL GENETICTHERAPY; DNA TRANSFER


L7 268 ANSWERS

TI Gene therapy approaches to neurological diseases.ST MEETING ABSTRACT; RAT; ANIMAL MODEL; GENE THERAPY

; MOTOR NEURON DEGENERATION; SPINAL CORD INJURY; PARKINSON'S DISEASE; NERVOUS SYSTEM; MOLECULAR GENETICS; THERAPEUTICMETHOD; NERVOUS SYSTEM DISEASE; TREATMENT; INJURY


Gibt es noch irgendwelche relevanten Klassifikationscodes?Wir unterbrechen die Sitzung kurz, um das abzuklären:

=> log h

SESSION WILL BE HELD FOR 60 MINUTES


Bibliographische Recherchen:Der biologische Aspekt

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:rrrk ....

PASSWORD:* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *

SESSION RESUMED IN FILE 'BIOSIS' AT 08:31:34 ON 17 AUG 1998

=> d his 1

(FILE 'BIOSIS' ENTERED AT 08:30:27 ON 17 AUG 1998)L7 268 S L2

=> e 12512/cc 5

E1 334953 12510/CCE2 334953 12510 PATHOLOGY, GENERAL AND MISCELLANEOUS-NECROSIS (

1971- )/CCE3 1755529 --> 12512/CCE4 1755529 12512 PATHOLOGY, GENERAL AND MISCELLANEOUS-THERAPY (1

971- )/CCE5 3202791 130/CC

=> s L5 and parkinson? and 12512/cc

939100 GENE###613792 THERAP?10075 GENE### THERAP?

(GENE###(W)THERAP?)421622 GENETIC?47650 ENGINEER?

.

.12450 MOL? CLON?

(MOL?(W)CLON?)24118 PARKINSON?

1755529 12512/CCL8 147 L5 AND PARKINSON? AND 12512/CC

=> d 4 ibib

L8 ANSWER 4 OF 147 BIOSIS COPYRIGHT 1998 BIOSISACCESSION NUMBER: 98:306924 BIOSISDOCUMENT NUMBER: 01306924TITLE: Characterization of intrastriatal

recombinant adeno-associatedvirus-mediated gene transfer of human tyrosinehydroxylase and human GTP-cyclohydrolase I in arat model of Parkinson's disease.

AUTHOR(S): Mandel R J; Rendahl K G; Spratt S K; Snyder R O;Cohen L K; Leff S E

CORPORATE SOURCE: Dep. Gene Therapy Applications, Cell Genesys Inc.,342 Lakeside Drive, Foster City, CA 94404, USA

SOURCE: Journal of Neuroscience 18 (11). 1998. 4271-4284.ISSN: 0270-6474

LANGUAGE: English


Bibliographische Recherchen:Der medizinische Aspekt

=> file medline

FILE 'MEDLINE' ENTERED AT 08:33:49 ON 17 AUG 1998FILE LAST UPDATED: 11 AUG 1998 (19980811/UP). FILE COVERS 1966 TO DATE.

THE MEDLINE FILE WAS RELOADED FEBRUARY 15, 1998, TO REFLECT THE ANNUALMESH (MEDICAL SUBJECT HEADING) CHANGES. ENTER HELP RLOAD FOR DETAILS.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATESUBSTANCE IDENTIFICATION.

=> e parkinson/ct

E# FREQUENCY AT TERM-- --------- -- ----E1 2 PARKING FACILITIES: ST, STANDARDS/CTE2 0 2 PARKING FACILITY/CTE3 0 1 --> PARKINSON/CTE4 0 2 PARKINSON DIS/CTE5 0 2 PARKINSON DIS POSTENCEPH/CTE6 0 2 PARKINSON DIS SYMPTOMATIC/CTE7 15880 28 PARKINSON DISEASE/CTE8 0 2 PARKINSON DISEASE, POST ENCEPHALITIC/CTE9 0 2 PARKINSON DISEASE, POST-ENCEPHALITIC/CTE10 321 36 PARKINSON DISEASE, POSTENCEPHALITIC/CTE11 6 PARKINSON DISEASE, POSTENCEPHALITIC: BL, BLOOD/C

TE12 9 PARKINSON DISEASE, POSTENCEPHALITIC: CF, CEREBRO

SPINAL FLUID/CT

=> ? dir

The following HELP messages are available to obtain information onthe MEDLINE File:

HELP ACCESSION - MEDLINE File Accession Number formatsHELP CONTENT - general MEDLINE File descriptionHELP COST - price schedule for the MEDLINE FileHELP CROSSOVER - file crossover searching in the MEDLINE FileHELP CTAG - list of Check Tags in the MEDLINE FileHELP DESK - information on MEDLINE File user assistanceHELP DFIELDS - list of display field codesHELP DT/TC - information about searching DT/TC fieldHELP EFIELDS - list of extract field codesHELP FIELDS - list of field and format help messages for the

MEDLINE FileHELP FORMAT - predefined formats for DISPLAY and PRINTHELP HIGHLIGHT - highlighting information in the MEDLINE FileHELP (L) - (L) operator use in the MEDLINE FileHELP LLIMIT - limiting Search Codes for L-numbersHELP (P) - (P) operator use in the MEDLINE FileHELP PRE-EXPLOSION - list of Subheading Pre-explosionsHELP RANGE - RANGE parameters for the MEDLINE FileHELP RCODE - relationship code parameters for MEDLINEHELP RLOAD - description of the February 15, 1998 reload

.

.

.



=> ? rcode

A thesaurus is present for the Controlled Terms (/CT), and theChemical Name (/CN) search fields in the MEDLINE File. A thesaurusis also present for inputting the MeSH Tree Numbers with the fieldqualifier /MN, though this is not a search or display field.

To display hierarchies of terms in a thesaurus, use the EXPANDcommand with a term followed by a plus symbol (+), a RelationshipCode, and field qualifier (/CT, /CN, or /MN), e.g., E PEPTICULCER+ALL/CT.

To use a thesaurus to automatically include additional Narrower,Broader, Related or other terms in a search, enter the SEARCH commandwith a term, followed by a plus symbol, (+), a Relationship Code, andfield qualifier, e.g., S PEPTIC ULCER+NT/CT.

An Automatic Relationship Code (ARC) has been assigned for thethesauri. (SELF and USE for the /CN thesaurus, SELF, USE and QUSEfor the /CT and /MN thesauri). The default SET value is OFF. If youwould like the system to automatically append these relationships anytime that you use the SEARCH or EXPAND commands with the /CT, or /CNfield codes, or the EXPAND command with the /MN field code, enter SETREL ON at an arrow prompt (=>). If you would like the system toappend the ARC values for a single SEARCH or EXPAND command, includeREL=ON in your command line, e.g.,

=> S NASAL SINUSES/CT REL=ON

The following Relationship Codes can be used with the EXPAND andSEARCH commands for the /CN Thesaurus.

RelationshipCode Description

------------ -----------

ALL All Associated Terms (SELF, CN, RN, EC, UF, USE,RR, HM, PA, INDX, NOTE, PNTE, RE)

AUTO Automatic Relationship (SELF, USE)HM Heading Mapped to (SELF, CN, RN, EC, RR, HM)NOTE All notes associated with the term

(SELF, CN, RN, EC, RR, INDX, PA, NOTE,PNTE, RE)

PFT Preferred and Forbidden Terms (SELF, CN, RN, EC,RR, UF, USE

RN CAS Registry Number associated with the nameor name associated with a CAS Registry Number(SELF, CN, RN, EC)

RR All associated CAS Registry Numbers (SELF, CN,RN, RR, EC)

.

.

.

.



=> e e7+all

E1 0 BT5 C Diseases/CTE2 18846 BT4 Nervous System Diseases/CTE3 9446 BT3 Central Nervous System Diseases/CTE4 29190 BT2 Brain Diseases/CTE5 2731 BT1 Basal Ganglia Diseases/CTE6 0 BT6 C Diseases/CTE7 18846 BT5 Nervous System Diseases/CTE8 9446 BT4 Central Nervous System Diseases/CTE9 29190 BT3 Brain Diseases/CTE10 2731 BT2 Basal Ganglia Diseases/CTE11 41 BT1 Multiple System Atrophy/CTE12 15880 --> Parkinson Disease/CTE13 15880 MN C10.228.140.79.612.375./CTE14 17958 MN C10.228.140.79.804./CT

DC an INDEX MEDICUS major descriptorNOTE Progressive, degenerative disease of

unknown etiology characterized byrhythmic tremor of the limbs, stoopedposture, slowness of voluntary movements,and masklike facial expression.Pathologically there is nerve cell loss inthe melanin-containing cells in thebrainstem and a corresponding reduction indopamine levels in the corpus striatum.Lewy bodies are present in the substantianigra and locus coeruleus.

INDX a basal ganglia dis; /drug ther: consideralso ANTIPARKINSON AGENTS; /chemind =PARKINSON DISEASE, SYMPTOMATIC /chem ind;X ref on Ramsay Hunt: named for Amerneurologist James Ramsay Hunt: spellwithout hyphen in titles & translations

ENTC CI: Parkinson Disease, SymptomaticAQ BL CF CL CN CO DH DI DT EC EH EM EN EP ET

GE HI IM ME MI MO NU PA PC PP PSPX RA RHRI RT SU TH UR US VE VI

HNTE 79; was PARKINSONISM 1967-78; wasPARALYSIS AGITANS 1963-66

ONTE use PARKINSON DISEASE to searchPARKINSONISM 1967-78 & PARALYSIS AGITANS1966

MHTH NLM 1967BXTH NLMBXTH U

E15 0 UF Diffuse Lewy Body Disease/CTE16 0 UF Lewy Body Disease/CTE17 0 UF Lewy Body Disease, Diffuse/CTE18 0 UF PARKINSON DIS/CTE19 0 UF Paralysis Agitans/CTE20 0 UF Parkinson's Disease/CTE21 0 UF Parkinsonism/CTE22 0 UF Parkinsons Disease/CTE23 0 UF Ramsay Hunt Paralysis Syndrome/CTE24 2312 NT1 Parkinson Disease, Symptomatic/CTE25 321 NT2 Parkinson Disease, Postencephalitic/CTE26 2307 RT Antiparkinson Agents/CTE27 306 RT Lewy Bodies/CT******END***



=> ? pre-explosion

Subheading Pre-Explosions

You can now search subheadings with the narrower hierarchyincluded automatically in the MEDLINE File without specifyingthem separately.

For example, S KANAMYCIN/CT(L)(AE OR TO OR PO)/CT can be searchedas => S KANAMYCIN/CT(L)AE./CT . In order to use this pre-explosionfeature, a period (.) must be placed after the two-letter codesubheading. The pre-exploded subheading hierarchy is as follows.

adverse effects (AE)poisoning (PO)toxicity (TO)

analysis (AN)blood (BL)cerebrospinal fluid (CF)isolation & purification (IP)urine (UR)

.

.

.

.

statistics & numeric data (SN)epidemiology (EP)

ethnology (EH)mortality (MO)

surgery (SU)transplantation (TR)

therapeutic use (TU)administration & dosage (AD)adverse effects (AE)contraindications (CT)poisoning (PO)

therapy (TH)diet therapy (DH)drug therapy (DT)nursing (NU)prevention & control (PC)radiotherapy (RT)rehabilitation (RH)surgery (SU)transplantation (TR)



=> s parkinson disease(L)th./ct

24312 PARKINSON1012385 DISEASE

18067 PARKINSON DISEASE(PARKINSON(W)DISEASE)

2355542 TH./CTL9 8691 PARKINSON DISEASE(L)TH./CT

=> e genetic engineering/ct 5

E# FREQUENCY AT TERM-- --------- -- ----E1 0 2 GENETIC ELEMENT, MOBILE/CTE2 0 2 GENETIC ELEMENTS, MOBILE/CTE3 4920 35 --> GENETIC ENGINEERING/CTE4 0 2 GENETIC ENGINEERING OF PROTEINS/CTE5 0 2 GENETIC ENGINEERING, PROTEIN/CT

=> e e3+all

E1 0 BT3 E Analytical, Diagnostic and Therapeutic Technicsand Equipment/CT

E2 0 BT2 Investigative Techniques/CTE3 4108 BT1 Genetic Techniques/CTE4 4920 --> Genetic Engineering/CTE5 33369 MN E5.393.420./CT

DC an INDEX MEDICUS major descriptorNOTE Directed modification of the gene complement

of a living organism by such techniques asaltering the DNA, substituting geneticmaterial by means of avirus, transplantingwhole nuclei, transplanting cell hybrids,etc.

INDX altering genes by various means; DF: GENETENGINEERING

AQ AE CL CT EC HI IS LJ MO MT NU PX SN ST TD UTVE

PNTE Eugenics (66-72)PNTE Genetics, Medical (66-72)HNTE 89; was GENETIC INTERVENTION 1973-88; was in

Cat E & G 1973-79ONTE use GENETIC ENGINEERING to search GENETIC

INTERVENTION 1973-88MHTH NLM 1973BXTH BIOETHICSBXTH NLMBXTH U

E6 0 UF Engineering, Genetic/CTE7 0 UF Enhancement, Genetic/CTE8 0 UF Enhancements, Genetic/CT

.

.

.

.



=> query (e5 or gene### regulat? or molecular clon? or recombina?)

GENE### REGULAT?(GENE###(W)REGULAT?)

MOLECULAR CLON?(MOLECULAR(W)CLON?)

L10 QUE (E5.393.420./CT OR GENE### REGULAT? OR MOLECULAR CLON? OR RECOMBINA?)

=> s L9 and L10

33369 E5.393.420./CT793107 GENE###369869 REGULAT?12843 GENE### REGULAT?

(GENE###(W)REGULAT?)568467 MOLECULAR203258 CLON?

8489 MOLECULAR CLON?(MOLECULAR(W)CLON?)

155130 RECOMBINA?L11 86 L9 AND L10

=> d trial

L11 ANSWER 1 OF 86 MEDLINETI In vivo L-DOPA production by genetically modified primary rat

fibroblast or 9L gliosarcoma cell grafts via coexpression ofGTPcyclohydrolase I with tyrosine hydroxylase.

CT Check Tags: Animal; Human; MaleAntioxidants: ME, metabolismAntiparkinson Agents: PD, pharmacologyApomorphine: PD, pharmacologyBehavior, Animal: DE, drug effectsBiopterin: AA, analogs & derivativesBiopterin: ME, metabolismCorpus Striatum: CH, chemistryCorpus Striatum: EN, enzymologyCorpus Striatum: PA, pathologyDisease Models, AnimalDopa: ME, metabolismFibroblasts: CY, cytologyFibroblasts: EN, enzymologyFibroblasts: TR, transplantationGene Expression Regulation, Enzymologic: PH, physiology

*Gene TherapyGliosarcoma

*GTP Cyclohydrolase: ME, metabolism*Levodopa: BI, biosynthesisMiceMicrodialysisParkinson Disease, Symptomatic: ME, metabolismParkinson Disease, Symptomatic: SU, surgery

*Parkinson Disease, Symptomatic: TH, therapy...



=> fil embase

=> e parkinson/ct

E# FREQUENCY AT TERM-- --------- -- ----E1 1 2 PARKINSAN/CTE2 1 PARKINSAN: DT, DRUG THERAPY/CTE3 0 1 --> PARKINSON/CTE4 0 2 PARKINSON DEMENTIA COMPLEX/CTE5 12989 7 PARKINSON DISEASE/CTE6 0 2 PARKINSON DISEASE, POSTENCEPHALITIC/CTE7 0 2 PARKINSON DISEASE, SYMPTOMATIC/CTE8 38 PARKINSON DISEASE: CN, CONGENITAL DISORDER/CTE9 36 PARKINSON DISEASE: CO, COMPLICATION/CTE10 1464 PARKINSON DISEASE: DI, DIAGNOSIS/CTE11 13 PARKINSON DISEASE: DM, DISEASE MANAGEMENT/CTE12 10 PARKINSON DISEASE: DR, DRUG RESISTANCE/CT

=> e e5+all

E1 12989 --> parkinson disease/CTHNTE Creation date 01 JUL 19: 79

E2 0 UF paralysis agitans/CTE3 0 UF parkinson dementia complex/CTE4 0 UF parkinson disease, postencephalitic/CTE5 0 UF parkinson disease, symptomatic/CTE6 30546 RMN C2.610.150.10.290./CTE7 55266 RMN C6.220.220./CT******END***

=> s e1

L12 12989 "PARKINSON DISEASE"/CT

=> ? lterms

Link terms are concept modifiers (subheadings) added whereappropriate to EMTREE terms. Link terms are divided into twogroups: drug links and disease links. Drug links may only beadded to EMTREE drug terms (facet D) and disease links may onlybe added to EMTREE terms for diseases (facet C). See HELP TREEfor further details on facets D and C. Link indexing has beenused in EMBASE since 1988, and by using these terms, searches areautomatically restricted from this year onward. Each link term isadditionally represented by a 2-letter code. Following is the listof DRUG and DISEASE links.



DRUG LINKS CODE DISEASE LINKS CODE---------- ---- ------------ ----adverse drug reaction AE complication COclinical trial CT congenital disorder CNdrug administration AD diagnosis DIdrug analysis AN (*) drug therapy DTdrug combination CB epidemiology EPdrug comparison CM etiology ETdrug concentration CR prevention PCdrug development DV radiotherapy RTdrug dose DO rehabilitation RHdrug interaction IT side effect SIdrug resistance DR surgery SUdrug therapy DT therapy THdrug toxicity TO (*)endogenous compound ECpharmaceutics PRpharmacokinetics PKpharmacology PD

(*) These link terms must be searches as fully spelled phrases, not2-letter codes because AN and TO are processed as stopwords.

Examples:

=> S CIMETIDINE/CT (L) DRUG ANALYSIS/CT=> S PARACETAMOL/CT (L) DRUG TOXICITY/CT

=> s L12(L)(DT or PC or TH or SU)

559378 DT140139 PC158141 TH261828 SU

L13 4071 L12(L)(DT OR PC OR TH OR SU)

=> ? emtags

Before 1991, a small number of subjects, about 200, were indexedusing an EMTAGS code instead of the EMTREE term. These subjects areall broad concepts and are used quite frequently when searching inthe EMBASE File. Always use the EMTAG code, instead of the EMTAGname, for comprehensive retrieval. Scope notes for EMTAGS arepresent in the printed EMTREE Thesaurus.

The EMTAGS used in the EMBASE file are as follows (* indicatesdeactivated tag):

EMTAGS TEXT EMTAGS TEXT0001 review 0021 newborn infant*

.

.0108 genetic engineering 0150 major clinical study

and gene technology 0151 case report..



=> s L13 and (0108/ct or gene### regulat? or molecular clon? or recombina?)

151339 0108/CT731719 GENE###313935 REGULAT?

8173 GENE### REGULAT?(GENE###(W)REGULAT?)

256729 "MOLECULAR"169058 CLON?43515 MOLECULAR CLON?

("MOLECULAR"(W)CLON?)104744 RECOMBINA?

L14 82 L13 AND (0108/CT OR GENE### REGULAT? OR MOLECULAR CLON?OR RECOMBINA?)

=> d trial

L14 ANSWER 1 OF 82 EMBASE COPYRIGHT 1998 ELSEVIER SCI. B.V.TI Viral vectors, tools for gene transfer in the nervous system.CT Medical Descriptors:

*virus vector*gene transfer*gene therapy*degenerative disease: DT, drug therapygene targetingherpes simplex virusadenoviruslentivirinaevirus morphologyneuroprotectionalzheimer disease: DT, drug therapyparkinson disease: DT, drug therapyhuntington chorea: DT, drug therapydrug delivery systemreviewpriority journalDrug Descriptors:*tyrosine 3 monooxygenase: DV, drug development*tyrosine 3 monooxygenase: DT, drug therapy*nerve growth factor: DV, drug development*nerve growth factor: DT, drug therapy*ciliary neurotrophic factor: DV, drug development*ciliary neurotrophic factor: DT, drug therapy*brain derived neurotrophic factor: DV, drug development*brain derived neurotrophic factor: DT, drug therapy*neurotrophin 3: DV, drug development*neurotrophin 3: DT, drug therapy*neurotrophin 4: DV, drug development*neurotrophin 4: DT, drug therapy

RN (tyrosine 3 monooxygenase) 9036-22-0; (nerve growth factor)9061-61-4


Bibliographische Recherchen:Alle Aspekt zusammengefasst

=> d his

INDEX 'BIOSIS, CAPLUS, EMBASE, MEDLINE, DDFU, LIFESCI' ENTERED AT08:26:49 ON 17 AUG 1998

SEA PARKINSON---------

16581 FILE BIOSIS5124 FILE CAPLUS

18360 FILE EMBASE24312 FILE MEDLINE2182 FILE DDFU1827 FILE LIFESCI

L1 QUE PARKINSON---------SEA L1 AND GENE### AND THERAP?

---------268 FILE BIOSIS200 FILE CAPLUS577 FILE EMBASE459 FILE MEDLINE16 FILE DDFU54 FILE LIFESCI

L2 QUE L1 AND GENE### AND THERAP?

FILE 'HCAPLUS' ENTERED AT 08:28:24 ON 17 AUG 1998E PARKINSON/CT

L3 5262 S E4,E7L4 3584 S L3 AND (CONTROL? OR ?TREAT? OR ?THERAP?)L5 QUE GENE### THERAP? OR GENETIC? ENGINEER? OR RECOMBIN? ORL6 146 S L4 AND L5

FILE 'BIOSIS' ENTERED AT 08:30:27 ON 17 AUG 1998L7 268 S L2

FILE 'STNGUIDE' ENTERED AT 08:31:41 ON 17 AUG 1998

FILE 'BIOSIS' ENTERED AT 08:32:04 ON 17 AUG 1998E 12512/CC 5

L8 147 S L5 AND PARKINSON? AND 12512/CC

FILE 'MEDLINE' ENTERED AT 08:33:49 ON 17 AUG 1998E PARKINSON/CTE E7+ALL

L9 8691 S PARKINSON DISEASE(L)TH./CTE GENETIC ENGINEERING/CT 5E E3+ALL

L10 QUERY (E5 OR GENE### REGULAT? OR MOLECULAR CLON? OR RECOML11 86 S L9 AND L10

FILE 'EMBASE' ENTERED AT 08:37:14 ON 17 AUG 1998E PARKINSON/CTE E5+ALL

L12 12989 S E1L13 4071 S L12(L)(DT OR PC OR TH OR SU)L14 82 S L13 AND (0108/CT OR GENE### REGULAT? OR MOLECULAR CLON?


Bibliographische Recherchen:Alle Aspekt zusammengefasst

=> set duporder file

SET COMMAND COMPLETED

=> dup rem L11 L14 L6 L8

FILE 'MEDLINE' ENTERED AT 08:40:54 ON 17 AUG 1998

FILE 'EMBASE' ENTERED AT 08:40:54 ON 17 AUG 1998COPYRIGHT (C) 1998 Elsevier Science B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 08:40:54 ON 17 AUG 1998USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.PLEASE SEE "HELP USAGETERMS" FOR DETAILS.COPYRIGHT (C) 1998 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 08:40:54 ON 17 AUG 1998COPYRIGHT (C) 1998 BIOSIS(R)PROCESSING COMPLETED FOR L11PROCESSING COMPLETED FOR L14PROCESSING COMPLETED FOR L6PROCESSING COMPLETED FOR L8L15 361 DUP REM L11 L14 L6 L8 (100 DUPLICATES REMOVED)

ANSWERS '1-86' FROM FILE MEDLINEANSWERS '87-145' FROM FILE EMBASEANSWERS '146-260' FROM FILE HCAPLUSANSWERS '261-361' FROM FILE BIOSIS

=> d ti 1 from each

L15 ANSWER 146 OF 361 HCAPLUS COPYRIGHT 1998 ACS DUPLICATE 24TI Targets for gene therapy of Parkinson's disease:

growth factors, signal transduction, and promoters

L15 ANSWER 261 OF 361 BIOSIS COPYRIGHT 1998 BIOSISTI A gene therapy approach for the treatment of

amyotrophic lateral sclerosis and Parkinson's disease.

L15 ANSWER 1 OF 361 MEDLINE DUPLICATE 1TI Characterization of intrastriatal recombinant

adeno-associated virus-mediated gene transfer of human tyrosinehydroxylase and human GTP-cyclohydrolase I in a rat model ofParkinson's disease.

L15 ANSWER 87 OF 361 EMBASE COPYRIGHT 1998 ELSEVIER SCI. B.V.DUPLICATE8

TI Potential use of herpes simplex virus (HSV) vectors for gene therapyof neurological disorders.


CAS Registry File

Das CAS Registry System ist der internationale Standard für Industrie,Wissenschaft und staatliche Kontrollorgane, mit dem chemische Substanzennachgewiesen werden. Das CAS REGISTRY File ist die grösste Datenbank fürSubstanz-informationen der Welt und beinhaltet sowohl Strukturen als auchchemische Verbindungen.

Das REGISTRY File enthält über 18 Millionen Datensätze über Substanzen, die inden Chemical Abstracts seit 1957 behandelt werden. Seit 1965 ist die jährlicheAnzahl an Substanzeinträgen von durchschnittlich 262'000 in den ersten 5 Jahrenauf durchschnittlich 1 Millionen in den letzten 5 Jahren gewachsen. Allein im 1997wurden mehr als 1,3 Millionen Substanzen eingetragen.

Jeder neuen Verbindung wird automatisch eine CAS Registry Number zugeordnet,die keine Informationen über die chemische Zusammensetzung enthält. Die CASRegistry Number wurde entworfen um als maschinelle Adresse innerhalb desSystem zu fungieren. Diese einmaligen Nummern überbrücken viele Unterschiede insystematischen, generischen, Handels- und Trivialnamen und verbindet dieseNamen mit den korrekten Molekularstrukturen. CAS Registry Numbers sind in allenCAS Datenbanken enthalten, und der komplette Satz von Registry Datenbank-strukturinformationen, Namen, Formeln und Ringdaten sind auf STN suchbar. DieCAS Registry Informationen sind auch in CAS Datenbanken erhältlich, die vonanderen Online-Systemen angeboten werden. CAS Registry Numbers werden invielen öffentlichen und privaten Datenbanken genutzt, weiterhin in Handbüchern undReferenzliteratur.

Prinzipiell stehen vier Möglichkeiten für die Substanzrecherche zur Verfügung, diehier in den CAS-Originalbezeichnungen aufgelistet werden:

DICTIONARY FILE SEARCHING: CHEMICAL NAMES

DICTIONARY FILE SEARCHING: MOLECULAR FORMULAS

STRUCTUR SEARCHING with STN EXPRESS

STRUCTUR SEARCHING with the COMMAND LANGUAGE


CAS Registry File:DICTIONARY FILE SEARCHING withCHEMICAL NAMES

Suchen mit vollständigen chemischen Namen:

Vollständige chemische Namen werden im Feld /CN gesucht. Empfehlenswert istdabei die Benutzung des EXPAND-Kommandos anstelle des SEARCH-Kommandos:

=> e poly(3-hydroxybutyrate)/cn 5E1 1 POLY(3-HYDROXY-8-(VINYLOXY)ACENAPHTHENE)/CNE2 1 POLY(3-HYDROXYBUTYL VINYL ETHER)/CNE3 1 --> POLY(3-HYDROXYBUTYRATE)/CNE4 1 POLY(3-HYDROXYBUTYRATE) DEPOLYMERASE/CNE5 1 POLY(3-HYDROXYBUTYRATE-3-HYDROXYVALERATE)/CN

=> s e3L1 1 "POLY(3-HYDROXYBUTYRATE)"/CN

Die aktuellen suchbaren Felder im REGISTRY FILE können mit dem Kommando=> ? sfi aufgelistet werden (help searchfields/sfields).

Das standardmässige Ausgabeformat im REGISTRY FILE (IDE) zeigt dienachfolgenden Felder an. Das LOCATOR FIELD /LC identifiziert dabei STN-FILESbzw. Daten-sammlungen, in denen weitere Informationen über die Substanzgefunden werden. In diesen FILES kann auch mit den CAS-Registry-Nummern (RN)gesucht werden.

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1997 ACSRN 26063-00-3 REGISTRYCN Butanoic acid, 3-hydroxy-, homopolymer (9CI) (CA INDEX NAME)OTHER CA INDEX NAMES:CN Butyric acid, 3-hydroxy-, polyesters (8CI)OTHER NAMES:CN .beta.-Hydroxybutanoic acid homopolymerCN .beta.-Hydroxybutyric acid homopolymerCN .beta.-Hydroxybutyric acid polymerCN 3-Hydroxybutyric acid homopolymerCN 3-Hydroxybutyric acid polymer



CN Poly(.beta.-hydroxybutyric acid)CN Poly(3-hydroxybutyrate)CN Poly(3-hydroxybutyric acid)CN Poly(hydroxybutyrate)CN Poly-.beta.-hydroxybutyrateMF (C4 H8 O3)xCI PMS, COMPCT Polyester, Polyester formedLC STN Files: AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, CA, CABA,

CANCERLIT, CAPLUS, CEN, CHEMCATS, CIN, CJACS, CSCHEM, EMBASE,IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MSDS-OHS, NAPRALERT, PIRA,PNI, PROMT, TOXLINE, TOXLIT, USPATFULL

CM 1

CRN 300-85-6CMF C4 H8 O3


1306 REFERENCES IN FILE CAPLUS (1967 TO DATE)

So können Sie jederzeit nach den Einträgen der einzelnen Files im /LC suchen:

L1 906 IPS/LCL2 0 KKF/LCL3 2131 PDLCOM/LCL4 0 PLASNEWS/LCL5 395 PLASPEC/LCL6 0 RAPRA/LC

Die aktuellen anzeigbaren Felder im REGISTRY FILE können mit dem Kommando=> ? dfi aufgelistet werden (help displayfields/dfields).



Trunkierungssymbole erhöhen die Variabilität bei einer Recherche:

S POLYETHYLENEGLYCOL?= kein oder beliebig viele Zeichen

S NEUROMEDIN##= kein oder max #-Anzahl Zeichen

S ANAL!SIS

S MI!ROCOMPUTER= genau 1 Zeichen an !-Stelle

Zusammensetzungen von verschiedenen Substanzen werden über ihreCOMPONENT REGISTRY NUMBER /CRN gesucht:

=> s ethylene/cnL1 1 ETHYLENE/CN

=> d rn

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1997 ACSRN 74-85-1 REGISTRY

=> s propylene/cnL2 1 PROPYLENE/CN

=> d rn


=> s dicyclopentadiene/cnL3 1 DICYCLOPENTADIENE/CN

=> d rn




=> s 74-85-1/crn and 115-07-1/crn and 77-73-6/crn9734 74-85-1/CRN4802 115-07-1/CRN1598 77-73-6/CRN

L4 165 74-85-1/CRN AND 115-07-1/CRN AND 77-73-6/CRN

=> d

L4 ANSWER 1 OF 165 REGISTRY COPYRIGHT 1997 ACSRN 188290-33-7 REGISTRYCN 4,7-Methano-1H-indene, 3a,4,7,7a-tetrahydro-, polymer with ethene,

1-octene and 1-propene (9CI) (CA INDEX NAME)OTHER CA INDEX NAMES .......OTHER NAMES:CN Ethylene-dicyclopentadiene-1-octene-propylene copolymerMF (C10 H12 . C8 H16 . C3 H6 . C2 H4)xCI PMSPCT Polyolefin, PolyotherSR CALC STN Files: CA, CAPLUS

CM 1CRN 115-07-1CMF C3 H6

H3C-CH=CH2

CM 2CRN 111-66-0CMF C8 H16

H2C=CH-(CH2)5-Me

CM 3CRN 77-73-6CMF C10 H12

CM 4CM 4CRN 74-85-1CMF C2 H4

H2C=CH2

1 REFERENCES IN FILE CA (1967 TO DATE)1 REFERENCES IN FILE CAPLUS (1967 TO DATE)



Alternatives Vorgehen: Statt DISPLAY der RN (und dann suchen): RN selektieren

=> s ethylene/cnL1 1 ETHYLENE/CN

=> s propylene/cnL2 1 PROPYLENE/CN

=> s dicyclopentadiene/cnL3 1 DICYCLOPENTADIENE/CN

=> s L1-L3L4 3 (L1 OR L2 OR L3)

=> sel rnE1 THROUGH E3 ASSIGNED

=> s e1/crn and e2/crn and e3/crn4802 115-07-1/CRN9734 74-85-1/CRN1598 77-73-6/CRN

L5 165 115-07-1/CRN AND 74-85-1/CRN AND 77-73-6/CRN

Die Anzahl Komponenten in einer MULTICOMPONENT SUBSTANCE im BASICINDEX ist im Feld NUMBER OF COMPONENTS /NC eingetragen. Es kann nachgenauen Zahlen oder numerischen Bereichen gesucht werden, z.B.

2/NC NC<2 NC<=22-3/NC NC>2 NC>=2



=> s L5 and nc=3459957 NC=3

L6 3 L5 AND NC=3

=> d cn 1-

L6 ANSWER 1 OF 3 REGISTRY COPYRIGHT 1997 ACSCN 4,7-Methano-1H-indene, 3a,4,7,7a-tetrahydro-, polymer with ethene

and 1-propene, block (9CI) (CA INDEX NAME)OTHER CA INDEX NAMES:CN 1-Propene, polymer with ethene and 3a,4,7,7a-tetrahydro-4,7-methano-

1H-indene, block (9CI)CN Ethene, polymer with 1-propene and 3a,4,7,7a-tetrahydro-4,7-methano-

1H-indene, block (9CI)


and 1-propene, chlorinated (CA INDEX NAME)


and 1-propene (9CI) (CA INDEX NAME)OTHER CA INDEX NAMES:CN 1-Propene, polymer with ethene and 3a,4,7,7a-tetrahydro-4,7-methano-

1H-indene (9CI)CN 4,7-Methanoindene, 3a,4,7,7a-tetrahydro-, polymer with ethylene and

propene (8CI)CN Ethene, polymer with 1-propene and 3a,4,7,7a-tetrahydro-4,7-methano-

1H-indene (9CI)CN Ethylene, polymer with propene and 3a,4,7,7a-tetrahydro-1,4-

methanoindene (8CI)CN Propene, polymer with ethylene and 3a,4,7,7a-tetrahydro-4,7-

methanoindene (8CI)OTHER NAMES:CN DCPD 1045CN Dicyclopentadiene-ethene-propene copolymer

.

.CN EPT 2120CN Ethylene-dicyclopentadiene-propene copolymer

.

.CN Mitsui EPT 1045CN Mitsui EPT 2120CN Propylene-dicyclopentadiene-ethylene copolymer



Suchen mit Namensegmenten:

Vielfach ist bei einer Suche der vollständige chemische Name nicht bekannt. EineSubstanz kann dann mit bekannten Segmenten des Namens gesucht werden.Namenssegmente befinden sich in den zwei REGISTRY Indexfeldern

BASIC INDEX

CHEMICAL NAME SEGMENT INDEX /CNS

Am Beispiel von 3,4-bis(2,2,2-trifluoroethoxy)benzamide soll aufgezeigt werden, inwelche Segmente in den beiden Feldern aufgeteilt wird:

Einträge im BASIC INDEX Einträge im Feld /CNS(natural segments)

3,4bis2,2,2trifluoroethoxybenzamide34bis2trifluoroethoxybenzamidetrifluoroethtrifluoro

fluoroethoxyfluoroeth

ethoxy

3,4bis2,2,2trifluoroethoxybenzamide



Die chemischen Namen sind also in verschiedene Stücke „aufzubrechen“. Um dieverchiedenen Stücke gezielt zu kombinieren, werden die Nachbarschafts-Operatoren(PROXIMITY OPERATORS) benutzt:

Proximity Operator Beziehung der Namensegmente

(W) Direkt nebeneinander,in der vorgegebenen Reihenfolge

(A) Direkt nebeneinander,in irgendeiner Reihenfolge

(L) Im gleichen Namen

(XW) Direkt nebeneinander,in der vorgegebenen Reihenfolge,mit einer beliebigen Anzahl Zeichendazwischen

Gesucht sind beispielsweise Polymere mit 3’-Deoxythymidinen und genau2 Komponenten:

=> e "3'" 5E1 2 2ZU/BIE2 7658752 3/BIE3 363709 --> 3'/BIE4 11921 3''/BIE5 4486 3'''/BI

=> e deoxy 5E6 1 DEOXOXANTHOPEROL/BIE7 2 DEOXSULF/BIE8 605783 --> DEOXY/BIE9 1 DEOXY5/BIE10 12 DEOXYA/BI

=> e thymidin 5E11 6 THYMIDI/BIE12 1 THYMIDILIC/BIE13 155 --> THYMIDIN/BIE14 103 THYMIDINATO/BIE15 19276 THYMIDINE/BI



=> s e3(w)e8(L)e15363709 "3'"/BI605783 DEOXY/BI19276 THYMIDINE/BI

L1 2337 "3'"/BI(W)DEOXY/BI(L)THYMIDINE/BI

=> s L1 and pms/ci707941 PMS/CI

L2 12 L1 AND PMS/CI

=> s L2 and 2/nc2175081 2/NC

L3 10 L2 AND 2/NC

=> d in 1-4

L3 ANSWER 1 OF 10 REGISTRY COPYRIGHT 1997 ACSIN 5'-Adenylic acid, 2'-deoxy-, homopolymer, complex with

P-deoxy-P-methylthymidylyl-(3'.fwdarw.5')-P-deoxy-P-methylthymidylyl-(3'.fwdarw.5')-P-deoxy-P-methylthymidylyl-(3'.fwdarw.5')-P-deoxy-P-methylthymidylyl-(3'.fwdarw.5')-P-deoxy-P-methylthymidylyl-(3'.fwdarw.5')-P-deoxy-P-methylthymidylyl-(3'.fwdarw.5')-P-deoxy-P-methylthymidylyl-(3'.fwdarw.5')-P-deoxy-P-methylthymidylyl-(3'.fwdarw.5')-P-deoxy-P-methylthymidylyl-(3'.fwdarw.5')-3'-amino-3'-deoxythymidine (1:1) (9CI)


5'-amino-5'-deoxythymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-3'-amino-3'-deoxythymidine (1:1) (9CI)


thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-3'-amino-3'-deoxythymidine(1:1) (9CI)

L3 ANSWER 4 OF 10 REGISTRY COPYRIGHT 1997 ACSIN 5'-Adenylic acid, homopolymer, complex with

5'-amino-5'-deoxythymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-thymidylyl-(3'.fwdarw.5')-3'-amino-3'-deoxythymidine (1:1) (9CI)



In welchen Fällen ist der /CNS Index anzuwenden?

Beispielsweise, wenn Namensegmente eindeutig (ohne weitere Zusätze)vorkommen sollten.

Zu finden sind (Fluormethyl)Pyridine, in welchen die Methylgruppenur ein Fluoratom enthalten darf:

=> s pyridine(xw)fluoromethyl394374 PYRIDINE274813 FLUOROMETHYL

L1 11720 PYRIDINE(XW)FLUOROMETHYL

=> d hit

L1 ANSWER 1 OF 11720 REGISTRY COPYRIGHT 1997 ACSCN [1,2,4]Triazolo[1,5-a]pyridine-2-sulfonamide,

5-chloro-N-[1-ethyl-5-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-7-methyl- (9CI) (CA INDEX NAME)

=> s pyridine(xw)fluoromethyl/cns394374 PYRIDINE

6538 FLUOROMETHYL/CNSL2 567 PYRIDINE(XW)FLUOROMETHYL/CNS

=> d hit

L2 ANSWER 1 OF 567 REGISTRY COPYRIGHT 1997 ACSCN Pyridine, 3-[3-(fluoromethyl)-1-methyl-2-pyrrolidinyl]-, trans-

(9CI) (CA INDEX NAME)



Suche nach Substanzgruppen:

Gesucht sind beispielsweise alle Polymere, die mindestens einen Ester(als Monomeres) enthalten und in U.S. Patenten beschrieben sind:

=> e esterE1 2 ESTENONE/BIE2 1 ESTEPROZ/BIE3 2697043 --> ESTER/BIE4 1 ESTERA/BIE5 5 ESTERAN/BIE6 1 ESTERANUM/BIE7 1208 ESTERASE/BIE8 3 ESTERASES/BIE9 2 ESTERASTIN/BIE10 5 ESTERATO/BIE11 2 ESTERBUT/BIE12 3 ESTERDI/BI

=> e left ester/cnsE13 2 PRESTEPHANINE/CNSE14 1 ESTEPROZ/CNSE15 2680890 --> ESTER/CNSE16 1 0LESTER/CNSE17 4 ABIESTER/CNSE18 1 ACRIESTER/CNSE19 79 ACRYESTER/CNSE20 6 ADESTER/CNSE21 1 ALKYLPHOSPHOTRIESTER/CNSE22 1 ANHYDROESTER/CNSE23 1 BESTER/CNSE24 12 BORESTER/CNS

=> s ?ester/cns and pms/ci and uspatfull/lc2695536 ?ESTER/CNS707941 PMS/CI

2369586 USPATFULL/LCL1 55831 ?ESTER/CNS AND PMS/CI AND USPATFULL/LC



Vollständige chemische Namen oder Namenssegmente enthalten oftSpezialsymbole, auf die bei einer Recherche in den Feldern /CN bzw. /CNSbesonders geachtet werden muss:

=> d queL1 6 SEA FILE=REGISTRY "METHYL-.BETA.-D-GLUCOFURANOSIDURONIC

ACID .GAMMA.-LACTONE"/CNSL2 7283 SEA FILE=REGISTRY "POLY[OXY(METHYL-1,2-ETHANEDIYL)],

.ALPHA.-HYDRO-.OMEGA.-HYDROXY-"/CNSL3 2 SEA FILE=REGISTRY L1 AND L2

Das Class Identifier Feld (/CI) enthält die Identifikation für breite Substanzklassen:

Code DefinitionAYS ALLOYCCS COORDINATION COMPOUNDCTS REGISTERED CONCEPTGRS GENERIC REGISTRATIONIDS INCOMPLETELY DEFINED SUBSTANCEMAN MANUAL REGISTRATIONMNS MINERALMXS MIXTUREPMS POLYMERRIS RADICAL IONRPS RING PARENTTIS TABULAR INORGANIC SUBSTANCEUVCB UNKNOWN OR VARIABLE COMPOSITION OR BIOLOGICAL SUBSTANCE


CAS Registry File:DICTIONARY FILE SEARCHING withMOLECULAR FORMULAS

Eine Substanz kann auch mit Hilfe der Summenformel bzw. Teilen davonrecherchiert werden. Solche Suchkriterien befinden in den zwei REGISTRYIndexfeldern

BASIC INDEX

MOLECULAR FORMULA /MF

Molekularformeln müssen in einem speziellen Format, in der Reihenfolge desHill System, eingegeben werden. Hier die wichtigsten Regeln:

Kohlenstoff zuerst, dann (falls vorhanden) Wasserstoff,dann alle anderen Elemente in alphabetischer Reihenfolge.

C8H18 C2AG2N8 C9H8CL4N8O

Anorganische Stoffe - wenn kein Kohlenstoff vorhanden ist:

H2O4S CLH CL6SB

Die vollständige Molekularformel befindet sich in /MF. Die Suche in diesem Feldbezieht sich also auf die exakte Formel. Teile der Molekularformel befinden sich imBasic Index. Die Suche im BI ergibt also Ergebnisse, bei denen sich die gesuchteFormel u.U. als Teil in einer Gesamtformel befindet.

Beispiele:

Suchbegriff im Feld /MF korrespondierende Einträge im BIC10H10N14O18 C10H10N14O18C10H12N2.C7H2CL2N2O6 C10H12N2

C7H2CL2N2O6(C8H8)x C8H8

Suchbeispiele:

=> s "(c3h8s2)x"/mfL1 1 "(C3H8S2)X"/MF

=> s c3h8s2L2 156 C3H8S2



Die Suche mit der Molekularformel ist weniger präzis als die Suche mit chemischenNamen oder mit der Strukturformel. Wenn eine Moleklarformel zuviele Treffer gibt,dann wird man mit anderen Kriterien verknüpfen müssen. Gesucht wirdbeispielsweise nach dieser Substanz:

NH2

NH2

=> e c10h10n2/mf 5E1 1 C10H10N14RH/MFE2 1 C10H10N14RH.C8H20N/MFE3 600 --> C10H10N2/MFE4 2 C10H10N2.1/2C6H2CLN3O6/MFE5 2 C10H10N2.1/2C6H3N3O6/MF

=> s e3 and diamin! and naphth? and 2,3600 C10H10N2/MF

232076 DIAMIN!655244 NAPHTH?508691 2,3

L1 1 C10H10N2/MF AND DIAMIN! AND NAPHTH? AND 2,3

=> d

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 1997 ACSRN 771-97-1 REGISTRYCN 2,3-Naphthalenediamine (7CI, 8CI, 9CI) (CA INDEX NAME)OTHER NAMES:CN 2,3-DiaminonaphthaleneFS 3D CONCORDMF C10 H10 N2CI COMLC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, CA,

CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX,CHEMLIST, CJACS, CSCHEM, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB,IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, SPECINFO, TOXLINE, TOXLIT,USPATFULL

(*File contains numerically searchable property data)Other Sources: DSL**, EINECS**, TSCA**

(**Enter CHEMLIST File for up-to-date regulatory information)

NH2

NH2


296 REFERENCES IN FILE CAPLUS (1967 TO DATE)11 REFERENCES IN FILE CAOLD (PRIOR TO 1967)



Die Suche mit Element-Informationen:

Es existieren Suchfelder für jedes Element in einer Molekularformel. Diese sindnumerische Felder und somit auch bereichs-suchbar. Beispielsweise wurden für dieFormel C11F8FEO3 folgende Element-Suchfelder generiert:

C11F8FEO3 11/C 8/F 1/FE 3/O8/X 1/M

Es gibt verschiedene weitere Suchfelder, in denen die individuellen Elemente ineiner Molekularformel definiert werden können. Zur Illustration wird C11F8FEO3benutzt:

Index Name Definition Beispiel/ElementSymbol

IndividuelleElemente

Numerischer Zählerjedes Elementes ineiner Molekularformel

11/C 8/F 1/FE 3/O8/X 1/M

/ELS ElementSymbol

Zeigt die Existenz einesElementes in einerMolekularformel an

C/ELS F/ELS FE/ELSO/ELS X/ELS M/ELS

/ELC ElementZähler(Count)

Numerischer Zählerder Elemente gesamthaftin einer Molekularformelim Basic Index

4/ELC

/ELC.SUB ElementZähler fürdie ganzeSubstanz

Numerischer Zählerder Elemente gesamthaftin einer Molekularformelim Feld /MF

4/ELC.SUB

/ELF ElementareFormel

Individuelle Molekularformel,bei der die numerischenKoeffizienten ersetzt werdendurch Leerzeichen

C F FE O/ELF

/ATC Atom Count Numerischer Zähler allerAtome für eine Molekular-formel im Basic Index

23/ATC

/PG Perioden-gruppenCode

A7/PG TI/PG B8/PG



Gesucht sind beispielsweise Einzelmonomere, die bestehen aus:

- Poly(Oxyethylen) auf einer Seite,

- einem fluorierten Methylrest auf der anderen Seite,

- in der Mitte eine beliebige Alkylkette,

- zwischen Alkylgruppe und PEG bzw. fluor. Methylrest jeweils eine Linkergruppe,die aus -CONHCrHsNHCO- besteht:

CxFyHz ---------- L --------- CqH2q -------- L -------- (C2H4O)n-H

=> s c2h4o and pms/ci and 5/elc54949 C2H4O

708135 PMS/CI3831545 5/ELC

L1 3653 C2H4O AND PMS/CI AND 5/ELC

=> s L1 and 2-3/f433883 2-3/F

L2 78 L1 AND 2-3/F

=> s L2 and 4/n1080000 4/N

L3 5 L2 AND 4/N

=> s l3 and 1/nc13190032 1/NC

L4 5 L3 AND 1/NC


CAS Registry File:STRUCTURE SEARCHING

Eine Strukturrecherche kann im ganzen REGISTRY FILE oder nur in einem Teildurchgeführt werden. „Polymer class terms“ sind besonders gut geeignet, um einsog. Subset beispielsweise für Polymerrecherchen zu definieren.

Zu finden sind beispielsweise Pyrenpolyester mit dem Strukturfragment

Nach dem Erstellen der Struktur mit STN Express:=>Uploading pyrene.str

L1 STRUCTURE UPLOADED

=> s L1 sam sssSAMPLE SEARCH INITIATED 10:58:01SAMPLE SCREEN SEARCH COMPLETED - 6221 TO ITERATE16.1% PROCESSED 1000 ITERATIONS 50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)SEARCH TIME: 00.00.03

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**BATCH **COMPLETE**

PROJECTED ITERATIONS: 119706 TO 129134PROJECTED ANSWERS: 12234 TO 15386

L2 50 SEA SSS SAM L1

=> s polyester/pctL3 117462 POLYESTER/PCT

=> s L1 subset=L3 full sssFULL SUBSET SEARCH INITIATED 10:58:49FULL SUBSET SCREEN SEARCH COMPLETED - 349 TO ITERATE100.0% PROCESSED 349 ITERATIONS 66 ANSWERSSEARCH TIME: 00.00.03

L4 66 SEA SUB=L3 SSS FUL L1



=> d 20

L4 ANSWER 20 OF 66 REGISTRY COPYRIGHT 1997 ACSRN 115720-77-9 REGISTRYCN 1,4-Benzenedicarbonitrile, compd. with poly[oxy[2-(1-pyrenylmethyl)-

1,3-propanediyl]oxy(1,4-dioxo-1,4-butanediyl)] (9CI) (CA INDEXNAME)

OTHER CA INDEX NAMES:CN Poly[oxy[2-(1-pyrenylmethyl)-1,3-propanediyl]oxy(1,4-dioxo-1,4-

butanediyl)], compd. with 1,4-benzenedicarbonitrile (9CI)MF (C24 H20 O4)n . x C8 H4 N2PCT PolyesterSR CALC STN Files: CA, CAPLUS

CM 1

CRN 65289-39-6CMF (C24 H20 O4)nCCI PMS

CM 2

CRN 623-26-7CMF C8 H4 N2

CN

CN




Nach der Vorbereitung und Abspeicherung mit dem Structure Drawing Programmvon STN EXPRESS und dem Logon wird die Substanz(datei) zur Strukturrechercheauf den STN-Rechner geladen. Folgende STN Files können dazu benutzt werden:

REGISTRY, ZREGISTRY, GMELIN, BEILSTEIN, CASREACT, MARPAT,MARPATPREVIEW, SPECINFO, CHEMINFORMRX, CHEMREACT, DJSMONLINE,DJSMDS, DRUGU, LREGISTRY, LBEILSTEIN, LCASREACT, LMARPAT.

In WPIDS, LWPI können die Fragmentation Codes gesucht werden,die mit einer Structure Query definiert wurden.

Die Standard-Strukturen können als folgende Suchtypen(ausser in WPIDS/LWPI) gesucht werden:

EXA Exact Search: Suche nach der exakten Substanz, inkl. Stereoisomeren,isotopenmarkierte Formen und Homopolymeren.

FAM Family Search: Suche nach der exakten Substanz plus Salze, Polymerenund anderen Multikomponent-Substanzen, die die exakte Substanz alsKomponente enthalten.

SSS Substructure Search: Suche nach allen Substanzen, die die definierteSubstruktur enthalten (Standard-Suchmethode).

CSS Closed Substructure Search: Suche nach allen Substanzen, die die definierteSubstruktur enthalten, jedoch Substitutionen nur an den als offen definiertenPositionen erlauben.

Nicht alle STN-Files, in denen nach Strukturen gesucht werden kann, erlauben alleSuchvarianten. Konsultieren Sie jeweils die einzelnen Datenbankbeschreibungen.

Die Suche kann limitiert werden auf:

SAM Einen nicht genau definierten Teil (Sample) des Files (Standardeinstellung).

RAN (Range) Einen bestimmten Bereich gemäss Registry Number.

SUB (Subset) Einen bestimmten Antwortsatz, der vorher definiert wurde.

FUL Das ganze File.

Nicht alle STN-Files, in denen nach Strukturen gesucht werden kann, erlauben alleLimitierungen. Konsultieren Sie jeweils die einzelnen Datenbankbeschreibungen.


Automatische Struktursuche für existierendeund "prophetische" Substanzen

Suchbeispiel: 1994 wurde ein Weltpatent über eine Serie von Substanzen mituntenstehender Struktur an die Firma Cephalon Inc. erteilt. Welche weiteren Firmenarbeiten an dieser Substanz und deren Derivaten?

A = Jede Substitution mit Ausnahme von HG1 = H oder jede andere Substitution

=> file caslink

FILE 'REGISTRY' ENTERED AT 13:23:08 ON 22 AUG 1998FILE 'MARPAT' ENTERED AT 13:23:08 ON 22 AUG 1998FILE 'MARPATPREV' ENTERED AT 13:23:08 ON 22 AUG 1998FILE 'CAPLUS' ENTERED AT 13:23:08 ON 22 AUG 1998

=>Uploading cephalon.str

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERSL1 STR

N

N

N

OA

Structure attributes must be viewed using STNExpress query preparation.Structure attributes must be viewed using STN Express query preparation.

N

N

N

O

A

G1

G1

G1



=> s L1

S L1 SSS SAM FILE=REGISTRYSAMPLE SEARCH INITIATED 13:26:10 FILE 'REGISTRY'SAMPLE SCREEN SEARCH COMPLETED - 207 TO ITERATE100.0% PROCESSED 207 ITERATIONS 28 ANSWERSSEARCH TIME: 00.00.03

FULL FILE PROJECTIONS: ONLINE **COMPLETE**BATCH **COMPLETE**


L2 28 SEA SSS SAM L11 FILES SEARCHED...

S L2 SSS SAM FILE=MARPATSAMPLE SEARCH INITIATED 13:26:15 FILE 'MARPAT'SAMPLE SCREEN SEARCH COMPLETED - 26 TO ITERATE100.0% PROCESSED 26 ITERATIONS 0 ANSWERSSEARCH TIME: 00.00.04

FULL FILE PROJECTIONS: ONLINE **COMPLETE**BATCH **COMPLETE**


L3 0 SEA SSS SAM L11 FILES SEARCHED...

=> d scan L2

L2 28 ANSWERS REGISTRY COPYRIGHT 1998 ACSIN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-

i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-5,16-bis[2-(methylthio)ethyl]-1-oxo-, methylester, [9S-(9.alpha.,10.beta.,12.alpha.)]- (9CI)

MF C33 H33 N3 O5 S2


Me

OMe

SMeMeS

N

O

HOO

N

NH

O

H S

R

R




L2 28 ANSWERS REGISTRY COPYRIGHT 1998 ACSIN 9,12-Epoxy-1H-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-

i][1,6]benzodiazocine-10-carboxylic acid, 2,3,9,10,11,12-hexahydro-10-methoxy-2,9-dimethyl-1-oxo-16-propoxy-, methyl ester (9CI)

MF C32 H31 N3 O6

n-PrO

Me

MeO

OMe

Me

N

OC

O

N

NO


=> s L1 sss full

S L1 SSS FUL FILE=REGISTRYFULL SEARCH INITIATED 13:27:02 FILE 'REGISTRY'FULL SCREEN SEARCH COMPLETED - 4163 TO ITERATE100.0% PROCESSED 4163 ITERATIONS 675 ANSWERSSEARCH TIME: 00.00.08

L4 675 SEA SSS FUL L11 FILES SEARCHED...

S L4 SSS FUL FILE=MARPATFULL SEARCH INITIATED 13:27:13 FILE 'MARPAT'FULL SCREEN SEARCH COMPLETED - 817 TO ITERATE100.0% PROCESSED 817 ITERATIONS 48 ANSWERSSEARCH TIME: 00.00.19


S L5 SSS FUL FILE=MARPATPREVFULL SEARCH INITIATED 13:27:34 FILE 'MARPATPREV'FULL SCREEN SEARCH COMPLETED - 2 TO ITERATE100.0% PROCESSED 2 ITERATIONS 0 ANSWERSSEARCH TIME: 00.00.02


S L4 FILE=CAPLUSL7 76 FILE CAPLUS

1 FILES SEARCHED...

SET DUPORDER FILESET COMMAND COMPLETED



DUP REM L6 L5 L7L6 HAS NO ANSWERSPROCESSING COMPLETED FOR L6PROCESSING COMPLETED FOR L5PROCESSING COMPLETED FOR L7L8 91 DUP REM L6 L5 L7 (33 DUPLICATES REMOVED)

ANSWERS '1-48' FROM FILE MARPATANSWERS '49-91' FROM FILE CAPLUS

=> ana L8 csL9 ANALYZE L8 1- CS : 84 TERMS

=> dL9 ANALYZE L8 1- CS : 84 TERMS

TERM # # OCC # DOC % DOC CS------ ------- ------ ------ ---------------

1 16 16 17.58 CEPHALON, INC., USA2 12 12 13.19 KYOWA HAKKO KOGYO CO., LTD.3 7 7 7.69 KYOWA HAKKO KOGYO CO., LTD., JAPAN4 5 5 5.49 BANYU PHARMACEUTICAL CO., LTD., JAPAN5 4 4 4.40 TOKYO RES. LAB., KYOWA HAKKO KOGYO CO., LTD.,6 3 3 3.30 ASAHI CHEMICAL IND, JAPAN7 3 3 3.30 ASAHI CHEMICAL INDUSTRY CO., LTD., JAPAN8 3 3 3.30 KITASATO INSTITUTE9 2 2 2.20 CEPHALON, INC., WEST CHESTER, PA, 19380, USA

10 2 2 2.20 CIBA-GEIGY A.-G., SWITZ.11 2 2 2.20 FREDENHAGEN, ANDREAS12 2 2 2.20 GOEDECKE AG, GERMANY13 2 2 2.20 MOERKER, THEOPHILE14 2 2 2.20 PETER, HEINRICH15 2 2 2.20 SCHERING CORP., USA

=> d with "cephalon"L9 ANALYZE L8 1- CS : 84 TERMS


1 16 16 17.58 CEPHALON, INC., USA9 2 2 2.20 CEPHALON, INC., WEST CHESTER, PA, 19380, USA

24 1 1 1.10 CEPHALON INCORPORATED, WEST CHESTOR, PA, 193827 1 1 1.10 DEP. CELL BIOL. CHEM., CEPHALON, INC., WEST C

=> edit L9ENTER (CHANGE), COMBINE, OR TITLE:combineENTER PREFERRED TERM NUMBER OR (?):1PREFERRED TERM: CEPHALON, INC., USA/CSENTER EQUIVALENT TERM NUMBERS OR (END):9,24,27EQUIVALENT TERM: CEPHALON, INC., WEST CHESTER, PA, 19380, USA/CSEQUIVALENT TERM: CEPHALON INCORPORATED, WEST CHESTOR, PA, 19380, USA/CSEQUIVALENT TERM: DEP. CELL BIOL. CHEM., CEPHALON, INC., WEST CHESTER, PA,19380, USA/CSENTER EQUIVALENT TERM NUMBERS OR (END):endAPPLY CHANGES? (Y)/N:.TERMS COMBINED



=> d with "kyowa"L9 ANALYZE L8 1- CS : 84 TERMS

(AFTER EDITS : 81 TERMS)


2 12 12 13.19 KYOWA HAKKO KOGYO CO., LTD.3 7 7 7.69 KYOWA HAKKO KOGYO CO., LTD., JAPAN5 4 4 4.40 TOKYO RES. LAB., KYOWA HAKKO KOGYO CO., LTD.,

49 1 1 1.10 KYOWA HAKKO KOGYO K. K., TOKYO, JAPAN50 1 1 1.10 KYOWA HAKKO KOGYO KK, JAPAN51 1 1 1.10 KYOWA HAKKO KOGYO60 1 1 1.10 PHARM. RES. LAB., KYOWA HAKKO KOGYO CO., LTD.61 1 1 1.10 PHARMACEUTICAL RESEARCH LABORATORIES, KYOWA H

=> edit L9ENTER (CHANGE), COMBINE, OR TITLE:combineENTER PREFERRED TERM NUMBER OR (?):2PREFERRED TERM: KYOWA HAKKO KOGYO CO., LTD./CSENTER EQUIVALENT TERM NUMBERS OR (END):3 5 49 50 51 60 61EQUIVALENT TERM: KYOWA HAKKO KOGYO CO., LTD., JAPAN/CSEQUIVALENT TERM: TOKYO RES. LAB., KYOWA HAKKO KOGYO CO., LTD., MACHIDA,194, JAPAN/CSEQUIVALENT TERM: KYOWA HAKKO KOGYO K. K., TOKYO, JAPAN/CSEQUIVALENT TERM: KYOWA HAKKO KOGYO KK, JAPAN/CSEQUIVALENT TERM: KYOWA HAKKO KOGYO/CSEQUIVALENT TERM: PHARM. RES. LAB., KYOWA HAKKO KOGYO CO., LTD., SHIZUOKA,411, JAPAN/CSEQUIVALENT TERM: PHARMACEUTICAL RESEARCH LABORATORIES, KYOWA HAKKO KOGYOCO. LTD., SHIZUOKA, 411, JAPAN/CSENTER EQUIVALENT TERM NUMBERS OR (END):endAPPLY CHANGES? (Y)/N:yTERMS COMBINED

=> d L9 ansL9 ANALYZE L8 1- CS : 84 TERMS

(AFTER EDITS : 74 TERMS)


1@ 28 28 30.77 KYOWA HAKKO KOGYO CO., LTD.(ANS: 2,4,5,7,8,11,12,13,14,15,16,17,19,30,31,32,36,38,50,58,61,66,79,83,87,88,90,91)

2@ 20 20 21.98 CEPHALON, INC., USA(ANS: 2,4,5,7,8,10,11,12,16,19,36,38,50,54,55,58,59,63,64,70)

3 5 5 5.49 BANYU PHARMACEUTICAL CO., LTD., JAPAN(ANS: 3,40,41,44,46)

4 3 3 3.30 ASAHI CHEMICAL IND, JAPAN(ANS: 9,42,78)

5 3 3 3.30 ASAHI CHEMICAL INDUSTRY CO., LTD., JAPAN(ANS: 24,26,27)

6 3 3 3.30 KITASATO INSTITUTE(ANS: 24,26,27)



7 2 2 2.20 CIBA-GEIGY A.-G., SWITZ.(ANS: 34,35)

8 2 2 2.20 FREDENHAGEN, ANDREAS(ANS: 34,35)

9 2 2 2.20 GOEDECKE AG, GERMANY(ANS: 22,23)

10 2 2 2.20 MOERKER, THEOPHILE(ANS: 34,35)

11 2 2 2.20 PETER, HEINRICH(ANS: 34,35)

12 2 2 2.20 SCHERING CORP., USA(ANS: 25,43)

@ INDICATES TERMS AFFECTED BY MOST RECENT EDITS

=> d L8 2,10,13 ti,pa

L8 ANSWER 2 OF 91 MARPAT COPYRIGHT 1998 ACS DUPLICATE 2TI synthesis and neurotropic activity of selected derivatives of K-252aPA Cephalon, Inc., USA; Kyowa Hakko Kogyo Co., Ltd.

L8 ANSWER 10 OF 91 MARPAT COPYRIGHT 1998 ACS DUPLICATE 10TI Aqueous indolocarbazole solutionsPA Cephalon, Inc., USA

L8 ANSWER 13 OF 91 MARPAT COPYRIGHT 1998 ACS DUPLICATE 13TI Thrombocytopenia inhibitors contg. indolocarbazole derivativesPA Kyowa Hakko Kogyo Kk, Japan


STN Files mit Bio-Sequenzen

REGISTRY GENBANK DGENE

Produzent CAS NCBI (US NIH) DERWENT

Protein-sequenzen

> 400'000 - > 90'000

Nukleinsäure-sequenzen

> 1'400'000 > 1'200'000 > 120'000

Quellen Literaturund Patente

seit1957/1965

Literaturund Patente

seit 1980

Patenteseit 1981

Sequenzabfragen JA NEIN(nur via Registry)

JA

CAS-Nummern(RN)

JA JA NEIN

BibliographischeReferenzen

JA,im CAPLUS

JA JA

Update täglich täglich zwei-wöchentlich


Suche nach Bio-Sequenzen mit STN

REGISTRY DGENE=> s => run getseq

Proteine Nukleinsäuren Proteine Nukleinsäuren

ExactSequence Search

/SQEP /SQEN /SQEP /SQEN

ExactFamilySequence Search

/SQEFP - /SQEFP -

SubsequenceSearch

/SQSP /SQSN /SQSP /SQSN

SubsequenceFamilySearch

/SQSFP - /SQSFP -


Offline-Vorbereitung und Online-Übergabemit STN Express

Methode 1 von 3: Mit einem Command File

Offline:

Prepare ... bedeutet: ein neues Command File anfertigenoder ein bestehendes editieren.

Achtung: immer mit dem Prompt =>

Online:Das Command File kann kostenlos im File STNGUIDE gestartet werden:

L1 QUE AGAAAAAAGGAGQGGYGG z.B. im STNGUIDEL2 RUN GETSEQ L1 im DGENE

L3 S L1/SQSP im REGISTRY



Methode 2 von 3: Mit dem Command Window

Offline:

Mit "Prepare Command File" (oder einem anderen Texteditor) die Kommandosschreiben, aber im Gegensatz zu den "Command Files" ohne Prompt =>

Online:

Laden Sie die Script-Datei (z.B. c:\stnexp\uscripts\cw-seq01.sc)



Klicken Sie auf die einzelne Linie rechts, um eine einzelne Zeile zu übergeben.Ein Klick auf das Symbol mit den vier Linien übergibt Zeile um Zeile nacheinander.Das rote Schloss muss aber mit einem Klick freigemacht werden.

Methode 3 von 3: Mit herkömmlichem Filetransfer

Online: Hinaufladen eines vorbereiteten ASCII-Textfiles

Ist stark von der verwendeten Datenleitung abhängig und funktioniert vielfach nicht.


Bio-Sequenzen im CAS REGISTRY FILE

Das REGISTRY File enthält über 2,5 Millionen Nukleinsäuresequenzen und über500'000 Polypeptide und Proteine (Stand Mitte 1998). Diese Substanzen sind überdie CAS Registry Nummern mit Referenzen in vielen wichtigen STN-Files gelinkt:

File Anzahl derBiosequenzenCAS-RN's *

GENBANK 1'249'306CAPLUS 747'394CA 745'616TOXLIT 350'759USPATFULL 76'782BIOSIS 28'293AGRICOLA 15'445MEDLINE 4^915TOXLINE 2'324CANCERLIT 1'843CHEMCATS 1'262DRUGU 736EMBASE 676MSDS 355RTECS 338NAPRALERT 325PROMT 293PHAR 285CHEMLIST 206

*) Basierend auf Proteinsequenzen mit mehr als 4 oder mehr Aminosäuren undNukleinsäuresequenzen mit 9 oder mehr Resten, StandMai 1997


Ursprung der Proteinsequenzenim CAS REGISTRY FILE

1. CA/CAPLUS Indexierung:

- Forschungsartikel- Patentansprüche und -beschreibungen aus über 32 Patentämtern

Patente sind eine äusserst wichtige Quelle für Biosequenzinformationen, weil sichüber 80 % der publizierten einschlägigen Technologien ausschliesslich in derPatentliteratur befindet.

Das REGISTRY File enthält Protein- und Peptidsequenzen bis zurück ins Jahr 1957.Allerdings behandeln diese frühen Einträge kleine bzw. natürlich vorkommendePeptide. Das grösste Wachstum der Einträge vieler grosser Proteinsequenzen gehtin die 80er-Jahre zurück, gepaart mit dem Aufkommen der Sequenzierungs-methoden.

Zur Zeit werden dem REGISTRY File monatlich etwa 2000-3000 neue Protein- undPeptidsequenzen zugefügt.

2. GENBANK:

- Proteinsequenzen abgeleitet von Nukleinsäuresequenzen

Wann wird eine Proteinsequenz für CA/CAPLUS indexiert?

Alle neu genannten Sequenzen in den von CAS aufgenommenen Dokumenten wirdindexiert, registriert und ins REGISTRY File beim ersten Aufkommen einer"vollständigen" Sequenz und für wichtige Strukturupdates aufgenommem.Vollständige Sequenzen sind:

- Eine vollständige Sequenz gemäss Autorendefinition

- Eine Sequenz abgeleitet von einer Nukleinsäuresequenz, beginnend miteinem AUG Codon oder einem anderen vom Autor spezifizierten Startcodonund endend mit einem Stopcodon


Beispiele Proteine und Peptideim CAS REGISTRY FILE

Natürlich vorkommende Proteine und Peptide:

- Sequenzen abgeleitet von Nukleinsäuresequenzenund gemäss Autorendefinition (gene translation)

- Sequenzen abgeleitet von der GENBANK-Datenbank (gene translation)

RN 160171-58-4 REGISTRYCN Dehydrogenase, glucose 6-phosphate (nicotinamide adenine

dinucleotide) [128-arginine,131-arginine] (Leuconostoc citreumstrain NCIMB 3351) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCESQL 485

SEQ 1 VAEIKTLVTF FGGTGDLAKR KLYPSVFNLY KKGYLQEHFA IVGTARQDLT51 DAEFKQLVRE SIADFTEDKA QAEAFIAHFS YRAHDVTDAA SYNILKQAIE

101 EAAEKFDIQG NRIFYMSVAP RFFGTIARYL RSEGLLADSG YNRLMIEKPF151 GTSYATAEEL QKDLENAFDD NQLFRIDHYL GKEMVQNIAA LRFGNPIFDA201 AWNKDYIKNV QVTLSEVLGV EERAGYYDTA GALLDMIQNH TMQIVGWLAM251 EKPDSFTDKD IRAAKNAAFN ALKIYDEAEV NKYFVRAQYG AGDTADFKPY301 LEEMDVPADS KNNTFIAGEL QFDLPRWEGV PFYVRSGKRL AAKQTRVDIV351 FKAGTFAFGS EQEAQEAVLS ILIDPKGGIE FKINSKSVED AFNTRMINLD401 WSISDEDKQN TPEPYERMIH DTMNGDGSNF ADWNGVAIAW KFVDAISAVY451 TADKAPLETY KSGSMGPEAS DKLLAENGDA WVFKG

MF UnspecifiedCI MANSR CALC STN Files: CA, CAPLUS




Chemisch modifizierte Proteine und Peptide:

RN 190335-87-6 REGISTRYCN L-Prolinamide, L-tyrosyl-D-alanyl-L-phenylalanylglycyl-L-tyrosyl-

(4R)-4-hydroxy-L-prolyl- (9CI) (CA INDEX NAME)FS PROTEIN SEQUENCE; STEREOSEARCHSQL 7NTE modified----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------terminal mod. Pro-7 - C-terminal amideuncommon Hyp-6 - -----------------------------------------------------------------------

SEQ 1 YAFGYXPMF C42 H52 N8 O10SR CALC STN Files: CA, CAPLUS, TOXLIT


Me

Ph

O

NN

O

OH

H2N ONH

O

NH

HO

O

NH

O

NH

O

NH2

SS

R

S S R S

PAGE 1-A

OH

PAGE 1-B




Multiketten-Proteine:

RN 185702-03-8 REGISTRYCN Relaxin (rat), 15B-L-aspartic acid-16B-L-leucine-17B-L-valine- (9CI)

(CA INDEX NAME)FS PROTEIN SEQUENCESQL 59,35,24NTE multichain----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------bridge Cys-14 - Cys-11' disulfide bridgebridge Cys-26 - Cys-24' disulfide bridgebridge Cys-10' - Cys-15' disulfide bridgeuncommon Glp-1' - -----------------------------------------------------------------------

SEQ 1 RVSEEWMDQV IQVCDLVYAR AWIEVCGASV GRLAL

SEQ 1 XSGALLSEQC CHIGCTRRSI AKLCMF C279 H450 N82 O84 S7CI MANSR CALC STN Files: CA, CAPLUS, TOXLIT


RN 187618-37-7 REGISTRYCN Cyclo(L-.alpha.-aspartyl-L-valyl-1-piperazineacetyl-L-isoleucyl-L-

leucyl-L-.alpha.-aspartyl-L-valyl-1-piperazineacetyl-L-isoleucyl-L-leucyl), bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCHSQL 10,5,5NTE multichain

modified (modifications unspecified)----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------bridge Gly-1 - Val-5' covalent bridgebridge Val-5 - Gly-1' covalent bridge----------------------------------------------------------------------

SEQ 1 GILDV

SEQ 1 GILDVMF C62 H108 N12 O14SR CALC STN Files: CA, CAPLUS

i-Bu

i-Bu

Et

Et

i-Pr

Pr-i

t-BuO

OBu-t

Me

Me

CH2C

O

NH

O

NH

O

NH

O

N

O CHNH

N

O

N

O

NH

N

CH

O

NH

ONH

O

NH

O

CH2 C

O



Proteine aus GENBANK-Nummern:

RN 185917-30-0 REGISTRYCN Protein (Arabidopsis thaliana mitochondria-encoded open reading

frame orf102) (9CI) (CA INDEX NAME)OTHER NAMES:CN GenBank Y08502-derived protein GI 1785778FS PROTEIN SEQUENCESQL 122

SEQ 1 MGYGVCHFYL LFIINGAPQG LVTPSRGLRQ GDPLSPYLFI LCTEVLSGLC51 RRAQEQGRLP GIRVSNNSPR INHLLFADDT SSARWIPLAA QIWPIFFLSM

101 RLFQGNPVNH PMSNLYFLGS LPMF UnspecifiedCI MANSR CALC STN Files: CA, CAPLUS, TOXLIT


Cyclische Peptide:

RN 190072-23-2 REGISTRYCN Cyclo[L-arginylglycyl-L-.alpha.-aspartyl-D-phenylalanyl-L-valyl-N6-

[6-[[(1,1-dimethylethoxy)carbonyl]amino]-1-oxohexyl]-L-lysyl] (9CI)(CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCHSQL 6NTE cyclic

modified----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------modification Lys-6 - undetermined modification----------------------------------------------------------------------

SEQ 1 RGDFVKMF C43 H69 N11 O11CI COMSR CA


(CH2)4

(CH2)3

(CH2)5

i-Pr

t-BuO Ph

CO2H

NH

ONH

ONH

O

NH

O

NH

O

NH

O

NH

O

NH

NH

H2N

NH

O

RS

S

S

S



Fusions-Proteine:

RN 188763-83-9 REGISTRYCN FKBP protein (human clone pET9dFKBPt/ZapSH2) fusion protein with

phosphoprotein ZAP-70 (human TCR receptor .zeta.-chain-associated70,000-molecular-weight) (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCESQL 378

SEQ 1 MGVQVETISP GDGRTFPKRG QTCVVHYTGM LEDGKKFDSS RDRNKPFKFM51 LGKQEVIRGW EEGVAQMSVG QRAKLTISPD YAYGATGHPG IIPPHATLVF

101 DVELLKLEGL VPRGSMPDPA AHLPFFYGSI SRAEAEEHLK LAGMADGLFL151 LRQCLRSLGG YVLSLVHDVR FHHFPIERQL NGTYAIAGGK AHCGPAELCE201 FYSRDPDGLP CNLRKPCNRP SGLEPQPGVF DCLRDAMVRD YVRQTWKLEG251 EALEQAIISQ APQVEKLIAT TAHERMPWYH SSLTREEAER KLYSGAQTDG301 KFLLRPRKEQ GTYALSLIYG KTVYHYLISQ DKAGKYCIPE GTKFDTLWQL351 VEYLKLKADG LIYCLKEACP NSSASNAS

MF UnspecifiedCI MANSR CALC STN Files: CA, CAPLUS, TOXLIT, USPATFULL




Peptid-Metallkomplexe;Sequenzen, die ungewöhnliche Aminosäuren enthalten usw.

RN 174900-52-8 REGISTRYCN Technetium-99Tc, [cyclo(L-homocysteinyl-N-methyl-L-phenylalanyl-L-

tyrosyl-D-tryptophyl-L-lysyl-L-valyl) (1.fwdarw.1')-sulfide with3-[(mercaptoacetyl)amino]-L-alanyl-L-lysyl-L-cysteinyl-L-lysinamidato(3-)]oxo-, (SP-5-24)- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCESQL 10,6,4NTE multichain

cyclic,linearmetal complexmodified (modifications unspecified)

----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------bridge Hcy-1 - Lys-1' covalent bridgeuncommon Hcy-1 - -uncommon Dpr-1' - -stereo Trp-4 - D----------------------------------------------------------------------

SEQ 1 XFYWKV

SEQ 1 XKCKMF C65 H93 N16 O13 S2 TcCI CCSSR CALC STN Files: CA, CAPLUS, TOXLIT

(CH2)4

Pr-i

Me

Ph

C

CH2

O

S

CH2

CH2

NH

ON

O

CH2

NH

O

NH

O

CH2NH

O

NH

O

CH2

NH2

HO

NH

PAGE 1-A

(CH2)4(CH2)4

O

99Tc

N

N

NH2

S

C

O

O

CH2

NH

O

NH

CH

CH2N

O

NH2H2N

3+

-

-

-

PAGE 2-A


Ursprung der Nukleinsäurequenzenim CAS REGISTRY FILE

Die Nukleinsäuresequenzen im REGISTRY File kommen aus zwei Quellen:

- Wissenschaftliche Literatur in den Chemical Abstracts- Datenbank GENBANK, registrierungsmässig bearbeitet vom CAS

Wann wird eine Nukleinsäuresequenz für CA/CAPLUS indexiert?

Die CAS-Indexeinträge werden beim ersten Aufkommen einer "vollständigen"Sequenz und für wichtige Strukturupdates durchgeführt. Vollständige Sequenzensind:

- Ein vollständiges Nukleinsäuremolekül gemäss Autorendefinition

- Die Region (Gen) innerhalb eines grossen Nukleinsäuremoleküls,welche alle Informationen für ein Protein oder ein RNA-Produkt enthält

- Ein genetisches Element (Promoter, Regulatorelement usw.)

Partielle Sequenzen (unvollständige Coding-Regionen, uncharakterisierte Lücken,mehrdeutige Strukturen) werden von CAS nicht registriert. Ausnahmen: BestehendeGENBANK-Accession Nummern für Sequenzen und Sequenzen aus Patent-ansprüchen.

Sequenzen, die sich auch nur um ein Nukleotid unterscheiden, werden separatregistriert. Identische Sequenzen mit verschiedenen Modifikationen werden separatregistriert.

Die Sequenzen folgender Nukleinsäureklassen können im REGISTRY Filegefunden werden:

- Natürlich vorkommende Nukleinsäuremoleküle- Gensequenzcodierungen für Protein- bzw. RNA-Produkte- Regulierende oder anders definierte genetische Elemente- Chemisch modifizierte Nukleinsäuren und Oligonucleotide- Oligonucleotidprobes und PCR Primers- Genetisch veränderte und synthetische Gene- Fusionsgene und -nukleinsäuren- Sequenzen mit ungewöhnlichen Nukleotiden


Beispiele Nukleinsequenzenim CAS REGISTRY FILE

DNA, double-stranded, ribosomal RNA gene plus flanking region fragment:

RN 183147-67-3 REGISTRYCN DNA (Elsinoe australis 5.8S rRNA gene plus flanks) (9CI) (CA INDEX

NAME)OTHER CA INDEX NAMES:CN Deoxyribonucleic acid (Elsinoe australis 5.8S ribosomal RNA gene

plus 5'- and 3'-flanking region fragment)FS NUCLEIC ACID SEQUENCESQL 601NA 142 a 170 c 156 g 133 tNTE doublestranded

SEQ 1 gtaggtgaac ctgcggaagg atcattaacg aggaagggtt tccgaaagga51 gcccgaactc cccacccttt gctgttgcga atctgttgct tcggcgggcc

101 cgccccccca tccctggggg ggcggccggg cctcaccgcc cggacagcgc151 ccgccggagg accgaatcaa ctctgttttt aaccataatg tcggagtact201 tttgtacaat caaattaaaa ctttcaacaa cggatctctt ggttctggca251 tcgatgaaga acgcagcgaa atgcgataag taatgtgaat tgcagaattc301 agtgaatcat cgaatctttg aacgcacatt gcgccccttg gtattccgag351 gggcatgcct gttcgagcgt catttcacca atcaagcccc gcttggtatt401 aggcgcctgg ccgccccccc cgtggccggc ccgcccgaaa tgcatcggcg451 aggcaccgac ccccggcgtg ttagaatttc gaaacgtcag gagcaccggt501 gttaacctct gccgtgaaac cttcaaacta ttttttctaa ggttgacctc551 ggatcaggta ggaatacccg ctgaacttaa gcatatcaat aagcggagga601 a

MF UnspecifiedCI MANSR CALC STN Files: CA, CAPLUS, TOXLIT




DNA, single stranded:

CN DNA (canine parvovirus clone pCPVEx17 coat protein VP 2 gene) (9CI)(CA INDEX NAME)

OTHER CA INDEX NAMES:CN Deoxyribonucleic acid (canine parvovirus clone pCPVEx17 coat protein

VP 2 gene)FS NUCLEIC ACID SEQUENCESQL 1755NA 616 a 277 c 348 g 514 tNTE singlestranded

SEQ 1 atgagtgatg gagcagttca accagacggt ggtcaacctg ctgtcagaaa51 tgaaagagct acaggatctg ggaacgggtc tggaggcggg ggtggtggtg

101 gttctggggg tgtggggatt tctacgggta ctttcaataa tcagacggaa151 tttaaatttt tggaaaacgg atgggtggaa atcacagcaa actcaagcag201 acttgtacat ttaaatatgc cagaaagtga aaaggataga agagtggttg251 taaataatat ggataaaact gcagttaacg gaaacatggc tttagatgat301 attcatgcac aaattgtaac accttggtca ttggttgatg caaatgcttg351 gggagtttgg tttaatccag gagattggca actaattgtt aatactatga401 gtgagttgca tttagttagt tttgaacaag aaatttttaa tgttgtttta451 aagactgttt cagaatctgc tactcagcca ccaactaaag tttataataa501 tgatttaact gcatcattga tggttgcatt agatagtaat aatactatgc551 catttactcc agcagctatg agatctgaga cattgggttt ttatccatgg601 aaaccaacca taccaactcc atggagatat tattttcaat gggatagaac651 attaatacca tctcatactg gaactagtgg cacaccaaca aatatatacc701 atggtacaga tccagatgat gttcaatttt atactattga aaattctgtg751 ccagtacact tactaagaac aggtgatgaa tttgctacag gaacattttt801 ttttgattgt aaaccatgta gactaacaca tacatggcaa acaaatagag851 cattgggctt accaccattt ctaaattctt tgcctcaatc tgaaggagct901 actaactttg gtgatatagg agttcaacaa gataaaagac gtggtgtaac951 tcaaatggga aatacaaact atattactga agctactatt atgagaccag

1001 ctgaggttgg ttatagtgca ccatattatt cttttgaggc gtctacacaa1051 gggccattta aaacacctat tgcagcagga cgggggggag cgcaaacata1101 tgaaaatcaa gcagcagatg gtgatccaag atatgcattt ggtagacaac1151 atggtcaaaa aactaccaca acaggagaaa cacctgagag atttacatat1201 atagcacatc aagatacagg aagatatcca gaaggagatt ggattcaaaa1251 tattaacttt aaccttcctg taacgaatga taatgtattg ctaccaacag1301 atccaattgg aggtaaaaca ggaattaact atactaatat atttaatact1351 tatggtcctt taactgcatt aaataatgta ccaccagttt atccaaatgg1401 tcaaatttgg gataaagaat ttgatactga cttaaaacca agacttcatg1451 taaatgcacc atttgtttgt caaaataatt gtcctggtca attatttgta1501 aaagttgcgc ctaatttaac aaatgaatat gatcctgatg catctgctaa1551 tatgtcaaga attgtaactt actcagattt ttggtggaaa ggtaaattag1601 tatttaaagc taaactaaga gcctcccata cttggaatcc aattcaacaa1651 atgagtatta atgtagataa ccaatttaac tatgtaccaa gtaatattgg1701 aggtatgaaa attgtatatg aaaaatctca actagcacct agaaaattat1751 attaa





DNA, regulatory element:

RN 124759-47-3 REGISTRYCN DNA (Dictyostelium discoideum clone A11-1200 -370/-305 temporal

regulatory element) (9CI) (CA INDEX NAME)OTHER CA INDEX NAMES:CN Deoxyribonucleic acid (Dictyostelium discoideum clone A11-1200

-370/-305 temporal regulatory element)FS NUCLEIC ACID SEQUENCESQL 67NA 25 a 1 c 11 g 30 tNTE doublestranded

SEQ 1 aaaaattgta aaaaaaaggg tttaaaaaac atgattggtt agatagattt51 tgtttttttt tttttgt

MF UnspecifiedCI MANSR CALC STN Files: CA, CAPLUS, TOXLIT


RNA, transfer:

RN 92092-43-8 REGISTRYCN RNA (Haloferax volcanii aspartic acid-specific transfer) (9CI) (CA

INDEX NAME)OTHER CA INDEX NAMES:CN Ribonucleic acid (Haloferax volcanii aspartic acid-specific

transfer)OTHER NAMES:CN Ribonucleic acid (Halobacterium volcanii aspartic acid-specific

transfer)FS NUCLEIC ACID SEQUENCESQL 76NA 10 a 26 c 26 g 14 uNTE singlestranded

modified----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------modified base g-1 5'-phosphatemodified base g-10 m22gmodified base u-13 pmodified base u-54 m1pmodified base u-55 pmodified base c-56 cmmodified base g-57 m1i----------------------------------------------------------------------

SEQ 1 gcccgggugg uguaguggcc caucauacga cccugucacg gucgugacgc51 ggguucgaau cccgccucgg gcgcca

MF UnspecifiedCI MAN



RNA, messenger:

CN RNA (synthetic .beta.-actin zipcode element-containing 3'-fragmentmessenger) (9CI) (CA INDEX NAME)

FS NUCLEIC ACID SEQUENCESQL 56NA 22 a 18 c 7 g 9 uNTE singlestranded

SEQ 1 uaaaccggac uguuaccaac acccacaccc ugugaugaaa caaaacccau51 aaaugc



RNA, ribosomal:

RN 172183-71-0 REGISTRYCN RNA (Methanococcus maripaludis strain JJ 23S ribosomal

197-nucleotide fragment) (9CI) (CA INDEX NAME)OTHER CA INDEX NAMES:CN Ribonucleic acid (Methanococcus maripaludis strain JJ 23S ribosomal

197-nucleotide fragment)OTHER NAMES:CN GenBank U39023FS NUCLEIC ACID SEQUENCESQL 197NA 52 a 40 c 63 g 39 t 3 nNTE singlestranded

SEQ 1 agtatattgt tgtgcgagct taagatcttc acgatcgtag gcgtagggaa51 accaacaagt ccgcaaaatc tatagggacg gggtcttaag ggcccggagt

101 cacagcaata tgacccgaaa ccgggngatc taggccgggg caaggtgaag151 tccctnaact gagggatgga ggcctgcaga gttgttgcng ttcgaag

MF UnspecifiedCI MANSR GenBankLC STN Files: CA, CAPLUS, GENBANK




Suchbare „Standard“-Felder:

=> ? sfi

FIELD NAME FIELD QUALIFIER

Basic Index /BI (or none)CAS Registry Number Locator /LCCAS Registry Number /RNClass Identifier /CIComponent Registry Number /CRNDefinition /DEFEntry Date /ED (numeric)Field Availability /FAFile Segment /FSNumber of References in the CA File /REF.CA (numeric)Number of References in the CA File /REF.CAD (numeric)for non-specific derivatives

Number of References in the CAOLD File /REF.CAOLD (numeric)Number of References in the CAplus File /REF.CAPLUS (numeric)Polymer Class Term /PCTUpdate Date /UP (numeric)

Nomenclature Fields-------------------

Chemical Name /CNChemical Name Segment /CNSHeading Parent /HPIndex Name Segment - Heading Parent /INS.HPIndex Name Segment - Non-Heading Parent /INS.NHPOther Name Segment /ONS

Molecular Formula Fields------------------------

Atom Count /ATC (numeric)Element Count /ELC (numeric)Element Count for Substance /ELC.SUB (numeric)Element Formula /ELFElement Ratio, xx /ELR.xx (numeric)

(xx = CH, CN, CO, HC, HN, HO,NC, NH, NO, OC, OH, ON)

Element Symbol /ELSElement Symbol for Multicomponent Formula /ELS.MCFFormula Weight /FW (numeric)Material Composition /MAC (mixed)Molecular Formula /MFNumber of Components /NC (numeric)Periodic Group /PGRelative Composition /RCSpecific Element Counts /CU, /NI, etc.(numeric)

The Element Formula (ELF) field requires spaces between the elementsin the formula, e.g., => S C H N O/ELF. The Molecular Formula (MF)field may be entered with or without spaces. Formula fragmentssearched in the Basic Index must be entered without spaces.



Anzeigbare (Display-) Felder:

=> ? dfi

SUBSTANCE INFORMATION FIELD CODES

AF Alternate Molecular FormulaAR Alternate CAS Registry NumberCCI Component Class IdentifierCCN Condensed Chemical Name (all names)CI Class IdentifierCIL Component Isotope at Unknown LocationCMF Component Molecular FormulaCN Chemical Name (up to 50)COMP CompositionCRN Component CAS Registry NumberDEF DefinitionDR Deleted CAS Registry NumberFCN All Chemical NamesFS File SegmentIL Isotope at Unknown LocationIN CA Index NameLC CAS Registry Number LocatorMF Molecular FormulaPCT Polymer Class TermPR Preferred CAS Registry NumberREF Number of References in CAplus, CA, aand CAOLD

files and the number of references in CA for thethe non-specific derivatives

RN CAS Registry NumberRR Replacing Registry NumberRSD Ring System DataSCN Short Chemical Name (IN and OTHER NAMES)SR Source of RegistrationSRSD Short Ring System DataSTR Structure Diagram with stereo bond and R/S/Z/E

designations, if availableSTF Flat Structure Diagram (no stereo bonds)STS Structure Diagram with stereo bonds, if available

Biosequence Field Codes:

NA Nucleic AcidNTE NoteSEQ Sequence (1-letter amino acid codes)SEQ3 Sequence (3-letter amino acid codes)SQL Sequence Length



Sequenz-Informationen:

=> ? ssq

Protein SequencesFour options are available for searching protein sequences usingamino acid codes. Each requires the corresponding field qualifierdescribed below. The sequence query is input using 1- and/or3-letter codes for the amino acids. Enter HELP AAC at an arrowprompt (=>) in the REGISTRY File for a list of codes for the commonamino acids. Enter HELP AAU at an arrow prompt for the codes forthe uncommon amino acids. Enter HELP SQQ at an arrow prompt forinformation on symbols used to allow for variability in subsequencequeries.

Exact Sequence Search of Proteins (/SQEP) retrieves sequences thatexactly match the search query. The search query must becompletely defined. Variability symbols are not allowed.

Exact Family Sequence Search of Proteins (/SQEFP) retrieves answersthat exactly match the query and answers in which family-equivalentsubstitution of the query amino acids occurs. Variabilitysymbols are not allowed.

Subsequence Search of Proteins (/SQSP) retrieves exact answers plussequences in which the query sequence is embedded. Variabilitysymbols are allowed.

Subsequence Family Search of Proteins (/SQSFP) retrieves exactsequences, subsequences, and answers in which family-equivalentsubstitution of the query amino acids occurs. For example, thequery ADHIFC/SQSFP retrieves the equivalent fragment ...PQKLYC..

The families of amino acid equivalents retrieved in protein familysearches are:

P, A, G, S, T (neutral, weakly hydrophobic)Q, N, E, D, B, Z (hydrophilic, acid amine)H, K, R (hydrophilic, basic)L, I, V, M (hydrophobic)F, Y, W (hydrophobic, aromatic)C (cross-link forming)

In addition to these sequence search methods, you also have theoption of searching the following fields with text or numericinformation on protein sequence features:

Definition Search code

Note /NTESequence Length /SQL

Left truncation may be used in the /NTE search field. A term withleft truncation must contain at least four characters, for example,=> S ?CHLOR?/NTE. The /SQL field is a numeric field and may besearched with numeric operators or ranges, e.g. 100-200/SQL.A protein sequence query (i.e. a query consisting of one or more ofthese fields: /SQEP, /SQSP, /SQEFP, /SQSFP, /SQL or /NTE) may becombined directly in a single search with only the following fields:/FS, /UP. However, any sequence field may be combined with any

L-numbered answer set in the REGISTRY File.



Sequenz-Informationen:

Nucleic Acid SequencesTwo options are available for searching nucleic acid sequences using1-letter codes. Each requires the corresponding field qualifierdescribed below. Enter HELP NUC at an arrow prompt in the REGISTRYFile for a list of codes for nucleic acids. Enter HELP SQQ forinformation on symbols used to allow for variability in subsequencequeries.

Exact Sequence Search of Nucleic Acids (/SQEN) retrieves sequencesthat exactly match the search query. The search query must becompletely defined. Ambiguity codes for nucleic acids are allowed.Variability symbols are not allowed.

Subsequence Search of Nucleic Acids (/SQSN) retrieves exact answersplus sequences in which the query sequence is embedded.Variability symbols are allowed.

In addition to these sequence search methods you also have the optionof searching the following fields with information on nucleic acidsequence features:

Definition Search code

Nucleic Acid (type) /NANucleic Acid Count /NA.CNTSequence Length /SQL

The /SQL field is a numeric field.

A nucleic acid sequence query (i.e. a query consisting of one ormore of these fields: /SQEN, /SQSN, /NA, /NA.CNT, /SQL) may becombined directly in a single search with only the following fields:/FS, /UP. However, any sequence field may be combined with anyL-numbered answer set in the REGISTRY File.



Codes für Aminosäuren:

=> ? aac

The following table lists the 1- and 3-letter codes that may be usedfor the common amino acids in sequence searches.

1-Letter Code 3-Letter Code Name------------- ------------- ----

A Ala AlanineB Asx Aspartic acid or AsparagineC Cys CysteineD Asp Aspartic acidE Glu Glutamic acidF Phe PhenylalanineG Gly GlycineH His HistidineI Ile IsoleucineK Lys LysineL Leu LeucineM Met MethionineN Asn AsparagineP Pro ProlineQ Gln GlutamineR Arg ArginineS Ser SerineT Thr ThreonineU Scy SelenocysteineV Val ValineW Trp TryptophanX Xxx UncommonY Tyr TyrosineZ Glx Glutamic acid or Glutamine

The codes B and Z may be used only in subsequence searches (/SQSPand /SQSFP).

The following table lists the 3-letter codes that may be used for thelesscommon amino acids. These amino acids are represented by X in the 1-lettersearch and display fields. The codes for the less common amino acids maybe used in exact (/SQEP) and subsequence (/SQSP) searches of proteins, butnot in family protein searches:



3-Letter Code Name------------- ----

Aaa alpha-amino acidAad 2-aminoadipic acid (2-aminohexanedioic acid)Aan alpha-asparagineAbu 2-aminobutanoic acidAca 2-aminocapric acid (2-aminodecanoic acid)Agn alpha-glutamineAib alpha-aminoisobutyric acid (2-aminoalanine)Apm 2-aminopimelic acid (2-aminoheptanedioic acid)App gamma-amino-beta-hydroxybenzenepentanoic acidAsu 2-aminosuberic acid (2-aminooctanedioic acid)Aze 2-carboxyazetidineBal beta-alanineBas beta-aspartic acidBly 3,6-diaminohexanoic acid (beta-lysine)Bua butanoic acidBux 4-amino-3-hydroxybutanoic acidCap gamma-amino-beta-hydroxycyclohexanepentanoic acid)Cit N5-aminocarbonylornithineCya 3-sulfoalanineDab 2,4-diaminobutanoic acidDpm diaminopimelic acidDpr 2,3-diaminopropanoic acidEdc S-ethylthiocysteineGgu gamma-glutamic acidGla gamma-carboxyglutamic acidGlc hydroxyacetic acid (glycolic acid)Glp pyroglutamic acidHar homoarginineHcy homocysteineHhs homohistidineHiv 2-hydroxyisovaleric acidHse homoserineHva 2-hydroxypentanoic acidHyl 5-hydroxylysineHyp 4-hydroxyprolineInc 2-carboxyoctahydroindoleIqc 3-carboxyisoquinolineIva isovalineLac 2-hydroxypropanoic acid (lactic acid)Maa mercaptoacetic acidMba mercaptobutanoic acidMhp 4-methyl-3-hydroxyprolineMpa mercaptopropanoic acidNle norleucineNty nortyrosineNva norvalineOaa omega-amino acidOrn ornithinePen penicillamine (3-mercaptovaline)Phg 2-phenylglycinePip 2-carboxypiperidineSar sarcosine (N-methylglycine)Spg 1-amino-1-carboxycyclopentaneSta statin (4-amino-3-hydroxy-6-methylheptanoic acid)Thi 3-thienylalanineTml epsilon-N-trimethyllysineTza 3-thiazolylalanineUnd undefinedWil alpha-amino-2,4-dioxopyrimidinepropanoic acid



Codes für Nukleinsäuren:

=> ? nuc

The following table lists the symbols and ambiguity codes fornucleotides that may be used in nucleic acid sequence searches.Ambiguity codes are found in nucleic acid sequences from GenBank (R)(registered trademark of the U.S. Department of Health and HumanServices).

Symbol Name or Definition------ ------------------

A adenineC cytosineG guanineT thymine (in DNA)U uracil (in RNA)

AmbiguityCodes Name or Definition--------- ------------------

Y pyrimidineR purineM aminoK ketoS strong interaction (3 H bonds)W weak interaction (2 H bonds)B not-AV not-T, not-UD not-CH not-GN unknown nucleotideX uncommon nucleotideZ non-specific nucleotide

(matches: Y,R,M,K,S,W,B,V,D,H,N,X)

Exact Sequence Searches of Nucleic Acids (/SQEN) allow all codesexcept Z and match the codes in the query exactly against the codesin the database.



Codes für Nukleinsäuren:

In subsequence queries, symbols for the specific nucleotides A,C,G,T,and U match only on those specific residues in sequences in thedatabase.

Symbol /SQSN matches on------ ----------------

A AC CG GT TU U

To ensure retrieval of GenBank sequences, ambiguity codes insubsequence queries are broadly translated in the following ways:

AmbiguityCodes /SQSN matches on--------- ----------------

B any code except A or XD any code except C or XH any code except G or XK any code except A,C,M or XM any code except G,T,U,K or XN any codeR any code except C,T,U,X or YS any code except A,T,U,W or XU T or UV any code except T,U or XW any code except G,C,S or XY any code except A,G,R or XX XZ any code except G,C,A,T or U

To override this broad translation of ambiguity codes, enclosean ambiguity code in [ ]. For example, [B][R][Y]/SQSN will matchonly on the sequence fragment BRY.



Such-Symbole:

=> ? sqq

The following symbols may be used in subsequence searches(/SQSP,/SQSFP, and /SQSN) to allow for variability in residues.

Symbol(s) Function Search Example:what the query retrieves

[ ] Specify alternate LGP[VL]/SQSP:residues LGP followed by

either V or L

[-] Exclude a specific ATTGC[-A]GAAG/SQSN:or the residue or alternate ATTGC followed bytilde residues any nucleotide except Ain followed by GAAGbrackets

{ } Repeat the preceding (FL){2}/SQSP:with a symbol, sequence, or FL repeated twice,number an L-number, E-number i.e. FLFL.or range or saved name for a

sequence queryGG(FL){1-3}/SQSP(or GG(FL){1,3}/SQSP):GGFL, or GGFLFL, orGGFLFLFL.

KLK(WD){0,}N/SQSP:KLKN or KLK followed byany number of repetitionsof WD followed by N,e.g., KLKWDN, KLKWDWDN,KLKWDWDWDN, etc.

CAT(CTG){1,}TATT/SQSN:CAT followed by one or morerepetitions of CTG followedby TATT,e.g. CATCTGTATT, CATCTGCTGTATT,CATCTGCTGCTGTATT etc.

? Repeat the preceding FLRRI(RP)?K/SQSP is equivalentsymbol, sequence, or to FLRRI(RP){0,1}K/SQSP:sequence query FLRRIK or FLRRIRPKzero or one time

* Repeat the preceding CAT(CTG)*TATT/SQSN is the samesymbol, sequence, or as CAT(CTG){0,}TATT/SQSN:sequence query CATTATT or CAT followed by anyzero or more times number of repetitions of CTG

followed by TATT, e.g.CATCTGTATT, CATCTGCTGTATT etc.



Such-Symbole:

+ Repeat the preceding CAT(CTG)+TATT/SQSN is equivalentsymbol, sequence, or to CAT(CTG){1,}TATT/SQSN:sequence query CAT followed by one or moreone or more times repetitions of CTG followed by

TATT,e.g. CATCTGTATT,CATCTGCTGTATT,CATCTGCTGCTGTATT etc.

In addition, the caret character may be used at the beginning orat the end of a sequence to search for that sequence at thebeginning or end of sequence field.

To require alternate sequence queries, separate the sequenceexpressions by the vertical bar.

Specifying Gaps

You may specify a gap in a sequence expression using the period (.)for one residue, the colon (:) for zero or one residue or theperiod (.) followed by an appropriate repeat expression. Thefollowing table summarizes all the options for specifying gaps insubsequence searches.

Symbol(s) Function Query Example:what the query retrieves

. a gap of one residue SY.RPG/SQSP:SY followed by one residuefollowed by RPG

.{m} a gap of m residues SY.{2}RPG/SQSP:or SY followed by any 2 residues

.[m.] followed by RPG

.{m,u} a gap of m to u residues GFF.{2,10}LSS/SQSP:or GFF followed by a gap of 2

.{m-u} to 10 residues followed by LSS

.? or : a gap of zero or AGA.?SRI/SQSFP is equivalentor .{0,1} one residue to AGA.{0,1}SRI/SQSFP:or .{0-1} AGA followed by zero or one

residue followed by SRI

.* or A gap of zero or more HLC.*TYG/SQSP is equivalent

.{0,} residues to HLC.{0,}TYG/SQSP:or HLC followed by a gap of zero

.{0-} or more residues followed byTYG



Such-Symbole:

.+ or A gap of one or more SY.+TH/SQSP is equivalent to

.{1,} residues SY.{1,}TH/SQSP:or .{1-} SY followed by any number of

residues followed by TH

Concatenating Queries

In addition to the variability symbols, you may use the & symbol tojoin together sequences or L-numbered, E-numbered or saved queries.The concatenation symbol may be used not only in subsequence searches(/SQSN, /SQSP, /SQSFP) but also in exact sequence searches ofproteins or nucleic acids (/SQEP, /SQEFP, /SQEN).

& Concatenate or join L1&L2&L3/SQSN:together sequences the sequence in L1 followed byor queries the sequence in L2 followed by

the sequence in L3.

Order of Precedence

More than one symbol may be used to create complex sequence queries.For example, the query L2&L5{1,3}/SQSN specifies that the sequencein L2 is to be followed by one to three repetitions of the sequencequery in L5. If you do not use parentheses in sequence queries, theoperations will be executed in the following order:

1. repeat symbols ? or * or +2. repeat expressions using curly braces, e.g. {3,6},3. concatenation symbol &,4. the vertical bar


Typische Beispiele von Sequenz-Recherchenim CAS REGISTRY FILE

Gesucht werden Analoge von Sandostatin mit der Sequenz FCFWKTCT.

=> file regFILE 'REGISTRY' ENTERED AT 10:53:22 ON 26 MAR 1997USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENTCOPYRIGHT (C) 1997 American Chemical Society (ACS)STRUCTURE FILE UPDATES: 21 MAR 97 HIGHEST RN 187521-07-9DICTIONARY FILE UPDATES: 25 MAR 97 HIGHEST RN 187454-69-9

=> s fcfwktct/sqep269 FCFWKTCT/SQEP

20183 SQL=8L1 269 FCFWKTCT/SQEP

(FCFWKTCT/SQEP AND SQL=8)

=> d sqd 1,50

L1 ANSWER 1 OF 269 REGISTRY COPYRIGHT 1997 ACSRN 183545-40-6 REGISTRYFS PROTEIN SEQUENCE; STEREOSEARCHSQL ***8***NTE modified (modifications unspecified)----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------bridge Cys-2 - Cys-7 sulfide bridgestereo Phe-1 - Dstereo Trp-4 - D----------------------------------------------------------------------

SEQ 1 FCFWKTCT========

HITS AT: 1-8

L1 ANSWER 50 OF 269 REGISTRY COPYRIGHT 1997 ACSRN 147790-78-1 REGISTRYFS PROTEIN SEQUENCESQL ***8***NTE modified----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------bridge Cys-2 - Cys-7 disulfide bridgemodification Phe-1 - undetermined modificationmodification Thr-8 - undetermined modification----------------------------------------------------------------------

SEQ 1 FCFWKTCT========

HITS AT: 1-8



Gesucht sind Proteine aus „human cytochrome c“,die die Subsequenz GLFGRKTGQAP enthalten.

=> s glfgrktgqap/sqspL2 90 GLFGRKTGQAP/SQSP

=> d cn sql seq 1,40

L2 ANSWER 1 OF 90 REGISTRY COPYRIGHT 1997 ACSCN 1-66-Cytochrome c (horse protein moiety reduced),

N-deacetyl-14-[S-[(acetylamino)methyl]-L-cysteine]-17-[S-[(acetylamino)methyl]-L-cysteine]- (9CI) (CA INDEX NAME)

SQL 66

SEQ 1 GDVEKGKKIF VQKCAQCHTV EKGGKHKTGP NLHGLFGRKT GQAPGFTYTD======= ====

51 ANKNKGITWK EETLMEHITS AT: 34-44

L2 ANSWER 40 OF 90 REGISTRY COPYRIGHT 1997 ACSCN Cytochrome c (horse protein moiety reduced), 5-[N6-(1-iminoethyl)-L-

lysine]-7-[N6-(1-iminoethyl)-L-lysine]-8-[N6-(1-iminoethyl)-L-lysine]-13-[N6-(1-iminoethyl)-L-lysine]-22-[N6-(1-iminoethyl)-L-lysine]-25-[N6-(1-iminoethyl)-L-lysine]-27-[N6-(1-iminoethyl)-L-lysine]-39-[N6-(1-iminoethyl)-L-lysine]-53-[N6-(1-iminoethyl)-L-lysine]-55-[N6-(1-iminoethyl)-L-lysine]-60-[N6-(1-iminoethyl)-L-lysine]-66-[N6-(1-iminoethyl)-L-lysine]-72-[N6-(1-iminoethyl)-L-lysine]-73-[N6-(1-iminoethyl)-L-lysine]-79-[N6-(1-iminoethyl)-L-lysine]-86-[N6-(1-iminoethyl)-L-lysine]-87-[N6-(1-iminoethyl)-L-lysine]-88-[N6-(1-iminoethyl)-L-lysine]-99-[N6-(1-iminoethyl)-L-lysine]-100-[N6-(1-iminoethyl)-L-lysine]- (9CI) (CA INDEX NAME)

SQL 104

SEQ 1 GDVEKGKKIF VQKCAQCHTV EKGGKHKTGP NLHGLFGRKT GQAPGFTYTD======= ====

51 ANKNKGITWK EETLMKYLEN PKKYIPGTKM IFAGIKKKTE REDLIAYLKK101 ATNE

HITS AT: 34-44



Gesucht sind Sequenzen, die funktionell gleich sind wie die SequenzAGCKNFFWKTFTSC von synthetischem Somatostatin.

=> s agcknffwktftsc/sqefp275 AGCKNFFWKTFTSC/SQEFP

10987 SQL=14L1 275 AGCKNFFWKTFTSC/SQEFP

(AGCKNFFWKTFTSC/SQEFP AND SQL=14)

=> d cn hit nte 9,45

L1 ANSWER 9 OF 275 REGISTRY COPYRIGHT 1997 ACSCN 3,14-Dicarbasomatostatin (sheep), 14-(L-2-aminobutanamide)- (9CI)

(CA INDEX NAME)OTHER CA INDEX NAMES:CN 1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclooctatriacontane, cyclic

peptide deriv.FS PROTEIN SEQUENCESQL ***14***

SEQ 1 AGCKNFFWKT FTSC========== ====

HITS AT: 1-14NTE modified----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------terminal mod. Cys-14 - C-terminal amidebridge Cys-3 - Cys-14 dicarba bridge----------------------------------------------------------------------

L1 ANSWER 45 OF 275 REGISTRY COPYRIGHT 1997 ACSCN L-Alanine, N-[N-[N-[N-[N-[DL-2-[4-[[(1,1-

dimethylethoxy)carbonyl]amino]butyl]-N-[1-[[N-[N-[N2-[N6-[(1,1-dimethylethoxy)carbonyl]-N2-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl]glycyl]-3-[(1,1-dimethylethyl)dithio]-L-alanyl]-L-lysyl]-L-asparaginyl]-L-phenylalanyl]-L-phenylalanyl]amino]-2-(1H-indol-3-yl)ethyl]-3-oxo-.beta.-alanyl]-O-(1,1-dimethylethyl)-L-threonyl]-L-phenylalanyl]-O-(1,1-dimethylethyl)-L-threonyl]-O-(1,1-dimethylethyl)-L-seryl]-3-[(1,1-dimethylethyl)dithio]-,1,1-dimethylethyl ester, monohydrochloride, (S)- (9CI) (CA INDEXNAME)

FS PROTEIN SEQUENCESQL ***14***

SEQ 1 AGCKNFFWKT FTSC========== ====

HITS AT: 1-14NTE modified----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------stereo Lys-9 - DLreplacement Trp-8 - azareplacement Lys-9 - carba----------------------------------------------------------------------



Gesucht sind Atriopeptin-Analoge, die RSSCF und QSGLG enthalten,getrennt durch eine Lücke von Null oder beliebig viele Aminosäuren.

=> s rsscf.*qsglg/sqspL2 385 RSSCF.*QSGLG/SQSP

=> d kwic 1,10,100


SEQ 1 SLRRSSCFGG RMDRIGAQSG LGCNSFRYK======= ========== ==

HITS AT: 4-22


SEQ 1 RSSCFGGRID RIGAQSGLGC NSFRY========== =========

HITS AT: 1-19


SEQ 1 RRSSCFGGRI DPIGAQSGLG CNSFRY========= ==========

HITS AT: 2-20

Gesucht sind Peptide von 10 oder weniger Aminosäuren,die die Sequenz RGDF enthalten.

=> s rgdf/sqsp and sql<=10278 RGDF/SQSP

177858 SQL<=10L3 278 RGDF/SQSP AND SQL<=10

=> d kwic 1,200

L3 ANSWER 1 OF 278 REGISTRY COPYRIGHT 1997 ACSFS PROTEIN SEQUENCE; STEREOSEARCHSQL ***10***

SEQ 1 CRGDFFASSC====

HITS AT: 2-5

L3 ANSWER 200 OF 278 REGISTRY COPYRIGHT 1997 ACSFS PROTEIN SEQUENCE; STEREOSEARCHSQL ***7***

SEQ 1 CRGDFXC====

HITS AT: 2-5



Suche nach Mehrfachketten.

=> s multichain/nteL4 8315 MULTICHAIN/NTE

=> d cn kwic seq

L4 ANSWER 1 OF 8315 REGISTRY COPYRIGHT 1997 ACSCN 1-71-Complement C5a [1-methionine,27-serine,71-cysteine] (human)

(71.fwdarw.1')-disulfide with L-cysteinyl-L-leucylglycyl-D-arginine(9CI) (CA INDEX NAME)

NTE ***multichain***

SEQ 1 MLQKKIEEIA AKYKHSVVKK CCYDGASVNN DETCEQRAAR ISLGPRCIKA51 FTECCVVASQ LRANISHKDM C

SEQ 1 CLGR

Suche nach Peptiden mit Ethoxycarbonyl als Blockergruppe.

=> s eoc/nteL5 139 EOC/NTE

=> d cn kwic seq

L5 ANSWER 1 OF 139 REGISTRY COPYRIGHT 1997 ACSCN L-Leucine, N-(ethoxycarbonyl)-L-phenylalanyl-L-valyl-L-lysyl- (9CI)

(CA INDEX NAME)NTE modified----------------------------------------------------------------------type ------ location ------ description

----------------------------------------------------------------------modification Phe-1 - ethoxycarbonyl<Eoc>----------------------------------------------------------------------

SEQ 1 FVKL



Suche nach einem Patent mit der SequenzCGCCCCTGCGTTACCCTCCCCGCCG.

=> s cgcccctgcgttaccctccccgccg/sqen1 CGCCCCTGCGTTACCCTCCCCGCCG/SQEN

6542 SQL=25L6 1 CGCCCCTGCGTTACCCTCCCCGCCG/SQEN

(CGCCCCTGCGTTACCCTCCCCGCCG/SQEN AND SQL=25)

=> d seq lc


SEQ 1 cgcccctgcg ttaccctccc cgccg========== ========== =====

HITS AT: 1-25LC STN Files: CA, CAPLUS, TOXLIT

=> fil caplusFILE 'CAPLUS' ENTERED AT 11:03:33 ON 26 MAR 1997USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENTCOPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)FILE COVERS 1967 - 26 Mar 1997 VOL 126 ISS 13FILE LAST UPDATED: 26 Mar 1997 (970326/ED)

=> s l1;d bib hitrnL7 1554 L1

L7 ANSWER 1 OF 1554 CAPLUS COPYRIGHT 1997 ACSAN 1997:184691 CAPLUSDN 126:171493TI Preparation of benzo[g]quinoline derivatives as selective

antagonists at somatostatin sst1 receptorsIN Neumann, Peter; Pfaeffli, Paul; Seiler, Max Peter; Swoboda, RobertPA Sandoz Ltd., Switz.; Sandoz-Patent-Gmbh; Sandoz-Erfindungen

Verwaltungsgesellschaft M.B.H.; Neumann, Peter; Pfaeffli, Paul;Seiler, Max Peter; Swoboda, Robert

SO PCT Int. Appl., 24 pp.CODEN: PIXXD2

PI WO 9703054 A1 970130DS W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,

ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,SE, SG

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FI, FR, GA, GB,GR, IE, IT, LU, MC, NL, PT, SE

AI WO 96-EP2969 960705PRAI GB 95-13880 950707

GB 96-3988 960226DT PatentLA EnglishIT ***38916-34-6*** , Somatostatin

RL: BPR (Biological process); BSU (Biological study, unclassified);MSC (Miscellaneous); BIOL (Biological study); PROC (Process)

(prepn. of benzo[g]quinoline derivs. as selective antagonists atsomatostatin sst1 receptors)


DGENE

Derwent GENESEQ

STN-Filekürzel: DGENE

Über 200'000 Patentdatensätze seit 1981

Nukleinsäuresequenzen von 10 oder mehr Basen

Aminosäuresequenzen von 4 oder mehr Resten

„Probes“ und „Primers“ jeder Länge

Die Sequenzen entstammen Patenten aus 40 Patentämtern

Mehr als die Hälfte der Sequenzen werden in keinen anderenPublikationen gefunden

Jede Sequenz, die in einem Patent beschrieben wird,erhält einen separaten Datensatz in DGENE

Die Patenttitel werden von Derwent standardisiert übersetzt.

Spezielle Abstracts, geschrieben von Bioinformatik-Experten

World Patents Index Familieninformation

Sequenzdaten inkl. Feature-Tabellen


DGENE

Einige Suchbeispiele:

Datenbankauswahl:=> fil dgene


Linkstrunkierung in „feature table“:=> s (?pyran? and ?gluco?)/feat

22 ?PYRAN?/FEAT65 ?GLUCO?/FEAT

L1 1 (?PYRAN? AND ?GLUCO?)/FEAT

Bildschirmausgabe von Titel und „feature table“:=> d ti feat

L1 ANSWER 1 OF 1 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDTI New sugar-modified peptide - has prolonged active period

FEATURE TABLE:Key |Location|Qualifier|===============+========+=========+==============================Disulfide_bond |1..6 | |Modified_site |2 |note |"phenolic hydroxy group is

| | |esterified with| | |9-(beta-glucopyranosyloxy)nona| | |noyl"

Modified_site |9 |note |"Gly-NH2"

Setzen der Anfrage für eine bestimmte Nukleinsäuresequenz:=> que cattgtagL2 QUE CATTGTAG

Setzen der Anfrage für eine bestimmte Proteinsequenz:=> que 'tyr-gly-phe-phe'L3 QUE 'TYR-GLY-PHE-PHE'

('TYR'(W)'GLY'(W)'PHE'(W)'PHE')

Starten einer Sequenzsuche:=> run getseq l2TYPE OF SEARCH ? (SQSP):sqsnL4 RUN STATEMENT CREATEDL4 374 CATTGTAG/SQSN


DGENE

=> d ti pa pi seq

L4 ANSWER 1 OF 374 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDTI DNA encoding decorin binding protein - useful for diagnosis and

treatment of Borrelia infection, esp. Lyme's diseasePA (TEXA) UNIV TEXAS A & M SYSTEMPI WO 9634106 A1 961031 228 ppSEQ

1 atgattaaat gtaataataa aacttttaac aatttactta aactaactat51 acttgttaac ctacttatat catgtggact aacaggagca acaaaaatca

101 aattagaatc atcagctaaa gccattgtag atgaaataga tgcaattaaa========

151 aaagaggctg ctcttaaggg tgtaaatttt gatgccttta aagataaaaa201 aacgggtagt ggggtatcaa aaaatccatt catacttgaa gcaaaagtgc251 gagctactac agtagcggaa aaattcgtaa tagcaataga agaggaagct301 actaaactta aagaaactgg aagtagtggt gaattctcag caatgtatga351 tttaatgttt gaagtctcaa aaccattaca agaattggga atacaagaga401 tgacaaaaac agtctcaatg gcagctgaag agaatcctcc aactacagct451 caaggagtgc ttgaaattgc aaaaaaaatg agagaaaaat tacaaagggt501 tcacaagaaa aaccaacaaa ccttaaagaa aaaaaatacc gaagaaagca551 ctgctaaatc gaaa

HITS AT: 123-130

Starten einer Sequenzsuche:=> run getseq l3TYPE OF SEARCH ? (SQSP):.L5 RUN STATEMENT CREATEDL5 23 'TYR-GLY-PHE-PHE'/SQSP

=> d ti pa pi seq

L5 ANSWER 1 OF 23 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDTI Inhibitor of cancer metastasis - contains N-acetyl:glucosaminyl

transferase-III isolated from rat kidneysPA (TAKI) TAKARA SHUZO CO LTDPI JP 08109139 A 960430 12 ppSEQ

1 mrryklflmf cmaglclisf lhffktlsyv tfprelasls pnlvssffwn51 napvtpqasp epggpdllrt plyshspllq plppskaaee lhrvdlvlpe

101 dtteyfvrtk aggvcfkpgt kmlerpppgr peekpegang ssarrppryl151 lsarertggr garrkwvecv clpgwhgpsc gvptvvqysn lptkerlvpr201 evprrvinai nvnhefdlld vrfhelgdvv dafvvcesnf taygeprplk251 fremltngtf eyirhkvlyv fldhfppggr qdgwiaddyl rtfltqdgvs301 rlrnlrpddv fiiddadeip ardgvlflkl ydgwtepfaf hmrtslygff

====351 wkqpgtlevv sgctvdmlqa vygldgirlr rrqyytmpnf rqyenrtghi401 lvqwslgspl hfagwhcswc ftpegiyfkl vsaqngdfpr wgdyedkrdl451 nyirglirtg gwfdgtqqey ppadpsehmy apkyllknyd rfhylldnpy501 qeprstaagg wrhrgpegrp pargkldeae v

HITS AT: 347-350


DGENE

Starten einer Sequenzsuche:=> run getseq

PLEASE ENTER SEQUENCE PATTERN OR ?:tataaaaTYPE OF SEARCH ? (SQSP):sqsnL6 RUN STATEMENT CREATEDL6 4427 TATAAAA/SQSN

Limitierung auf eine bestimmte Sequenzlänge:=> s l6 and 33-75/sql

31007 33-75/SQLL7 168 L6 AND 33-75/SQL

=> d ti pa pi seq

L7 ANSWER 1 OF 168 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDTI New DNA constructs associated with a transposase gene - used to

produce bacterial cells which have multiple copies of desired DNAintegrated into their genome(s) by transposition

PA (NOVO) NOVO-NORDISK ASPI WO 9623073 A1 960801 144 ppSEQ

1 caagtgttcg cttcgctctc acggagctgt aatataaaaa ccttc=======

HITS AT: 33-39

Sequence Similarity Searching:

„FASTA-like“ Suchalgorithmus (Pearson & Lipman) Antwortsätze sortiert nach „Smith-Waterman similarity score“

=> que vittendtqtvfvdmprlerrranpkdvaavilgggegtkL8 QUE VITTENDTQTVFVDMPRLERRRANPKDVAAVILGGGEGTK

=> run getsimPLEASE ENTER SEQUENCE QUERY OR ?:l8

10000 SEQUENCES PROCESSED20000 SEQUENCES PROCESSED30000 SEQUENCES PROCESSED40000 SEQUENCES PROCESSED50000 SEQUENCES PROCESSED60000 SEQUENCES PROCESSED70000 SEQUENCES PROCESSED80000 SEQUENCES PROCESSED90000 SEQUENCES PROCESSED

272 ANSWERS FOUND ABOVE A THRESHOLD OF 43


DGENE

SimilarityScore

255 ||||||||||

128 |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Answer Count 50 100 150 200 250

HOW MANY ANSWERS WOULD YOU LIKE TO KEEP ? (ALL) OR ?:.L9 RUN STATEMENT CREATEDL9 272 VITTENDTQTVFVDMPRLERRRANPKDVAAVILGGGEGTK/SQP

Answer set arranged by accession number; to sort by descendingsimilarity score, enter at an arrow prompt (=>) "sor score d".

=> d ti pa align 1 15

L9 ANSWER 1 OF 272 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDTI Borna disease virus (BDV) nucleotide and protein sequences - useful

for the diagnosis and treatment of infection and non-BDV relatedneuro-logic and neuro-psychiatric disease

PA (REGC) UNIV CALIFORNIAALIGN Smith-Waterman score: 51

17 aa overlap starting at 242prlerrranpkdvaavi:::.::: . ... ..prlkrrrrdtqqieylv

L9 ANSWER 15 OF 272 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDTI New molecular presentation system - comprising a viral protein from

a small insect virus in which heterologous amino acid sequences areinserted

PA (UNNA-N) UNITED NATIONS IND DEV ORGALIGN Smith-Waterman score: 45

24 aa overlap starting at 16vittendtqtvfvdmprlerrran:.:: . . . ..:: ::: :vvtttqtapvpqqnvprngrrrrn


RUN GETSEQ

For searching sequences with the GETSEQ run package, differentoptions are available. Each requires the corresponding field qualifier:

Nucleic acid sequence:

SQEN: Exact Sequence Search of Nucleic Acids

SQSN: Subsequence Search of Nucleic Acids (exact sequencesand sequences with embeded query sequence)

Protein sequence:

SQEP: Exact Sequence Search of Proteins

SQEFP: Exact Family Sequence Search of Proteins (answers thatexactly match the query and answers in which family-equivalent substitution of the query amino acids occurs.

SQSP: Subsequence Search of Proteins (exact answers plussequences in which query sequence is embedded.)

SQSFP: Subsequence Family Search of Proteins (exact sequences,subsequences, and answers in which family-equivalentsubstitution of the query amino acids occurs)


Typisches Beispiel einer Sequenz-Recherche nachNukleinsäuren mit RUN GETSEQ in der Datenbank DGENE:

=> fil dgene

FILE 'DGENE' ENTERED AT 14:35:22 ON 14 MAR 1997COPYRIGHT (C) 1997 DERWENT INFORMATION LTD

=> run getseq

PLEASE ENTER SEQUENCE PATTERN OR ?:gaattcTYPE OF SEARCH ? (SQSP):sqsnL1 RUN STATEMENT CREATEDL1 14138 GAATTC/SQSN

=> d all

L1 ANSWER 1 OF 14138 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDAN 96N-Q99357 DNA DGENETI Nucleic acid encoding barley ADP ribosylation factor - used to

promote the growth of cells, calli or transformed plantsPA (SAPB) SAPPORO BREWERIESPI JP 08009978 A 960116 10 ppAI JP 94-173354 940701PRAI JP 94-173354 940701PSL Example 5; Page 7DED 17 JUL 1996 (first entry)DT PatentLA JapaneseOS 96-110276 [12]DESC Barley ADP ribosylation factor cDNA PCR primerKW Barley; ADP; ribosylation factor; callus; transformed plant; growth

promoter; adenosine diphosphate; primer; ssORGN SyntheticAB The primer pair Q99356/57 was used for the PCR amplification of

barley ADP ribosylation factor (ARF) cDNA. ARF can be used topromote plant growth, and an expression vector contg. the ARF cDNAcan be used for the prodn. of cells, calli or transformed plantswith promoted growth. The cDNA (clone R151) was obtd. from a barleyroot cDNA library. The R151 protein was structurally analysed andfound to have about 90% homology to human, bovine or yeast ARF atan amino acid level

NA 7 A; 5 C; 9 G; 12 T;SQL 33SEQ

1 acggaattct taggacttgt tggcaatgtt gct======

HITS AT: 4-9


Typisches Beispiel einer Sequenz-Recherche nachProteinen mit RUN GETSEQ in der Datenbank DGENE:

=> run getseq

PLEASE ENTER SEQUENCE PATTERN OR ?:leqwfaTYPE OF SEARCH ? (SQSP):.L2 RUN STATEMENT CREATEDL2 1 LEQWFA/SQSP

=> d all

L2 ANSWER 1 OF 1 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDAN 93P-R32888 peptide DGENETI New cyclic hexa:peptide derivs., are tachy:quinine antagonists -

useful for treating arthritis, asthma, inflammation, tumours,gastrointestinal hypermotility, migraine, hypertension, etc

IN Arcamone F M; Giachetti A; Maggi C A; Patacchini R; Pestellini V;Quartara L

PA (MENA) MENARINI IND FARM RIUNITE SRLPI WO 9303059 A 930218 26 ppAI WO 92-EP1760 920803PRAI IT 91-MI2231 910808

IT 92-FI0128 920619PSL Claim 17; Page 23DED 15 JUN 1993 (first entry)DT PatentLA EnglishOS 93-076440 [09]DESC Tachyquinine antagonist peptideKW Arthritis; asthma; inflamation; tumour growth, neuritis; neuralgia;

gastrointestinal hypermotility; Huntington's disease; migraine;hypertension; incontinence; urticaria; carcinoid syndrome symptoms;influenza; colds

ORGN SyntheticAB The peptide is a tachyquinine antagonist and is useful for treating

arthritis, asthma, inflammation, tumour growth, gastrointestinalhypermotility, Huntington's disease, neuritis, neuralgia, migraine,hypertension, incontinence, urticaria, carcinoid syndrome symptoms,influenza and colds

AA 1 A; 0 R; 0 N; 0 D; 0 B; 0 C; 1 Q; 1 E; 0 Z; 0 G; 0 H; 0I; 1 L; 0 K; 0 M; 1 F; 0 P; 0 S; 0 T; 1 W; 0 Y; 0 V;

SQL 6SEQ

1 leqwfa======

HITS AT: 1-6

FEATURE TABLE:Key |Location|Qualifier|===============+========+=========+========================Modified_site |2 |note |"Glu(NHBzl, NMeBzl,

| | |NHCH2C6H11, NMeCH2C6H11,| | |NHCH2[1-adamantyl] or| | |NMeCH2[1-adamantyl])"

Modified_site |6 |note |"beta-alanine"


Patentfamilien-Recherche in der Datenbank DGENE:

=> fil dgene

=> run getseqPLEASE ENTER SEQUENCE PATTERN OR ?:LAGLLTYPE OF SEARCH ? (SQSP):.L1 RUN STATEMENT CREATEDL1 141 LAGLL/SQSP

=> fsort L1

SET SMARTSELECT ONSET COMMAND COMPLETED

SET HIGHLIGHTING OFFSET COMMAND COMPLETED

SET AUDIT OFFSET COMMAND COMPLETED

SEL L1 1- PN,APPSL2 SEL L1 1- PN APPS : 263 TERMS

'L2' DELETEDL2 141 FSO L1

22 Multi-record Families Answers 1-99Family 1 Answers 1-2Family 2 Answers 3-12Family 3 Answers 13-14Family 4 Answers 15-16Family 5 Answers 17-19Family 6 Answers 20-21Family 7 Answers 22-29Family 8 Answers 30-32Family 9 Answers 33-34Family 10 Answers 35-36Family 11 Answers 37-57...Family 21 Answers 94-97Family 22 Answers 98-99

42 Individual Records Answers 100-1410 Non-patent Records

SET SMARTSELECT OFFSET COMMAND COMPLETED

SET HIGHLIGHTING ONSET COMMAND COMPLETED

SET AUDIT ONSET COMMAND COMPLETED



=> d iall 33-34

L2 ANSWER 33 OF 141 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDFAMILY 9

ACCESSION NUMBER: 95P-R82995 Protein DGENETITLE: New acute phase response factor - for developing

inhibitory agents for treating diseases induced bycytokine(s) such as IL-6, e.g. inflammatory diseases

INVENTOR: Akira S; Kishimoto TPATENT ASSIGNEE: (KISH-I)KISHIMOTO T

PATENT INFO: EP 676469 A2 951011 31 ppAPPLICATION INFO: EP 95-104670 950329PRIORITY INFO: JP 94-65825 940404

PAT. SEQ. LOC: Claim 10; Page 20-22 <- Lokalisation der SequenzDATA ENTRY DATE: 25 MAR 1996 (first entry)DOCUMENT TYPE: PatentLANGUAGE: EnglishOTHER SOURCE: 95-346089 [45]CROSS REFERENCES: N-PSDB: 95N-T05619DESCRIPTION: Mouse liver acute phase response factorKEYWORD: Mouse; acute phase response factor; transcription

factor; interleukin-6; signal transmission; liver;antibody; antisense; ribozyme; antiinflammatory;antitumor; hypotensive; therapy

ORGANISM: Mus musculusABSTRACT:

The sequence represents a mouse acute phase response factor (APRF),a transcription factor related to signal transmission ofinterleukin-6 (IL-6). The protein is encoded by a cDNA, isolatedfrom a mouse liver cDNA library using a polymerase chain reactionproduct (amplified using primers derived from an IL-6-treated mouseliver peptide) as a probe. APRF-inhibitors, e.g. antibodies,antisense oligonucleotides or ribozymes, may be used to treatdiseases induced by IL-6, e.g. inflammatory disease, leukemia,cancer, osteoclasia, pulmonary hypertension, etc

AMINO ACID COUNTS:44 A; 35 R; 38 N; 33 D; 0 B; 14 C; 60 Q; 58 E; 0 Z;39 G; 13 H; 42 I; 82 L; 47 K; 26 M; 30 F; 34 P; 51 S;47 T; 15 W; 21 Y; 41 V;

SEQUENCE LENGTH: 770SEQUENCE

1 maqwnqlqql dtryleqlhq lysdsfpmel rqflapwies qdwayaaske51 shatlvfhnl lgeidqqysr flqesnvlyq hnlrrikqfl qsrylekpme

101 iarivarclw eesrllqtaa taaqqggqan hptaavvtek qqmleqhlqd151 vrkrvqdleq kmkvvenlqd dfdfnyktlk sqgdmqdlng nnqsvtrqkm201 qqleqmltal dqmrrsivse lagllsamey vqktltdeel adwkrrqqia

=====251 ciggppnicl drlenwitsl aesqlqtrqq ikkleelqqk vsykgdpivq301 hrpmleeriv elfrnlmksa fvverqpcmp mhpdrplvik tgvqfttkvr351 llvkfpelny qlkikvcidk dsgdvaalrg srkfnilgtn tkvinmeesn401 ngslsaefkh ltlreqrcgn ggrancdasl ivteelhlit fetevyhqgl451 kidlethslp vvvisnicqm pnawasilwy nmltnnpknv nfftkppigt501 wdqvaevlsw qfssttkrgl sieqlttlae kllgpgvnys gcqitwakfc551 kenmagkgfs fwvwldniid lvkkyilalw negyimgfis kererailst601 kppgtfllrf sesskeggvt ftwvekdisg ktqiqsvepy tkqqlnnmsf651 aeiimgykim datnilvspl vylypdipke eafgkycrpe sqehpeadpg701 saapylktkf icvtpttcsn tidlpmsprt ldslmqfgnn gegaepsagg751 qfesltfdmd ltsecatspm

HITS AT: 221-225



L2 ANSWER 34 OF 141 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDFAMILY 9

ACCESSION NUMBER: 95P-R82993 protein DGENETITLE: New acute phase response factor - for developing

inhibitory agents for treating diseases induced bycytokine(s) such as IL-6, e.g. inflammatory diseases

INVENTOR: Akira S; Kishimoto TPATENT ASSIGNEE: (KISH-I)KISHIMOTO T

PATENT INFO: EP 676469 A2 951011 31 ppAPPLICATION INFO: EP 95-104670 950329PRIORITY INFO: JP 94-65825 940404

PAT. SEQ. LOC: Claim 3; Page 9-12 <- Lokalisation der SequenzDATA ENTRY DATE: 25 MAR 1996 (first entry)DOCUMENT TYPE: PatentLANGUAGE: EnglishOTHER SOURCE: 95-346089 [45]CROSS REFERENCES: N-PSDB: 95N-T05616DESCRIPTION: Human placenta acute phase response factor proteinKEYWORD: human; acute phase response factor; transcription

factor; interleukin-6; signal transmission; placenta;antibody; antisense; ribozyme; antiinflammatory;antitumor; hypotensive; therapy

ORGANISM: Homo sapiensABSTRACT:

The sequence corresponds to a human acute phase response factor(APRF), a transcription factor related to signal transmission ofinterleukin-6 (IL-6). The protein is expressed from a humanplacenta cDNA, isolated using an IL-6-treated mouse liver cDNAprobe. APRF-inhibitors, e.g. antibodies, antisenseoligonucleotides or ribozymes, may be used to treat diseasesinduced by IL-6, e.g. inflammatory disease, leukemia, cancer,osteoclasia, pulmonary hypertension, etc

AMINO ACID COUNTS:45 A; 35 R; 39 N; 32 D; 0 B; 14 C; 59 Q; 59 E; 0 Z;39 G; 14 H; 41 I; 84 L; 45 K; 27 M; 29 F; 33 P; 52 S;46 T; 15 W; 22 Y; 40 V;

SEQUENCE LENGTH: 770SEQUENCE

1 maqwnqlqql dtryleqlhq lysdsfpmel rqflapwies qdwayaaske51 shatlvfhnl lgeidqqysr flqesnvlyq hnlrrikqfl qsrylekpme

101 iarivarclw eesrllqtaa taaqqggqan hptaavvtek qqmleqhlqd151 vrkrvqdleq kmkvvenlqd dfdfnyktlk sqgdmqdlng nnqsvtrqkm201 qqleqmltal dqmrrsivse lagllsamey vqktltdeel adwkrrqqia

=====251 ciggppnicl drlenwitsl aesqlqtrqq ikkleelhqk vsykgdpivq301 hrpmleeriv elfrnlmksa fvverqpcmp mhpdrplvik tgvqfttkvr351 llvkfpelny qlkikvcidk dsgdvaalrg srkfnilgtn tkvmnmeesn401 ngslsaefkh ltlreqrcgn ggrancdasl ivteelhlit fetevyhqgl451 kidlethsls vvvisnicqm pnawasilwy nmltnnpknv nfftkppigt501 wdqvaevlsw qfssttkrgl sieqlttlae kllgpgvnys gcqitwanfc551 kenmagkgfs ywvwldniid lvkkyilalw negyimgfis lererailst601 kppgtfllrf sesskeggvt ftwvekdisg ktqiqsvepy tkqqlnnmsf651 aeiimgykim datnillspl vylypdipke eafgkycrpe sqehpeadpg701 saapylktkf icvtpttcsn tidlpmspra ldslmqfgnn gegaepsagg751 qfesltfdme ltsecatspm

HITS AT: 221-225


Der Nutzen der Patentinformation

Nach Schätzung der Fachleute sind inPatenten 85 bis 90 % des gesamtenveröffentlichten technischen Wissensgespeichert !

Etwa 70 % der in Patentschriftenenthaltenen Informationen bleibenmindestens fünf Jahre exklusiv auf diesesMedium beschränkt und werden nicht ananderer Stelle publiziert !

Rund 1/3 der Forschungsausgaben könntengespart werden, wenn Fachdatenbanken(inkl. Patent-DB) besser genutzt würden !


Der Nutzen der Patentinformation

Doppelentwicklungen vermeiden !

Jede technische Weuterentwicklung kann als Sprung nach oben angesehen werden. VieleEntwicklungen basieren aber nicht auf dem neuesten Wissen, sondern setzen zu tief an.Dies wird Doppelentwicklung genannt. Im nachfolgenden Bild „Aquarium-Modell“ werdendie vier Fälle dargestellt, die es bei einer Neu- bzw. Weiterentwicklung geben kann. DasWasser im Aquarium soll den Stand der Technik, d.h. das bekannte technische Wissen aufeinem bestimmten technischen Gebiet darstellen. Es kommt ständig neues technisches Wissenhinzu, so dass die Wasseroberfläche fortwährend ansteigt.

Die vier Pfeile stellen Entwicklungssprünge dar. Der linke Pfeil A zeigt den optimalen Fall.Eine Entwicklung setzt exakt auf der Oberfläche des technischen Wissens auf und vollbringtden Sprung nach oben. In der Regel kennt auch ein gut unterrichtetes Unternehmen nur 80 bis90 % des weltweiten Wissens. Dementsprechend setzt Pfeil B etwas unterhalb der Oberflächean. Dies reicht aus, um ein Schutzrecht zu erhalten.

Häufig erfolgen Entwicklungssprünge, wie es Pfeil C zeigt. Nach Abschluss der Entwicklungstellt sich heraus, dass sie zum Teil bereits bekannt sind.

Bei über einem Drittel aller Entwicklungen zeigt sich nach ihrem Beenden, dass sie nicht neusind und somit im Stand der Technik hätten gefunden werden können (Pfeil D).


Patentrecherchen bei STN


Merkmale der Patentrecherchen:

Recherche nach Freitext

=> s genetic engineering

Recherche nach der Patentklassifikation

=> s c12n015/ic

Namensrecherchennach Patentanmelder, nach Erfinder

=> e genentech/pa => e lewis r/in

Publikations- und Anmeldedaten

=> s 920601-920630/pd

Familienrecherchen

=> fsearch l4

Patentstatistik

=> select

=> analyze


Kostenloses Klassifizieren:

Beispiel: Gesucht werden Herstellungspatente cyclischer Peptide,bei denen in Lösung gearbeitet wird.

In den Datenbanken USPATFULL und Chemical Abstracts liegt die IPC mit vollständigemText als Online-Thesaurus auf. Da in der Datenbank ZCA keine Anschaltkosten, dafür aberSuchtermgebühren erhoben werden, sollte man sich hier auf ein Blättern mit EXPANDbeschränken.

=> fil zcaCOST IN DEUTSCHMARKS SINCE FILE TOTAL


FILE 'ZCA' ENTERED AT 15:42:33 ON 25 MAR 1997USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENTCOPYRIGHT (C) 1997 AMERICAN CHEMICAL SOCIETY (ACS)FILE COVERS 1967 - 18 Mar 1997 (970318/ED) VOL 126 ISS 12

=> e peptides/icE# FREQUENCY AT TERM-- --------- -- ----E1 0 1 PEPSTATIN/ICE2 0 1 PEPTIDASES DRUG INGREDIENT/ICE3 0 2 --> PEPTIDES/ICE4 0 1 PEPTIDES * ADSORPTION, SELECTIVE; PREPARATION BY

SELECTIVE ADSORPTION PROCESS/ICE5 0 1 PEPTIDES * ALGAE; PEPTIDES FROM ALGAE/ICE6 0 1 PEPTIDES * ANALYSIS; INVESTIGATION/ICE7 0 1 PEPTIDES * ANGIOTENSINS/ICE8 0 1 PEPTIDES * ANIMALS, HUMAN BEINGS; PEPTIDES FROM

ANIMALS, HUMAN BEINGS/ICE9 0 1 PEPTIDES * ASPARTAM/ICE10 0 1 PEPTIDES * BACTERIA; PEPTIDES FROM BACTERIA/ICE11 0 1 PEPTIDES * BESTATIN/ICE12 0 1 PEPTIDES * BRADYKININS/IC

=> eE13 0 1 PEPTIDES * CALCITONINS/ICE14 0 1 PEPTIDES * CHROMATOGRAPHY; PREPARATION/ICE15 0 1 PEPTIDES * CLEANING/ICE16 0 1 PEPTIDES * COLLAGEN/ICE17 0 1 PEPTIDES * CORTICOTROPINS/ICE18 0 1 PEPTIDES * DEPSIPEPTIDES/ICE19 0 1 PEPTIDES * DIPEPTIDES/ICE20 0 1 PEPTIDES * DRUG INGREDIENT/ICE21 0 1 PEPTIDES * ELASTIN/ICE22 0 1 PEPTIDES * ELEDOISINS/ICE23 0 1 PEPTIDES * ENDORPHINS/ICE24 0 1 PEPTIDES * FOCUSING, ISOELECTRIC; PREPARATION/IC



=> eE25 0 1 PEPTIDES * FUNGI; PEPTIDES FROM FUNGI/ICE26 0 1 PEPTIDES * GASTRINS/ICE27 0 1 PEPTIDES * GELATIN/ICE28 0 1 PEPTIDES * GLUCAGONS/ICE29 0 1 PEPTIDES * GONADOTROPIN RELEASING HORMONE;

GONADOLIBERIN/ICE30 0 1 PEPTIDES * GRAMICIDINS A, B, D/ICE31 0 1 PEPTIDES * IMMUNOGLOBULINS/ICE32 0 1 PEPTIDES * INGREDIENTS OF FOOD/ICE33 0 1 PEPTIDES * INSULINS/ICE34 0 1 PEPTIDES * ION-EXCHANGE; PREPARATION/ICE35 0 1 PEPTIDES * KALLIDINS/ICE36 0 1 PEPTIDES * KERATIN/IC

=> eE37 0 1 PEPTIDES * LICHENS; PEPTIDES FROM LICHENS/ICE38 0 1 PEPTIDES * LIPOTROPINS/ICE39 0 1 PEPTIDES * MELANOSTATIN/ICE40 0 1 PEPTIDES * MELANOTROPINS/ICE41 0 1 PEPTIDES * MURAMYL PEPTIDES/ICE42 0 1 PEPTIDES * MYOSIN/ICE43 0 1 PEPTIDES * OXYTOCINS/ICE44 0 1 PEPTIDES * PEPSTATIN/ICE45 0 1 PEPTIDES * PLANTS; PEPTIDES FROM PLANTS/ICE46 0 1 PEPTIDES * PRECIPITATION; PREPARATION/ICE47 0 1 PEPTIDES * PREPARATION/ICE48 0 1 PEPTIDES * RECOVERY, ENZYMATIC/IC

=> e e47+ktE49 0 --> peptides * preparation/ICE50 386 KT C07K001-00/IC********* END *********

=> e e50+ntONLY NT1 TERMS ARE ASSIGNED E-NUMBERS.E51 386 --> C07K001-00/IC

General processes for the preparation of peptides(4)

( IPC EDITION: 4-6 )E52 132 NT1 C07K001-02/IC

. in solution (4)( IPC EDITION: 4-6 )

E53 232 NT1 C07K001-04/IC. on carriers (4)


. using protecting groups or activating agents (4)( IPC EDITION: 4-6 )

E55 85 NT1 C07K001-10/IC. using coupling agents (4)


. by chemical modification of precursor peptides(6)

( IPC EDITION: 6 )E57 74 NT1 C07K001-12/IC

. by hydrolysis (4)( IPC EDITION: 4-6 )

.

.



=> fil wpindexCOST IN DEUTSCHMARKS SINCE FILE TOTAL


FILE 'WPINDEX' ENTERED AT 15:43:44 ON 25 MAR 1997COPYRIGHT (C) 1997 DERWENT INFORMATION LTDFILE LAST UPDATED: 20 MAR 97 <970320/UP>MOST RECENT DERWENT WEEK 9712 <199712/DW>'TRIAL' IS DEFAULT FORMAT FOR 'WPINDEX' FILE

=> s e52 and cyclic464 C07K001-02/IC

(C07K001-02/IC)47707 CYCLIC

L1 51 C07K001-02/IC AND CYCLIC

=> d an ti pa pi 1-3

L1 ANSWER 1 OF 51 WPINDEX COPYRIGHT 1997 DERWENT INFORMATION LTDAN 95-060947 [08] WPINDEXTI Prepn. and purification of ***cyclic*** peptide cpds. - by

oxidative cyclisation of sulphydryl gps. with iodine andchromatographic sepn. without removal of iodine.

PA (FERR) FERRING BV; (FERR) FERRING ABPI WO 9501368 A1 950112 (9508)* EN 23 pp C07K001-00

EP 710243 A1 960508 (9623) EN C07K001-00US 5596078 A 970121 (9710) 8 pp C07K001-02 <--

L1 ANSWER 2 OF 51 WPINDEX COPYRIGHT 1997 DERWENT INFORMATION LTDAN 94-333115 [41] WPINDEXTI Prepn. of ***cyclic*** peptide(s) - with incorporation of

N-methyl arginine to form prods. useful as platelet glyco-proteinIIb/IIIa inhibitors.

PA (DUPO) DU PONT MERCK PHARM COPI WO 9422911 A2 941013 (9441)* EN 161 pp C07K007-56

AU 9466976 A 941024 (9505) C07K007-56EP 694041 A1 960131 (9609) EN C07K007-56WO 9422911 A3 950112 (9610) C07K007-56NZ 265753 A 961126 (9701) C07K001-10JP 08509709 W 961015 (9705) 135 pp C07K005-103

L1 ANSWER 3 OF 51 WPINDEX COPYRIGHT 1997 DERWENT INFORMATION LTDAN 94-333113 [41] WPINDEXTI ***Cyclic*** penta peptide prepn in 4 stages - from tri - and di

-peptide cpds via new intermediates, used as platelet glyco protein(IIb)/(IIIa) inhibitors.

PA (DUPO) DU PONT MERCK PHARM COPI WO 9422909 A1 941013 (9441)* EN 94 pp C07K005-12

AU 9464157 A 941024 (9505) C07K005-12EP 691986 A1 960117 (9608) EN C07K005-12JP 08509708 W 961015 (9705) 67 pp C07K005-103



=> fil dgeneCOST IN DEUTSCHMARKS SINCE FILE TOTAL



=> s e52 and cyclic'IC' IS NOT A VALID FIELD CODE

0 C07K001-02/IC3614 CYCLIC

L2 0 C07K001-02/IC AND CYCLIC

=> s L1<pn> oder => trans L1 pn

*** SmartSELECT INITIATED ***

COST IN DEUTSCHMARKS SINCE FILE TOTALENTRY SESSION

FULL ESTIMATED COST 1,15 17,05

FILE 'WPINDEX' ENTERED AT 15:44:54 ON 25 MAR 1997COPYRIGHT (C) 1997 DERWENT INFORMATION LTD'TRIAL' IS DEFAULT FORMAT FOR 'WPINDEX' FILE

SET SMARTSELECT ONSET COMMAND COMPLETED

SEL L1 1- PNL3 SEL L1 1- PN : 431 TERMS

SET SMARTSELECT OFFSET COMMAND COMPLETED

COST IN DEUTSCHMARKS SINCE FILE TOTALENTRY SESSION

FULL ESTIMATED COST 15,88 32,93

FILE 'DGENE' ENTERED AT 15:45:00 ON 25 MAR 1997COPYRIGHT (C) 1997 DERWENT INFORMATION LTD

S L3L4 243 L3L5 QUE TERMS FROM L3 WITH NO HITS: 409 TERMS

=> d an ti seq l4

L4 ANSWER 1 OF 243 DGENE COPYRIGHT 1997 DERWENT INFORMATION LTDAN 94P-R69270 peptide DGENETI New cyclic penta:peptide(s) having a gamma-turn and a beta-turn -

used as NK2 receptor antagonists for treating asthma, inflammationor arthritis

SEQ1 dwllw


DRUGPAT

Produzent: IMS World Publications (GB)

Patentinformationen über mehr als 1'200 Arzneiwirkstoffe(im Verkauf bzw. Phase III)

Über 31'000 Referenzen, über 56 berücksichtigt

Ein DRUGPAT-Dokument beinhaltet:

- Eine Produkte-Identifikation (generischer Name,Handelsname, Laboratoriumscode, CAS-Nummer,Struktur)

- Therapeutische Klassifikationscodes

- Patentanmelderfirma

- Patentnummer(n)

- Patent-Ablaufdatum

- Kommentare

- Mögliche Tabellenformate:

CCTAB COTAB CYTAB IDETABCN X X XPA X XCC X XPN X XPC XDS XAP XRN X


DRUGPAT

FILE 'DRUGPAT' ENTERED AT 13:58:00 ON 18 MAR 1997COPYRIGHT (C) 1997 IMSWORLD Publications Ltd.FILE COVERS 1987 TO 5 Mar 1997 (970305/ED)

=> s lansoprazole/cnL1 28 LANSOPRAZOLE/CN

=> d iall 4

L1 ANSWER 4 OF 28 DRUGPAT COPYRIGHT 1997 IMSWORLD

ACCESSION NUMBER: 95:16198 DRUGPATSOURCE: Patents International, (28 Feb 1996)GENERIC NAME: lansoprazoleLABORATORY CODE: AG 1749; CG 4801; A 65006TRADE NAME: TAKEPRON; OGAST; LANZOR; AGOPTON; PREVACID;

LANZO; OPIREN; BAMALITE; ZOTONCAS REGISTRY NUMBER: 103577-45-3STRUCTURE:

CLASSIFICATION: A2 Antacids and AntiulcerantsCLINICAL APPLICATION: gastrointestinal ulcerPATENT ASSIGNEE: Takeda (Japan)SUPPLEMENTARY TERM: Process; Equivalent to product

Publication ExpirationNumber Date Date----------- ---------- ---------

PATENT INFORMATION: SU 1507211 19890907 20050814

PRIORITY INFORMATION: JP 84-171069 19840816

COUNTRY COMMENTS:The USSR ceased to exist on 25 December 1991. All USSR patents valid on25 December 1991 automatically remain in force in the Russian Federation.

ABSTRACT:Takeda has a later patent family covering compositions of lansoprazole,particularly for the prevention or treatment of Campylobacter infections.The priority quoted is Japan no 32374 of 10 February 1989, giving normalexpiry dates worldwide around February 2010. The European equivalent, EP382489 B, should normally expire on 6 February 2010. Takeda has a patentfamily claiming spherical granule compositions of lansoprazole. Thepriority quoted is Japan no 19178 of 29 January 1987, giving normalexpiry dates around January 2008 for most equivalents. The Europeanequivalent, EP 277741 B, should normally expire on 25 January 2008. TheUS equivalent, US 5026560, should normally expire on 25 June 2008. On 8June 1995 the amendments to the US patent law under the General Agreementon Tariffs and Trade (GATT) came into force. The estimated expiry date ofUS 5026560 is not affected. Takeda has a patent family claiming coated


DRUGPAT

tablets or granules of lansoprazole. The priority quoted is Japan no38059 of 21 February 1986 giving normal expiry dates around February 2007for most equivalents. The European equivalent, EP 237200 B, shouldnormally expire on 13 February 2007. US equivalent 5045321 shouldnormally expire on 3 September 2008, term unaffected. The term of USequivalent 5093132 has been disclaimed from 3 September 2008. The term ofthe disclaimer is also not affected.

=> s deracyn/tnL2 47 DERACYN/TN

=> d iall;display l2 cotab 1-10

L2 ANSWER 1 OF 47 DRUGPAT COPYRIGHT 1997 IMSWORLD

ACCESSION NUMBER: 95:2476 DRUGPATSOURCE: Patents International, (28 Apr 1994)GENERIC NAME: adinazolam; adinazolam mesylate; adinazolam

mesilateLABORATORY CODE: U 41123F; U 41123TRADE NAME: DERACYNCAS REGISTRY NUMBER: 37115-32-5STRUCTURE:

DERIVATIVE(S): 37115-51-8 mesilate57938-82-6 monomesilate64449-10-1 N-oxide

CLASSIFICATION: N5C Psycholeptics - Anxiolytics; N6APsychoanaleptics - Antidepressants

CLINICAL APPLICATION: anxiety; depressionPATENT ASSIGNEE: Upjohn (USA)SUPPLEMENTARY TERM: Composition; Equivalent to product

Publication ExpirationNumber Date Date----------- ---------- ---------

PATENT INFORMATION: DE 2356369 19840823 19911112

PRIORITY INFORMATION: US 72-309213 19721124US 73-320475 19730102

COUNTRY COMMENTS:The West German patent claims compositions of adinazolam


DRUGPAT

ABSTRACT:Ciba Geigy and Takeda synthesised adinazolam independently and both triedto obtain product claims to it. Takeda has the earlier priority date, andthe unofficial register in the UK patent office states that Ciba Geigy`sUK patent, no 1393256, has lapsed, so Takeda has probably obtained rightsin most countries. Upjohn also synthesised adinazolam at about the sametime and tried to obtain product protection, but the priority date islater than either Ciba Geigy`s or Takeda`s. Upjohn does however have aproduct patent in the USA. All three patent families are quoted here, butfor a definitive statement on the status of any of the patents quoted,the local patent office must be consulted

L2 File DRUGPAT COPYRIGHT 1997 IMSWORLD

ANS| Patent Assignee | Compound |Patent No.===+========================+==========+===========

1|Upjohn (USA) |adinazolam|DE 2356369---+------------------------+----------+-----------

2|Upjohn (USA) |adinazolam|US 4264615---+------------------------+----------+-----------

3|Upjohn (USA) |adinazolam|US 4250094---+------------------------+----------+-----------

4|Upjohn (USA) |adinazolam|ZA 7308378---+------------------------+----------+-----------

5|Upjohn (USA) |adinazolam|FR 2207719---+------------------------+----------+-----------

6|Upjohn (USA) |adinazolam|BE 807752---+------------------------+----------+-----------

7|Upjohn (USA) |adinazolam|AU 490584---+------------------------+----------+-----------

8|Ciba Geigy (Switzerland)|adinazolam|---+------------------------+----------+-----------

9|Ciba Geigy (Switzerland)|adinazolam|SU 444370---+------------------------+----------+-----------10|Ciba Geigy (Switzerland)|adinazolam|GB 1393256

---+------------------------+----------+-----------

=> d costCOST IN DEUTSCHMARKS SINCE FILE TOTAL

ENTRY SESSIONCONNECT CHARGES 8,88 12,98DISPLAY CHARGES 339,56 339,56OTHER CHARGES 1,88 1,88

------- -------FULL ESTIMATED COST 350,32 354,42

IN FILE 'DRUGPAT' AT 14:00:17 ON 18 MAR 1997


So können Sie sich weiterbilden:

Das InfoLit-Schulungskonzept:

STNEinsteigerforum

½ Tag

STNMessenger

2 Tage

STNBio-/Gentech

2 Tage

STNPatente2 Tage

CAS/FIZ Chemie

Dictionary1 Tag

Internetprofessionell

1 Tag

STN Easy1 Tag

STN PatenteErfahrungsworks.

1 Tag

IntranetWerkzeuge

1 Tag

STN Messengerprofessional

1 Tag

STNExpress

1 Tag

STNSubstanzrecher.

2 Tage

CAS/FIZ Chemie

CAPLUS1 Tag

CAS/FIZ Chemie

MARPAT1 Tag

CAS/FIZ Chemie

Struktursuche1 Tag

ChemieEnergieBio-/GentechPatente

DerwentBCE1 Tag

DerwentPolymer Ind.

1 Tag

IN01

EF02-07

EA01-02

ME01 BG01

ME02 SE01 CH11

CAS/FIZ Chemie

CASREACT/CheminformRX1 Tag

CAS/FIZ Chemie

Struktursuche für Fortgeschr.1 Tag


Quellenangaben/weiterführende Literatur:

Damon D. Ridley: ONLINE SEARCHING: A SCIENTIST’S PERSPECTIVE.A Guide for the Chemical and Life Sciences. John Wiley & Sons, 1996

Hedda Schulz, Ursula Georgy: Von CA bic CAS online. Datenbanken in der Chemie.Springer Verlag 1994

F. Böhm, E. Thomä: Leitfaden zu STN-Patentdatenbanken, Karlsruhe, November 1996http://www.patent-inf.tu-ilmenau.de/schulungszentrum/guide/

Die Datenbankproduzenten bei STN:http://www.fiz-karlsruhe.de/db_suppl.html

Die Datenbanken von STN:http://www.fiz-karlsruhe.de/onlin_db.html

stn seminar bio- und gentechnologie bei stn (1998)

Health & Medicine